| Posted by Dave Cavenaugh 08-13-2010 |
WASHINGTON UPDATE |
 |
|
Vol.12 No. 2
COTT Washington Update -- 2010 VOLUME 12 NUMBER 2 The COTT Washington Update is posted on our website, www.cott1.org. To receive the Update directly, send an e-mail to COTT at cott-dc@earthlink.net. > ACBSA Meets To Consider MSM Blood Donor Deferral Policy Changes On June 10-11 the Department of Health and Human Services’ Advisory Committee On Blood Safety and Availability (ACBSA) met in Washington DC to consider change in the blood donor deferral policy regarding “men who have had sex with men”, or MSM. Currently, a potential male donor who reports having had sex, even once, with another male at any time since 1977, is permanently deferred from donating blood. In the last Update we reported on the proposal to lift the ban which came from Gay Mens Health Crisis in New York and was supported by twenty-one Senators in a joint letter to FDA Commissioner Margaret Hamburg in March of this year. Change in the deferral policy was also supported by the American Red Cross, the American Association of Blood Banks and Americas Blood Centers. The ACBSA heard from both experts and community-based organizations regarding the proposed change. In April, COTT had asked for a meeting of the Plasma Users Coalition (PUC) to discuss this important and potentially very controversial issue. Simultaneously, in the spirit of better collaboration and communication across the global community the PUC adopted a new name and logo to bring this coalition more in tune with the European Users Coalition, which goes by the name PLUS for PLasma USers. A-PLUS was the name adopted: American Plasma Users. The first order of business for A-PLUS was to attempt to develop a consensus within the users coalition on the MSM question and provide coherent and substantive testimony and recommendations on behalf of the users of blood, blood components and blood products regarding the proposed changes. World Hemophilia Federation (WFH) President Mark Skinner and COTT President Corey Dubin were tasked to draft the A-PLUS testimony and to establish a dialogue with Gay Mens Health Crisis before the June meeting of the ACBSA. For COTT’s Board of Directors, this was a situation that presented a very serious conundrum. During the 1990s COTT had worked closely with the Gay, Lesbian, Bisexual and Transgender (GLBT) communities on issues of HIV/AIDS, chairing the Community Constituency Group at the National Institutes of Health, which was the community structure for what was then called “Trials Without Walls”, a community based clinical trials initiative for HIV/AIDS drug trials. Through this work and other activities around speeding development of AIDS drugs, COTT worked with many GLBT organizations. COTT Board members were concerned that despite the controversial and potentially explosive nature of this issue, COTT must again work closely with Gay and Bisexual communities to explore what change in the donor deferral policy for MSM might look like and how we get to that change in a manner that increases the overall safety of our nation’s blood supply. Upon gaining the support of the A-PLUS member organizations we began to seek a meeting with Gay Mens Health Crisis (GMHC), in order to open a dialogue before the June 11 ACBSA meeting in Washington. On June 4th Mark Skinner of WFH, Neil Frick of NHF, and Corey Dubin and Dave Cavenaugh of COTT met with the senior policy staff of GMHC at its offices in New York. The discussions were substantive and candid and led to a proposal to craft a joint letter between hemophilia community organizations and leading Gay and Lesbian rights organizations to be presented at the ACBSA. As a result 2 COTT, NHF, HFA and WFH joined with GMHC, Human Rights Campaign, AIDS Action Council, National Gay and Lesbian Task Force, and AmFar, in issuing a joint letter to the ACBSA, released to the press on June 9TH, the daybefore the ACBSA meeting (included as Attachment #1 at end of this Update). As always COTT views the blood supply in a landscape manner, that is, with an awareness that any changes in policy or regulation concerning blood almost certainly has impacts and consequences for other elements of the blood system, thus having an overall effect potentially much larger than the policy change under consideration. It was vital that the proposals under study here be considered in the context of the overall safety and regulation of that system. Mark Skinner delivered the A-PLUS testimony to the Advisory Committee at the ACBSA meeting. It included an acknowledgement that the current policy needs to be changed, and that such changes must be based on existing science. He then presented a research agenda that would, through a series of studies, further our overall understanding of the donor deferral landscape, and how previously deferred donors should, if supported by the science, be re-entered into the donor pool. A very good presentation was also given by Dr. Ganz of Canadian Blood Services which has been wrestling with this issue for some time and has decided not to re-enter MSM donors at this time. At the core of the issue for a number of the members of the ACBSA, were the very high HIV transmission rates in Gay and Bisexual communities and whether or not the rates of new infections are a marker for unknown threats or pathogens. This is a question that must be studied if we are going to better understand the risk horizon for re-entering MSM donors. On July 27th, representatives of the bleeding disorders communities and Gay Mens Health Crisis met with Dr. Keith Hoots, Director of the Division of Blood Resources at the National Heart, Lung and Blood Institute ( NHLBI) of the NIH , and his staff, concerning plans for studies under review. The meeting was another positive step in moving the research agenda forward in a timely and deliberate manner. COTT would like to thank the GMHC Policy team, including Nathan Schaefer and Sean Cahill for their forward looking vision and their commitment to change that enhances the overall safety of our nation’s blood supply through more effective policy development and updated and more focused science. In addition to the Joint letter to the ACBSA (Attachment #1), also included in this Update are the Executive Summary of the A-Plus Coalition paper (Attachment #2), and the final recommendations of the Advisory Committee to DHHS Secretary Sibelius (Attachment #3). > CONGRESS Electoral politics around the coming November Mid-Term elections are in full swing, with the polarization of loyalties front and center. Nevertheless, Congress has passed a number of important bills so far this session. The most prominent of this is groundbreaking financial reform legislation, with unprecedented consumer advocacy provisions. The bill consumed much of Congress’ time over the past few months: Introduced and approved bv the House last December, the Senate was unwilling to approve it until this May; It only became law toward the end of July. On another front, sweeping energy legislation, with many “green” requirements, has languished even more, and has been put off until fall. Concerns over the confirmation of our new Supreme Court nominee, over the enormous effort in Afghanistan, and the ecological and economic disaster along the coastline of the southeastern US, are additional matters before Congress and the President. In a year in which Congress once again declined to pass clear immigration legislation, states have taken the lead. Recent federal court rejection of the Arizona state law passed last year shows the electricity around this issue. Other state actions are in the air more than ever: some have modeled bills after the Arizona 3 immigration language; some are suing to block the federal Health Care Reform legislation in their state (see below), and most are desperate for assistance in meeting record demands for low-income assistance at a time of lean state coffers. Fortunately after much cliff-hanging the Senate approved a $26 billion fund to keep 160,000 teachers employed ($10 billion) and countless other human services and health providers as well ($16 billion for strapped Medicaid programs). House passage and signature into law are expected as the Congress goes into its six-week summer recess. Concerning the opposition to the Health Care Reform laws, the August 2 federal ruling that a Virginia suit to block the bill’s mandated expansions of Medicaid and requirements of coverage can stand, and the Missouri August 10th vote to similarly oppose the mandated coverage (72% in the latest poll, outcome predictable), show the level of unrest in the earliest days of the unfolding of this paradigm shift in American corporate health care. Out in the real world, the steps involved in the implementation of the Health Care Reform legislation earlier this year continue to unfold. High-Risk Pools: States have been asked if they will operate their own; over 35 have said they will not which means the federal government will step in to operate a pool program in each of those states. Lawsuits have been filed to contest this alleged incursion into states’ rights; stay tuned. Other issues in operation of these pools: 1) Assuring that the few state-run pools offer the correct full spectrum of benefits; 2) How lifetime and annual caps are to be addressed; and 3) the concern, addressed by states and by any other observers, as to who shall pay for the programs once the paltry $5 Billion in the bill for all states’ programs, for four years, until larger reform takes shape in 2014 is exhausted. The real access problem in our community, however, and one not yet overturned, is the requirement that to participate in one of these pools a person must have been un-insured for a period of six months. Hospital Oversight: In several areas of the legislation, hospitals are directed to improve their services to low-income persons. Non-profit hospitals, found in a recent study to have very poor statistics regarding such compassionate care, are being told to increase it. Many hospitals are now benefitting from the expansions of the 340b Prescription Drug Pricing Program; their start-up phase in the program is turning out to include monitoring and oversight as well. MLR: The Medical Loss Ratio, reflecting an insurance company’s expenditures on patient care versus other matters such as administration, advertising, and profit, requires for many to meet the standards set in the new law that substantial internal changes occur. The first wave of such changes turned out to be that the companies were moving every administrative function they could think of to be counted under the patient care column. Despite broad publicity when this was found, many such ‘skating around the law’ changes are expected to remain. Oversight, again, hopefully will provide monitoring and a public view, forcing insurers to actually spend appropriately for care. COTT attended a workshop held at the Center for American Progress with two of the four senior staff of the new Office of Consumer Information and Insurance Oversight, one State Insurance Commissioner, the CEO of a major national health plan, and the Chief of Staff of the Justice Department’s Antitrust Division. All of the above emerging issues were discussed, but in response to a COTT question about plans to aid those with high-cost conditions like hemophilia in gaining access to High Risk Pools, the Oversight office staff merely indicated such issues were being ‘worked on.’ We mentioned the fact that no-one with hemophilia could meet the law’s requirement of being uninsured for six months previously, but this was not addressed. 4 > AGENCIES Earlier this spring, FDA held a one-day workshop entitled “Voting and Nonvoting Consumer Representatives Meeting.” COTT, HFA, and a number of other community organizations including the CJD Foundation attended. The presenters distinguished between voting and non-voting membership, and between the expectations of a consumer representative and those for a patient representative. Basically a consumer representative is, in FDA’s eyes, familiar with the disease in question (although they may not have it themselves), and is also able to comment on the many issues concerning treatment of that disease, from pharmaceutical enticements and pressures, to the need for better training for providers to facilitate early diagnosis (used here merely as an example). The patient representative, on the other hand, is only to provide comment on the experiences of having the disease. We found these distinctions to be arbitrary and denigrating. Most people with a chronic, high-cost, potentially fatal disease know quite a bit about the policy issues concerning it, in addition to having a more than adequate ability to comment on the experiences of the disease as well. The FDA Center for Biologics Evaluation and Research (CBER) which regulates blood product production, held a one-day workshop in early May entitled, “Blood Quantitative Risk Assessment Workshop.” The differences between risk assessment, risk management, and risk communication were pointed out. What was not revealed, except in very global terms, was how the Risk Assessment staff and the program staff interact. The June meeting of the Department-level Advisory Committee on Blood Safety & Availability is discussed above in conjunction with the Blood Donor Deferral Policies Changes. Our regular feature of excerpts from recent FDA Enforcement Reports can be found at the end of this Update as Attachment #4. It is lengthy; a rapid scan will reveal some surprising and striking yellowhighlighted violations, however. > INDUSTRY COTT has been working for months with the national office of the AFL-CIO at their request, working to support walk-outs and other labor actions by its affiliates with members employed in Red Cross blood collection, processing and distribution operations. Workers told the union of Red Cross management practices – mandatory 14-hour days, blood drives with no nurse available, “training” of mobile van drivers as phlebotomists (blood drawers) and the like. The workers underscored the fact that, in addition to creating onerous workplace conditions, these strictures were actually causing an increase in errors in the collection, processing and distribution of blood collected. Accordingly, the union contacted COTT and other organizations in the blood and blood products using community, to elicit their support for pressure on management concerning these practices. AFL-CIO recently put up a multi-page website detailing these problems, and presenting a detailed historical timeline of Red Cross’ blood operations, and violations therein documented by FDA: www.blooddrivesafety.com.On May 19th, a Committee created out of this work, the Workers Committee for Blood Safety, held a press conference in Washington on these issues. Speakers included the Vice President of AFL-CIO, the director of the National Consumers League, and the government and policy directors for COTT and the Hemophilia 5 Federation. According to Congressional Quarterly’s report on the press conference in their HealthBeat the following day: “The p r o bl e m s a r e so ch r o ni c tha t r e g ul a to rs a r e a c c e p ti ng the m a s a ma tte r of c o u r s e, sai d Da v e C a v e n a ug h, the g o v e r n m e nt r el a ti o ns di r e c t o r fo r the C o m mi tte e of Te n Tho usa n d, a g r o u p tha t r e p r e s e nts he m o p hilia p ati e nts. … “Ho w this has b e c o m e a n a c c e p t a bl e p a rt of ou r na ti on al bl o o d sup pl y la nd s c a p e is un c o ns ci o n a bl e,” said C a v e n a u g h. The g r o u p sa ys its na m e ste m s f r o m th e num b e r of he m o p hilia p ati e nts w h o b e c a m e inf e ct e d with HIV. A copy of COTT’s Press Statement for the event is included in this Update as Attachment #5. The FDA in June at last announced the fines for the two Notice of Violations letters that Red Cross received last October -- $16 million. The total levied against the organization since the Court granted the 2003 FDA request to begin fines as its compliance demands were being ignored now amounts to over $37 million. > COALITIONS COTT attended a rally in May of the new National Viral Hepatitis Roundtable, a merger of Hepatitis B and Hepatitis C advocacy groups. The combined forces of over one hundred members, in yellow “Silent No More” T-shirts and signs, are expected to have more luck with legislation for hepatitis care than was true previously. A bill, H.R. 3974, introduced in October by Rep. Mike Honda (D-CA), provides for widespread provider training to facilitate detection. > COTT OPERATIONS COTT participated in the premiere of the movie “Bad Blood: A Cautionary Tale” in New York City in July, with a discussion after the film with a panel comprised of a national hemophilia organization, a representative of Gay Mens Health Crisis, and the Executive Director of the association of plasma producers. Similar panel discussions will be held at the movie’s Washington premiere, on September 28, 2010, and later in the Fall in San Francisco. Stay tuned for specifics. Our heartfelt thanks goes out to Marilyn Ness and Necessary Films of new York for an excellent film that brings the AIDS/Blood epidemic in the hemophilia community to light for a whole new generation of viewers who do not know what happened . COTT acknowledges the assistance of Hemophilia Health Services and Factor Support Network in publication of this issue of the COTT Washington Update. Committee of Ten Thousand 236 Massachusetts Ave., NE Suite 609 Washington, DC 20002 800-488-2688 * 202-543-6720 fax cott-dc@earthlink.net * WWW.COTT1.ORG Attachment #1: Joint COTT-MSM Statement 6 Joint Statement on Addressing the MSM Blood Ban by Groups Representing People Living with Hemophilia, Gay Men and People Living with HIV/AIDS The Department of Health & Human Services, Advisory Committee on Blood Safety and Availability will be reviewing the current Food and Drug Administration (FDA) policy recommending that men who have sex with another man (MSM) even one time since 1977 should be deferred indefinitely from donating blood. In the following joint letter advocacy organizations representing both the Gay & Lesbian Communities and the Plasma User Communities have signed on to demonstrate their past and ongoing ability to work together on issues surrounding the safety of our nation’s blood and our public health. “As the Department of Health and Human Services' Advisory Committee on Blood Safety and Availability (ACBSA) prepares to evaluate the longstanding deferral of all men who have had sex with men (MSM) from donating blood, the organizations listed below wish to clarify a recently encountered misperception. Advocates invested in any change of such a policy report a perceived disconnect between the positions of leading gay rights and hemophilia representatives. We reject this notion. The communities have more in common than current discourse reflects. Both gay men and people with hemophilia have been disproportionately impacted by the HIV epidemic. Critical advancements in HIV prevention, treatment, and research can be linked directly to the years of successful advocacy by both communities. For most of the past quarter century, these two communities have worked toward shared goals, including caring for people living with HIV and preventing the virus’s spread. The organizations listed below continue to share a strong commitment to the safety of our nation's blood supply and it is with this in mind that we urge the ACBSA to recommend any scientific research that is necessary to allow for the thoughtful consideration of alternative policies regarding donor deferral. We look forward to working with the Advisory Committee, and the broader federal government, to critically examine and evaluate alternative polices for MSM blood donors that maintain or enhance the safety of blood and blood products.” AIDS Action Council AmFAR Committee of Ten Thousand Gay Men's Health Crisis Hemophilia Federation of America Human RIghts Campaign National Gay and Lesbian Task Force National Hemophilia Foundation World Federation of Hemophilia 7 Attachment #2: Executive Summary of Plasma Users’ Combined Report EXECUTIVE SUMMARY of the statement on behalf of the AMERICAN PLASMA USERS COALITION (A-PLUS) before the Advisory Committee on Blood Safety and Availability Department of Health and Human Services Thirty-eighth Meeting June 10-11, 2010 The Universities at Shady Grove, Rockville, MD MSM Blood Donor Deferral Policy The American Plasma Users Coalition (A-PLUS) is a coalition, formerly known as the Plasma User Coalition (PUC), of national patient organizations created to address the unique needs of patients with rare diseases that use life-saving plasma protein therapies. The organizations representing these patients share a common desire to ensure that the patient voice is heard when relevant public polices, regulations, directives, guidelines and recommendations which have a major impact on their access to safe and effective therapy and treatment are considered. Together our coalition represents more than 125,000 Americans living with chronic disorders dependent upon plasma protein therapies for their daily living. In addition, there are thousands more that remain undiagnosed. Partners in our coalition include: Alpha-1 Association Alpha-1 Foundation GBS/CIDP Foundation International Committee of Ten Thousand Hemophilia Federation of America Immune Deficiency Foundation Jeffrey Modell Foundation National Hemophilia Foundation Platelet Disorder Support Association Patient Services Incorporated A-PLUS appreciates this opportunity to present our views regarding the Advisory Committee on Blood Safety and Availability’s (ACBSA) review of the current Food and Drug Administration (FDA) policy recommending that men who have sex with another man (MSM) even one time since 1977 should be deferred indefinitely from donating blood. Both gay men and those in the plasma user community have been disproportionately impacted by the HIV epidemic. Our communities have a long history of working together on shared goals related to providing HIV support, research advocacy, treatment access, and prevention programs. We share a historical common bond. Together, we are committed to ensuring the overall safety of the nation’s blood supply. At this time, A-PLUS does not believe that the currently available knowledge and data are sufficient to support a change to the existing donor deferral policy. We acknowledge that the scientific basis for the permanent deferral requires review. However, we do not currently have enough information to determine if a 8 one-year, five-year, ten-year, or another deferral period is more appropriate than the existing permanent lifetime deferral. Selection of another interval could also be perceived as arbitrary or lacking scientific foundation. However, this is not the end of the discussion. We believe that there are a number of factors which should be fully evaluated before making a revision to the policy and we support research focused on high risk behaviors of both MSM and heterosexuals. Such evaluation and research could lead to a policy revision that maintains or enhances the safety of blood and blood products. Today we are calling for a research agenda to be undertaken to address several critical areas with the following goals: 1. Achieving a better understanding of known and emerging pathogens in specific populations including MSM and heterosexual populations; 2. Developing policy that recognizes societal aspects of the blood system’s safety and risk tolerance; 3. Developing alternate donor deferral strategies and the risk of blood-borne diseases; 4. Establishing a framework for accelerated approval of pathogen reduction, removal and/or inactivation technologies for fresh components; and 5. Understanding the implications of a revision on the supply and availability of treatment products globally. If we progress in earnest with such a research strategy, and obtain reassuring answers, we foresee a time when a revision would be appropriate and donor deferrals could be made on a more individualized, behavioral-based risk review for both MSM and heterosexual donors. We urge all stakeholders, including donors and end-users, to aggressively work together to seek answers. Equally important, is for the government to commit the necessary funding to ensure that this occurs in a timely manner. Our specific recommendations for research in the context of the research agenda mentioned above are summarized below. SUMMARY OF RESEARCH RECOMMENDATIONS I. The ACBSA consideration of this issue should not supplant the rigorous scientific review of the FDA and BPAC. II. We must achieve a better understanding of known and emerging pathogens in specific populations including MSM and heterosexual populations. III. We must give due consideration in policy development to the societal aspects of the blood system’s safety and risk tolerance. IV. We must consider alternate donor deferral strategies and the resulting risk of blood-borne diseases. V. We must factor into the equation the risk of multiple and cumulative exposure for those dependent upon blood and plasma therapies for their daily living. 9 VI. We must establish a framework for accelerated approval of pathogen reduction, removal and/or inactivation technologies for fresh components and where necessary, support research to develop the technology. VII. We must understand the implications of a revision of the donor deferral policy on the supply and availability of treatment products globally prior to changing the deferral policy. VIII. We must have a robust comprehensive hemovigilance and biovigilance program. IX. We call upon the Department of Health and Human Services to encourage accelerated development and use of pathogen reduction technologies for fresh (labile) components. X. We must implement a robust donor education program as part of any revised donor deferral policy. =================== 10 Attachment 3: Final Recommendations of the Advisory Committee on Blood Safety and Availability HHS Advisory Committee on Blood Safety and Availability On June 10-11, 2010, the HHS Advisory Committee on Blood Safety and Availability (ACBSA) met to discuss the current Food and Drug Administration (FDA) policy on men who have sex with other men (MSM). FDA’s current policy states that men who have had sex with other men at any time since 1977 are currently deferred as blood donors. The ACBSA engaged in deliberations and discussed the following: important factors to consider in making a policy change; scientific information including risk assessments; whether any additional studies are needed before implementing a policy change or following a policy change; monitoring tools or surveillance activities that could be implemented, and whether those should be implemented before implementing any policy change; and, whether additional safety measures, if any, are needed to assure blood safety under a revised deferral policy. The ACBSA took two votes during the meeting. The first was to vote on whether the current policy should be changed at the present time. In the second, the Committee was asked to identify studies needed to establish a basis for a change in policy and to recommend further action needed, if any, to monitor and improve blood safety. Committee Question: Should the current indefinite deferral for men who have had sex with another man even one time since 1977 be changed at the present time? Committee Vote: 6 = Yes; 9 = No Committee Recommendations The HHS’s Advisory Committee on Blood Safety and Availability (the Committee or ACBSA) is sensitive to the blood system and broader societal issues related to the current deferral policy for males who have had sex with another man even (MSM) one time since 1977. Whereas we believe that the current donor deferral policies are suboptimal in permitting some potentially high risk donations while preventing some potentially low risk donations, we find that currently available scientific data are inadequate to support change to a specific alternative policy; therefore, until further evaluation, the committee recommends that the current indefinite deferral for men who have had sex with another man even one time since 1977 not be changed at the present time. To develop and validate candidate alternative policies, we recommend research in the following areas: 1. Validate modifications to the donor questionnaire that would better differentiate low versus high risk MSM and heterosexuals, including studies to investigate 11 Transfusion Transmitted Infectious Disease (TTID) and Sexual Transmitted Disease (STD) markers in potential donor subsets; 1. Establish ongoing national hemovigilance program for TTID markers in blood donors linked to analysis of demographic, behavioral, and other risk factors: a. Obtain a baseline on prevalence and incidence of TTIDs, b. Characterize risk in different donor subgroups (e.g., younger age), and c. Use above characteristics for continuous quality improvement of the donor deferral process; 1. Determine the feasibility of donor pre-testing to limit risk while characterizing donors who might be recruited under modified eligibility criteria; 1. Investigate the impact of revised donor criteria on the global availability of plasma products; 1. Evaluation of data from other countries that have changed their high risk donor evaluation programs, including MSM; and 1. Periodic reassessment of transfusion safety including consideration of multiple and cumulative blood product exposures to recipients. Additionally, the Committee recommends the following actions. 1. Implement the January 2008 ACBSA recommendation to adopt pathogen reduction technologies for all transfusible blood components 1. Create a more robust donor education program focusing on high risk behaviors that is more inclusive of all donor groups, emphasizing the link between safe donation and recipient health 1. The Department should take action to investigate and reduce the risk of Quarantine Release Errors (QREs) in blood collection establishments 1. Recognizing the relationship between acceptance of risk of transfusion and protection from harms, further consideration should be given to mechanisms for compensation for blood injuries consistent with the recommendations of the Institute of Medicine and the U.S. Congress Committee vote: Unanimous yes (15 votes) 12 Attachment #4: Recent FDA Enforcement Report excerpts __________ April 14 __________ PRODUCT 1) Recovered Plasma. Recall # B-0458-10; 2) Red Blood Cells Leukocytes Reduced. Recall # B-0459-10; 3) Plasma Frozen Within 24 hours (FP24). Recall # B-0460-10; CODE 1) Unit: 003LK21499; 2) Units: 03KW26270, 003LK21499; 3) Unit: 03KW26270 RECALLING FIRM/MANUFACTURER The American National Red Cross – Southern Region, Douglasville, GA, by telephone and facsimile on March 27, 2009 and by letters dated March 27, 2009 and May 29, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed. VOLUME OF PRODUCT IN COMMERCE 4 units DISTRIBUTION GA, AL ___________________________________ PRODUCT Platelets Pheresis- 7d Leukocytes Reduced. Recall # B-0889-10 CODE Unit: 9919347 RECALLING FIRM/MANUFACTURER Florida’s Blood Centers, Inc., Orlando, FL, by letter on March 28, 2008. Firm initiated recall is complete. REASON Blood product, found to be contaminated with Corynebacterium species and Staphylococcus species using the BacT ALERT System, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION FL ___________________________________ PRODUCT 1) Red Blood Cells Leukocytes Reduced. Recall # B-0921-10; 2) Cryoprecipitated AHF. Recall # B-0922-10; 3) Fresh Frozen Plasma. Recall # B-0923-10; 4) Plasma Frozen within 24 hours (FP24). Recall # B-0924-10; 5) Red Blood Cells. Recall # B-0925-10; 6) Red Blood Cells Leukocytes Reduced Irradiated. Recall # B-0926-10; 7) Plasma Cryoprecipitate Reduced. Recall # B-0927-10 CODE 1) Units: 040FV20572, 040FV20573, 040FV20575, 040FV20576, 040FV20580, 040FV20581, 040FV20583, 040FW42763, 040FY52466, 040FY52467, 040FY52469, 040FY52470, 040FY52471, 040FY52472, 040FY52479, 040FY52480, 040FY52481, 040FY52482, 040FY52483, 040FY52485, 040FY52486, 040FZ37560, 040FZ37767, 040FZ37773, 040FZ37808, 040GE99339, 040GE99342, 040GE99346, 040GE99353, 040GE99374, 040GG09346, 040GJ73393, 040GJ73396, 040GJ73398, 040GJ73399, 040GJ73410, 040GJ73411, 040GJ73415, 040GJ73416, 040GM13796, 040GM13847, 040GS94724, 040GS94726, 040GS94864, 040GS94916, 040GT64381, 040GT64383, 040GT64384, 040GT64385, 040GZ07866, 040GZ07888, 040GZ07892, 040GZ07911, 040GZ07924, 040GZ07975, 040GZ07979, 040GZ08202, 040LE26687, 040LE26692, 040LE26702, 040LE26705, 040LE26710, 040LT35510, 040LT35514, 040LT35515, 040LT35516, 040LT35521, 040LT35527, 040LT35528, 040LT35529, 040LT35531, 040LT35675, 040LZ29379, 040FJ64623, 040FJ64641, 040FJ64648, 040FJ64900, 040FJ64902, 040FJ64910, 040FJ64918, 040FJ64924, 040FL40274, 040FL40278, 040FL40280, 040FL40281, 040FL40289, 040FL40294, 040FN34730, 040FN34732, 040FN34737, 040FN34741, 040FN34744, 040FN34745, 040FN34749, 040FN34752, 040FN34754, 040FN34757, 040FV20425, 040FW42479, 040FW42491, 040FW42500, 040FW42502, 040FW42504, 040FX39040, 040FX39042, 040FX39049, 040FX39055, 040FX39058, 040FX39417, 040FX39421, 040FX39422, 040FX39423, 040FX39428, 040FX39433, 040FX39436, 040FX39438, 040FX39440, 040FY51458, 040FY52128, 040FY52129, 040FY52131, 040FZ37486, 040GE97422, 040GE97426, 040GE97434, 040GE97441, 040GE97485, 040GE97512, 040GE97515, 040GE97947, 040GE97965, 040GE97982, 040GE98007, 040GE98029, 040GE98074, 040GE98099, 040GE99317, 040GF84695, 040GF84696, 040GF84704, 040GF84706, 040GF84715, 040GF84718, 040GF84726, 040GF84730, 040GF84733, 040GF84738, 040GF84745, 040GF84749, 040GF84751, 040GF84757, 040GF84928, 040GF84932, 040GF84958, 040GF84962, 040GF84993, 040GG08094, 040GG08100, 040GG08109, 040GG08115, 040GG08118, 040GG08123, 040GG08449, 040GG08451, 040GG08467, 040GG08468, 040GG08485, 040GG08489, 040GG08499, 040GG08527, 040GG08544, 040GG09242, 040GG09248, 040GG09252, 040GH84565, 040GH84568, 040GH84571, 040GH84573, 040GH84577, 040GH84580, 040GH84584, 040GH84590, 040GH84593, 040GH84598, 040GH84607, 040GH84608, 040GH85239, 040GH85245, 040GH85286, 040GH85299, 040GH85303, 040GH85316, 040GH85321, 040GH85326, 040GH85329, 040GH85343, 040GH85347, 040GH85389, 040GH85417, 040GH85425, 040GH85438, 040GH85446, 040GH85533, 040GH85535, 040GH85536, 040GH85548, 040GH85555, 040GH85561, 040GH85563, 040GH85565, 040GH85568, 040GH85571, 040GH85573, 040GH85575, 040GH85577, 040GH85579, 040GH86093, 040GH86099, 040GH86134, 040GK73527, 040GK73529, 040GK73530, 040GK73536, 040GK73537, 040GK73540, 040GK73544, 040GK73547, 040GK73548, 040GK73968, 040GK73973, 040GK73974, 040GK73980, 040GK73982, 040GK73986, 040GK73989, 040GK73992, 040GK73993, 040GK74007, 040GK74009, 040GK74012, 040GK74016, 040GK74017, 040GK74027, 040GL17893, 040GL17895, 040GL17906, 040GL17914, 040GL17916, 040GL17924, 040GL17926, 040GL17929, 040GL18956, 040GL18959, 040GM12588, 040GM12590, 040GM12591, 040GM12592, 040GM12594, 040GM12595, 040GM12596, 040GM12597, 040GM12600, 040GM12602, 040GM12604, 040GM12606, 040GM12607, 040GM12613, 040GM12614, 040GM12928, 040GM12931, 040GM12934, 040GM12940, 040GM12941, 040GM12949, 040GM12953, 040GM12956, 040GN23504, 040GN23509, 040GN23519, 040GN23523, 040GN23718, 040GN23735, 040GQ11157, 040GQ11170, 040GQ11181, 040GQ11192, 040GQ11194, 040GQ11253, 040GQ11258, 040GQ11259, 040GQ11265, 040GQ11267, 040GQ11277, 040GR90737, 040GR91032, 040GR91035, 040GR91043, 040GR91052, 040GR91053, 040GR91055, 040GR91057, 040GR91434, 040GR91440, 040GR91454, 040GR91462, 040GR91464, 040GR91470, 040GR91481, 040GR91491, 040GR91495, 040GS93365, 040GS93368, 040GS93370, 040GS93374, 040GS93393, 040GS93430, 040GS93456, 040GS93585, 040GS93586, 040GS93591, 040GS93603, 040GS93609, 040GS93615, 040GS93619, 040GS93626, 040GS93945, 040GS93947, 040GS93951, 040GS93953, 040GS93960, 040GS93968, 040GS93969, 040GS93973, 040GS93976, 040GS93977, 040GT63918, 040GV58863, 040GV58866, 040GV58869, 040GV58872, 040GV58877, 040GV58885, 040GV58887, 040GV58892, 040GV59003, 040GV59005, 040GV59024, 040GV59029, 040GV59048, 040GV59052, 040GV59053, 040GV59054, 040GW69176, 040GW69179, 040GW69182, 040GW69185, 040GW69188, 040GW69194, 040GW69200, 040GW69201, 040GW69205, 040GW69208, 040GW69730, 040GW69742, 040GX66515, 040GX66756, 040GX66761, 040GX66763, 040GX66769, 040GX66776, 040GX66779, 040GX66783, 040GX66784, 040GX66788, 040KL07343, 040KL07347, 040KL07350, 040KL07353, 040KL07357, 040KL07359, 040KL07361, 040KL07363, 040KL07367, 040KL07369, 040KL07372, 040KM06703, 040KM06705, 040KM06707, 040KM06711, 040KM06712, 040KM06714, 040KM06717, 040KN04150, 040KN04151, 040KN04155, 040KN04157, 040KN04159, 040KN04170, 040KN04175, 040KN04179, 040KN04180, 040KN04197, 040KN04201, 040KN04204, 040KN04206, 040KN04211, 040KN04214, 040KN04217, 040LE25915, 040LE25917, 040LE25918, 040LE25921, 040LE25923, 040LE25929, 040LE25933, 040LE26473, 040LL06444, 040LL06446, 040LL06451, 040LL06454, 040LL06459, 040LT33409, 040LT33410, 040LT33412, 040LT33415, 040LT33416, 040LT33417, 040LT33418, 040LT33419, 040LT33422, 040LT33521, 040LT33523, 040LT33526, 040LT33527, 040LT33533, 040LT33534, 040LT33539, 040LT33540, 040LT33541, 040LT33542, 040LT33546, 040LT33547, 040LT33550, 040LT33693, 040LT33694, 040LT33695, 040LT33697, 040LT33698, 040LT33701, 040LT33702, 040LT33703, 040LT33704, 040LT33706, 040LT33710, 040LT33711, 040LT33712, 040LT33714, 040LT33715, 040LT33717, 040LT33718, 040LT33719, 040LT33721, 040LT33724, 040LT33725, 040LT34548, 040LT35186, 040LT35517, 040LT35678, 040LV15944, 040LV15946, 040LV15948, 040LV15954, 040LV15955, 040LV15956, 040LW35735, 040LW35737, 040LW35739, 040LW35741, 040LW35746, 040LX14916, 040LX14919, 040LX14922, 040LX14923, 040LX14924, 040LX14926, 040LX15027, 040LX15032, 040LX15038, 040LX15041, 040LX15051, 040LX15054, 040LX15057, 040LX15356, 040LX15365, 040LX15369, 040LX15380, 040LX15388, 040LX15407, 040LY13726, 040LZ28726, 040LZ28743, 040LZ28752, 040LZ28758, 040LZ28775, 040LZ28779, 040LZ28782, 040LZ28792, 040FJ64897, 040FL40285, 040FL40290, 040FW42506, 040FY52468, 040GG09344, 040GH85288, 040GH85332, 040GS93948, 040GX66531, 040LV15949; 2) Units: 040FN34730, 040FN34732, 040FN34737, 040FN34741, 040FN34745, 040FN34749, 040FN34757, 040FV20425, 040FV20446, 040FW42767, 040FZ37556, 040FZ37557, 040FZ37558, 040FZ37560, 040FZ37561, 040FZ37565, 040FZ37767, 040FZ37778, 040FZ37798, 040GE97390, 040GE97410, 040GE97441, 040GE97473, 040GE99317, 040GE99329, 040GE99342, 040GE97391, 040GE97395, 040GE97396, 040GE97397, 040GE97399, 040GE97404, 040GE97420, 040GE97422, 040GE97426, 040GE97429, 040GE97480, 040GE97491, 040GE97499, 040GE97503, 040GE97523, 040GE97525, 040GE97544, 040GE97553, 040GE97556, 040GE99310, 040GE99315, 040GE99325, 040GE99351, 040GF84688, 040GF84696, 040GF84704, 040GF84726, 040GF84733, 040GF84738, 040GF84745, 040GF84757, 040GG08086, 040GG08094, 040GG08101, 040GG08109, 040GG08115, 040GG08121, 040GG08123, 040GG09217, 040GG09242, 040GG09248, 040GG09252, 040GH85387, 040GH85389, 040GH85399, 040GH85401, 040GH85417, 040GH85420, 040GH85425, 040GH85431, 040GH86099, 040GH86134, 040GK73982, 040GK73986, 040GK73989, 040GK74007, 040GK74009, 040GK74016, 040GK74017, 040GK74027, 040GM12931, 040GM12940, 040GM12953, 040GM12928, 040GM12934, 040GM12937, 040GM12941, 040GM12949, 040GM12956, 040GM12959, 040GM13780, 040GM13805, 040GM13842, 040GM13845, 040GN23514, 040GN23519, 040GN23713, 040GN23715, 040GN23723, 040GN23730, 040GN23534, 040GN23735, 040GQ11139, 040GQ11151, 040GQ11157, 040GQ11170, 040GQ11175, 040GQ11183, 040GQ11190, 040GQ11192, 040GQ11194, 040GQ11229, 040GQ11232, 040GQ11249, 040GQ11253, 040GQ11258, 040GQ11259, 040GQ11261, 040GQ11265, 040GQ11267, 040GQ11270, 040GQ11275, 040GR91032, 040GR91033, 040GR91035, 040GR91036, 040GR91039, 040GR91440, 040GR91043, 040GR91044, 040GR91046, 040GR91052, 040GR91055, 040GR91057, 040GR91437, 040GS93365, 040GS93368, 040GS93370, 040GS93374, 040GS93377, 040GS93403, 040GS93405, 040GS93411, 040GS93414, 040GS93422, 040GS93429, 040GS93430, 040GS93433, 040GS93436, 040GS93440, 040GS93442, 040GS93446, 040GS93452, 040GS93612, 040GS93615, 040GS93619, 040GS93626, 040GS94916, 040GT63898, 040GV58863, 040GV58866, 040GV58869, 040GV58872, 040GV58877, 040GV58881, 040GV58885, 040GV58887, 040GV58892, 040GW69176, 040GW69182, 040GW69179, 040GW69188, 040GW69194, 040GW69200, 040GW69201, 040GW69205, 040GW69208, 040GW69893, 040GZ07377, 040GZ07877, 040GZ07880, 040GZ07884, 040GZ07886, 040GZ07888, 040GZ07911, 040GZ07974, 040GZ07979, 040LE25915, 040LE25917, 040LE25918, 040LE25923, 040LE25933, 040LE25935, 040LE26687, 040LE26688, 040LE26692, 040LE26702, 040LT33409, 040LT33410, 040LT33412, 040LT33414, 040LT33415, 040LT33416, 040LT33417, 040LT33418, 040LT33419, 040LT33422, 040LT33527, 040LT33545, 040LT33546, 040LT33547, 040LT33549, 040LT33550, 040LT33693, 040LT33694, 040LT33695, 040LT33698, 040LT33701, 040LT33702, 040LT33703, 040LT33704, 040LT33706, 040LT33710, 040LT33711, 040LT33714, 040LT33715, 040LT33717, 040LT33718, 040LT33719, 040LT33721, 040LT33723, 040LT33724, 040LT33725, 040LT33726, 040LT33727, 040LT34548, 040LT35176, 040LT35186, 040LT35189, 13 040LT35190, 040LT35510, 040LT35515, 040LT35516, 040LT35517, 040LT35521, 040LT35522, 040LT35527, 040LT35529, 040LT35531, 040LT35687, 040LT35175, 040LT35177, 040LT35514, 040LT35528, 040LT35678, 040LT35688, 040LX14916, 040LX14923, 040LX14926, 040LX15032, 040LX15038, 040LX15041, 040LX15051, 040LX15054, 040LX15356, 040LX15357, 040LX15359, 040LX15362, 040LX15364, 040LX15365, 040LX15369, 040LX15374, 040LX15380, 040LX15384, 040LX15386, 040LX15388, 040LX15390, 040LX15392, 040LX15394, 040LX15397, 040LX15400, 040LX15407, 040LX15409, 040LZ28726, 040LZ28743, 040LZ28752, 040LZ28775, 040LZ28779, 040LZ28792, 040GF84740, 040GF84751, 040GH85398, 040GN23718, 040GN23720, 040GS93409, 040GS93456, 040LX15057; 3) Units: 040FJ64918, 040FX39048, 040FX39058, 040FX39063, 040FX39067, 040GF84984, 040GG09338, 040GL17906, 040GL17916, 040GL17929, 040GR90719, 040GR90726, 040GR90733, 040GW69742, 040GX66776, 040GX66779, 040GX66788, 040KM06703, 040KM06709, 040KM06711, 040KN04151, 040KN04157, 040KN04159, 040KN04197, 040KN04204, 040KN04211, 040KN04214, 040LV15954, 040LV15955, 040LW35735, 040GS93980 (4 units); 4) Units: 040FC22037, 040FJ64621, 040FJ64633, 040FJ64637, 040FJ64658, 040FJ64892, 040FJ64894, 040FJ64902, 040FJ64908, 040FJ64914, 040FJ64915, 040FJ64919, 040FJ64926, 040FJ64927, 040FJ64932, 040FL40280, 040FV20582, 040FW41936, 040FW41939, 040FW41940, 040FW41941, 040FW42479, 040FW42487, 040FW42490, 040FW42500, 040FX39035, 040FX39042, 040FX39049, 040FX39055, 040FX39408, 040FX39417, 040FX39433, 040FY51452, 040FY51456, 040FY51459, 040FY52102, 040FY52104, 040FY52114, 040FY52119, 040FY52125, 040FY52466, 040FY52467, 040FY52469, 040FY52470, 040FY52472, 040FY52473, 040FY52479, 040FY52480, 040GE98073, 040GE98099, 040GE99374, 040GG08499, 040GH84584, 040GH84577, 040GH84590, 040GH84593, 040GH85242, 040GH85282, 040GH85299, 040GH85316, 040GH85535, 040GH85536, 040GH85538, 040GH85544, 040GH85546, 040GH85548, 040GH85553, 040GH85555, 040GH85565, 040GH85568, 040GH85571, 040GH85573, 040GH85575, 040GJ73393, 040GJ73415, 040GK73547, 040GK73548, 040GL18960, 040GM12591, 040GM12592, 040GM12594, 040GM12595, 040GM12596, 040GM12597, 040GM12600, 040GM12604, 040GR90699, 040GR90702, 040GR90705, 040GR90728, 040GS93945, 040GS93947, 040GS93962, 040GS93951, 040GS93960, 040GV59039, 040GW69565, 040GW69568, 040GW69570, 040GW69571, 040GW69730, 040GX66509, 040GX66751, 040GX66761, 040GX66763, 040KL07343, 040KL07347, 040KL07350, 040KL07361, 040KL07363, 040LT35670, 040LZ29379; 5) Units: 040FW42758, 040FY52488, 040FZ37556, 040FZ37561, 040FZ37565, 040GE99310, 040GE99315, 040GE99325, 040GE99329, 040GE99334, 040GJ73405, 040GJ73412, 040GM13773, 040GM13775, 040GM13778, 040GM13780, 040GM13805, 040GM13842, 040GM13845, 040GS93589, 040GS94705, 040GT64550, 040GW69873, 040GW69877, 040GW69879, 040GW69891, 040GW69893, 040GW69896, 040GW69898, 040GZ07974, 040GZ07982, 040GZ07986, 040LT35522, 040LT35670, 040FC22037, 040FC22044, 040FC22047, 040FC22073, 040FC22076, 040FC22078, 040FJ64621, 040FJ64625, 040FJ64633, 040FJ64637, 040FJ64658, 040FJ64892, 040FJ64906, 040FJ64908, 040FJ64914, 040FJ64915, 040FJ64919, 040FJ64926, 040FJ64927, 040FJ64932, 040FV20446, 040FW41936, 040FW41938, 040FW41939, 040FW41940, 040FW41941, 040FW41942, 040FW42490, 040FW42494, 040FW42495, 040FW42499, 040FX39035, 040FX39036, 040FX39048, 040FX39063, 040FX39067, 040FX39408, 040FY51452, 040FY51454, 040FY51456, 040FY51459, 040FY52102, 040FY52104, 040FY52106, 040FY52109, 040FY52114, 040FY52119, 040GE97390, 040GE97391, 040GE97395, 040GE97396, 040GE97397, 040GE97399, 040GE97404, 040GE97410, 040GE97420, 040GE97429, 040GE97473, 040GE97480, 040GE97491, 040GE97503, 040GE97523, 040GE97525, 040GE97544, 040GE97553, 040GE97556, 040GE98073, 040GF84688, 040GF84922, 040GF84972, 040GF84982, 040GG08086, 040GG08121, 040GG08511, 040GG09217, 040GG09222, 040GG09332, 040GG09338, 040GH85237, 040GH85242, 040GH85251, 040GH85387, 040GH85398, 040GH85399, 040GH85401, 040GH85420, 040GH85532, 040GH85538, 040GH85542, 040GH85544, 040GH85546, 040GK73550, 040GN23514, 040GN23531, 040GN23534, 040GN23705, 040GN23708, 040GN23713, 040GN23715, 040GN23720, 040GN23723, 040GN23730, 040GQ11139, 040GQ11151, 040GQ11190, 040GQ11229, 040GQ11232, 040GQ11249, 040GQ11261, 040GQ11275, 040GR90689, 040GR90694, 040GR90698, 040GR90699, 040GR90701, 040GR90702, 040GR90705, 040GR90711, 040GR90717, 040GR90719, 040GR90723, 040GR90726, 040GR90728, 040GR90733, 040GR90734, 040GR90738, 040GR91033, 040GR91039, 040GR91044, 040GR91046, 040GR91834, 040GS93377, 040GS93380, 040GS93391, 040GS93400, 040GS93403, 040GS93405, 040GS93409, 040GS93411, 040GS93414, 040GS93429, 040GS93433, 040GS93436, 040GS93440, 040GS93442, 040GS93446, 040GS93452, 040GS93601, 040GT63898, 040GV59017, 040GX66509, 040GX66520, 040GX66751, 040GX66754, 040GZ07377, 040LT33414, 040LT33727, 040LT35175, 040LT35176, 040LT35177, 040LT35189, 040LX15357, 040LX15359, 040LX15362, 040LX15384, 040LX15386, 040LX15394, 040LX15397, 040LX15400; 6) Units: 040GE99351, 040GS93961, 040GZ07926, 040LX15371, 040FW42760, 040GE99359, 040GZ07877, 040GZ07880, 040GZ07886, 040GZ07910, 040LT35509, 040LT35687, 040LT35688, 040FV20428, 040FY51460, 040FY52125, 040FY52135, 040GE97476, 040GF84984, 040GF84998, 040GG08101, 040GG09334, 040GH85276, 040GH85282, 040GH85291, 040GH85312, 040GM12937, 040GM12959, 040GQ11166, 040GQ11175, 040GQ11183, 040GR91036, 040GS93396, 040GS93962, 040GS93965, 040GV59020, 040GV59031, 040GV59035, 040GV59039, 040LE25935, 040LE26453, 040LE26455, 040LT33545, 040LT33723, 040LT33726, 040LT35190, 040LX15374, 040LX15375, 040LX15390, 040LX15392, 040LX15409; 7) Units: 040LT33695, 040LT33717, 040GH85425, 040GH85431, 040LT33714, 040LX15392, 040LX15409 RECALLING FIRM/MANUFACTURER American National Red Cross Heart of America Region, Peoria IL, by telephone on February 28, 2009 and letters dated March 6, 2009. Firm initiated recall is complete. REASON Blood products, collected in a manner that may have compromised the sterility of the units, were distributed. VOLUME OF PRODUCT IN COMMERCE 1,228 units DISTRIBUTION CT, GA, IL, KY, MD, MN, MO, NE, NJ, OH, PA, TN, WI, IA, AL ___________________________________ PRODUCT Platelets Pheresis Leukocytes Reduced. Recall # B-0936-10 CODE Unit: 154833198 (2 units) RECALLING FIRM/MANUFACTURER Recalling Firm: Blood Systems, Inc., Scottsdale, AZ, by letter dated December 26, 2007. Manufacturer: Blood Systems, Inc., Lubbock Center, Lubbock, TX. Firm initiated recall is complete. REASON Blood products, which were labeled as leukoreduced, but were not tested to verify white blood cell count, were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION TX ___________________________________ PRODUCT Red Blood Cells Leukocytes Reduced. Recall # B-0937-10 CODE Unit: 158307101 RECALLING FIRM/MANUFACTURER Recalling Firm: Blood Systems, Inc., Scottsdale, AZ, by letter dated December 26, 2007. Manufacturer: Blood Systems, Inc., Lubbock Center, Lubbock, TX. Firm initiated recall is complete. REASON Blood product, collected from a donor taking the medication Methotrexate, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION TX ___________________________________ PRODUCT Source Plasma. Recall # B-0940-10 CODE Units: TA2116335, TA2117150, TA2117722, TA2122331, TA2122648, TA2122997, TA2123393, TA2123754, TA2124490, TA2124830, TA2125357, TA2125580, TA2126755, TA2126924, TA2152311, TA2153097, TA2153570, TA2156097, TA2156360, TA2156841, TA2157014, TA2157741, TA2157989, TA2158463, TA2158771, TA2159323, TA2159636, TA2160119, TA2160428, TA2160894, TA2161686, TA2161899, TA2162263, TA2162493, TA2168627, TA2169090, TA2169350, TA2169804, TA2170153, TA2170506, TA2170817, TA2172249, TA2172467, TA2172866, TA2173118, TA2173607, TA2173797, TA2174295, TA2174497 RECALLING FIRM/MANUFACTURER Recalling Firm: DCI Biologicals Texarkana LLC, Gallup, NM, by e-mail, facsimile, and letter on July 14, 2008. Manufacturer: DCI Biologicals Texarkana, LLC, Texarkana, AR. Firm initiated recall is complete. REASON Blood products, collected from a donor with a history of intravenous (IV) drug use, were distributed. VOLUME OF PRODUCT IN COMMERCE 49 units DISTRIBUTION England ___________________________________ PRODUCT Source Plasma. Recall # B-0941-10 CODE Units: TA2096960, TA2097400, TA2097886, TA2098088, TA2098563, TA2098839, TA2099376, TA2099607, TA2100253, TA2100564, TA2100970, TA2101419, TA2101865, TA2102055, TA2102483, TA2102892, TA2103425, TA2103613, TA2104142, TA2104533, TA2105677, TA2106040, TA2106501, TA2106950, TA2107483, TA2107829, TA2108527, TA2108876, TA2109396, TA2109644, TA2110222, TA2110414, TA2111039, TA2111361, TA2111798, TA2112148, TA2112569, TA2112997, TA2113421, TA2113792, TA2114211, TA2114623, TA2114967, TA2115584, TA2115779, TA2116313, TA2116589, TA2118202, TA2118606, TA2118984, TA2119342, TA2119569, TA2120063, TA2120360, TA2120645, TA2121209, TA2121354, TA2121841, TA2122101, TA2122585, TA2122847, TA2123335, TA2123550, TA2124104, TA2124317, TA2124801, TA2126217, TA2126523, TA2127038, TA2127206, TA2127786, TA2128075, TA2128730, TA2129090, TA2129655, TA2129802, TA2130330, TA2130737, TA2131315, TA2131647, TA2132264, TA2132585 RECALLING FIRM/MANUFACTURER Recalling Firm: DCI Biologicals Texarkana LLC, Gallup, NM, by e-mail, facsimile, and letter dated July 16, 2008. Manufacturer: DCI Biologicals Texarkana, LLC, Texarkana, AR. Firm initiated recall is complete. REASON Blood products, collected from a donor with a history of being stuck with a dirty needle, were distributed. VOLUME OF PRODUCT IN COMMERCE 82 units DISTRIBUTION England ___________________________________ 14 PRODUCT Source Plasma, Recall # B-0967-10 CODE Units: TA0001771, TA0001853, TA0002016, TA0002191, TA0002541, TA0002752, TA0003267, TA0003958, TA0004091, TA0005462, TA0005604, TA0005891, TA0005993, TA0006221, TA0006362, TA0006587, TA0007471, TA0007571, TA0007802, TA0007907, TA0008243, TA0008354, TA0009535, TA0009674, TA0009964, TA0010106, TA2082273, TA2082864, TA2082997, TA2083547, TA2083790, TA2084182, TA2084388, TA2084839, TA2085268, TA2085681, TA2091101, TA2091651, TA2121282, TA2121504, TA2122082, TA2122230, TA2122658, TA2122904, TA2123340, TA2123643, TA2124176, TA2124371, TA2125030, TA2125302, TA2125735, TA2126385, TA2127604, TA2128014, TA2128863, TA2133032, TA2137021, TA2137865, TA2138788, TA2139170, TA2139596, TA2140023, TA2140521, TA2140809, TA2141235, TA2141675, TA2142088, TA2142454, TA2142990, TA2143484, TA2145094, TA2147140, TA2147759, TA2147982, TA2148541, TA2148809, TA2149347, TA2149640, TA2150286, TA2150655, TA2151236, TA2151530, TA2152078, TA2152435, TA2152929, TA2153213, TA2153675, TA2154353, TA2154695, TA2156102, TA2156386, TA2156937, TA2157019, TA2157554, TA2157691, TA2158248, TA2158554, TA2159059, TA2159326, TA2159988, TA2161833, TA2161983, TA2163445, TA2163682, TA2164053, TA2164439, TA2164735, TA2166498, TA2166673, TA2167524, TA2167951, TA2168236, TA0010463, TA0010660, TA0010873, TA0011081, TA0011373, TA0011512, TA0011770, TA0011899, TA0012233, TA0012380, TA0012658, TA2000743, TA2002067, TA2005366, TA2005456, TA2005739, TA2005865, TA2006117, TA2006262, TA2006598, TA2006816, TA2006963, TA2007212, TA2007366, TA2007598, TA2007830, TA2008080, TA2008301, TA2008481, TA2008750, TA2040447, TA2040773, TA2041012, TA2041327, TA2041669, TA2042024, TA2042376, TA2042657, TA2043131, TA2043531, TA2043869, TA2044262, TA2044828, TA2045124, TA2045484, TA2045671, TA2046025, TA2046221, TA2046584, TA2046827, TA2047125, TA2047419, TA2047755, TA2048060, TA2048410, TA2048741, TA2049067, TA2049388, TA2049780, TA2049980, TA2050441, TA2050646, TA2051124, TA2051302, TA2051787, TA2051967, TA2052391, TA2052610, TA2053081, TA2053236, TA2053754, TA2053986, TA2054428, TA2054601, TA2055070, TA2055154, TA2055732, TA2055938, TA2056529, TA2056808, TA2057165, TA2057538, TA2057971, TA2058170, TA2058791, TA2059048, TA2059555, TA2059756, TA2060185, TA2060480, TA2061078, TA2061243, TA2061725, TA2061995, TA2062442, TA2062722, TA2063169, TA2063441, TA2063946, TA2064222, TA2064801, TA2065074, TA2065472, TA2065757, TA2066223, TA2066559, TA2066976, TA2067271, TA2067886, TA2068061, TA2068622, TA2068767, TA2069323, TA2069504, TA2069958, TA2070293, TA2070716, TA2070978, TA2071457, TA2071720, TA2072170, TA2072418, TA2072916, TA2073156, TA2073711, TA2073917, TA2074364, TA2074761, TA2077162, TA2077705, TA2078000, TA2078424, TA2078632, TA2079107, TA2079764, TA2080030, TA2080367, TA2080581, TA2080890, TA2081735, TA2082014 RECALLING FIRM/MANUFACTURER Recalling Firm: DCI Biologicals Texarkana LLC, Gallup, NM, by e-mail, facsimile, and letter on July 9, 2008 and July 14, 2008. Manufacturer: DCI Biologicals Texarkana, LLC, Texarkana, AR. Firm initiated recall is complete. REASON Blood products, collected from a donor with a history of high-risk behavior, were distributed. VOLUME OF PRODUCT IN COMMERCE 253 units DISTRIBUTION NC, England, Austria ___________________________________ PRODUCT 1) Plasma Frozen. Recall # B-0970-10; 2) Red Blood Cells Leukocytes Reduced. Recall # B-0971-10 CODE 1) Units: 53R41729, 2) Units: 53R41729, 53FN20097 RECALLING FIRM/MANUFACTURER American National Red Cross-Greater Chesapeake & Potomac Region, Baltimore, MD, by electronic notification on July 18, 2007 and by letter dated July 20, 2007. Firm initiated recall is complete. REASON Blood products, collected from a donor for whom donor suitability was not adequately determined, were distributed. VOLUME OF PRODUCT IN COMMERCE 3 units DISTRIBUTION D.C., MD ___________________________________ PRODUCT 1) Red Blood Cells, Leukocytes Reduced. Recall # B-0976-10; 2) Platelets, Pooled, Leukocytes Reduced. Recall # B-0977-10; 3) Plasma Frozen Within 24 hours (FP24). Recall # B-0978-10 CODE 1) and 3) Unit: 13GV90319; 2) Pool #576 (containing units 13GV90319, 13GV90314, 13GV90325, 13KF14788, 13KF14801) RECALLING FIRM/MANUFACTURER American Red Cross Southeastern Michigan Region, Detroit, MI, by telephone on August 21, 2008 and by letter dated September 5, 2008. Firm initiated recall is complete. REASON Blood products, collected from a donor for whom donor suitability was not adequately determined, were distributed. VOLUME OF PRODUCT IN COMMERCE 3 units DISTRIBUTION MI, OH ___________________________________ PRODUCT 1) Red Blood Cells Leukocytes Reduced. Recall # B-0993-10; 2) Fresh Frozen Plasma. Recall # B-0994-10; 3) Platelets, Leukocytes Reduced. Recall # B-0995-10 CODE 1) Units: 13GV53916 and 13GX96049; 2) and 3) Unit: 13GX96049 RECALLING FIRM/MANUFACTURER American Red Cross Southeastern Michigan Region, Detroit, MI, by telephone on November 5, 2007 and follow-up letter dated November 21, 2007. Firm initiated recall is complete. REASON Blood products, which were collected from a donor who had medical history of hepatitis A, were distributed. VOLUME OF PRODUCT IN COMMERCE 4 units DISTRIBUTION MI, OH ___________________________________ PRODUCT Red Blood Cells Leukocytes Reduced. Recall # B-0996-10 CODE Unit: 18GX17549 RECALLING FIRM/MANUFACTURER American National Red Cross Great Lakes Region, Lansing, MI, by telephone on January 15, 2008 and by follow-up letter dated January 23, 2008. Firm initiated recall is complete. REASON Blood product, collected from a donor who did not meet acceptance criteria during donor screening process, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION MI ___________________________________ PRODUCT Source Plasma. Recall # B-0997-10 CODE Units: 4150064695, 4150065189, 4150063943, 4150063597, 4150069709, 4150067080 RECALLING FIRM/MANUFACTURER CSL Plasma, Inc., Wichita, KS, by letter on October 8, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor who received a tattoo within 12 months of donating, were distributed. VOLUME OF PRODUCT IN COMMERCE 6 units DISTRIBUTION Germany, IL ___________________________________ PRODUCT Source Plasma. Recall # B-1000-10 CODE Units: MQ073496, MQ072824 RECALLING FIRM/MANUFACTURER Plasma Biological Services Inc., Columbia, MO, by fax on October 26, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION NC ___________________________________ PRODUCT Red Blood Cells Leukocytes Reduced. Recall # B-1007-10 CODE Unit: 2230346 RECALLING FIRM/MANUFACTURER Suncoast Communities Blood Bank, Inc., Sarasota, FL, by fax on August 25, 2008. Firm initiated recall is complete. REASON Blood product, which tested reactive for syphilis, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION 15 FL ___________________________________ PRODUCT 1) Red Blood Cells. Recall # B-1031-10; 2) Platelets. Recall # B-1032-10; 3) Fresh Frozen Plasma. Recall # B-1033-10 CODE 1), 2), and 3) Unit: W288009006203 RECALLING FIRM/MANUFACTURER Lifesource, Glenview, IL, by facsimile on September 23, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor who was taking the medication Coumadin, were distributed. VOLUME OF PRODUCT IN COMMERCE 3 units DISTRIBUTION PA, IL ___________________________________ PRODUCT Source Plasma. Recall # B-1048-10 CODE Units: 4070160340, 4070156647, 4070144029, 4070143655 RECALLING FIRM/MANUFACTURER CSL Plasma Inc., Chattanooga, TN, by letter dated November 9, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor who was previously deferred for testing reactive for the hepatitis C virus (HCV), were distributed. VOLUME OF PRODUCT IN COMMERCE 4 units DISTRIBUTION Germany, IL ___________________________________ ______________________ PRODUCT Recovered Plasma. Recall # B-0767-10 CODE Unit: 003E68576 RECALLING FIRM/MANUFACTURER Recalling Firm: The American National Red Cross, Douglasville, GA, by facsimile and electronic (LOGIC) on November 28, 2007 and by letter on November 29, 2007. Manufacturer: The American National Red Cross – Southern Region, Douglasville, GA. Firm initiated recall is complete. REASON Blood product, collected from a donor for whom donor suitability was not adequately determined, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION CA ___________________________________PRODUCT Red Blood Cells (Apheresis) Leukocytes Reduced. Recall # B-0670-10 CODE Unit: 017FS61854 RECALLING FIRM/MANUFACTURER The American National Red Cross - North Central Region, Saint Paul, MN, by fax on March 11, 2009. Firm initiated recall is complete. REASON Blood product, collected from a previously deferred donor, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION MA ___________________________________ PRODUCT Recovered Plasma. Recall # B-0767-10 CODE Unit: 003E68576 RECALLING FIRM/MANUFACTURER Recalling Firm: The American National Red Cross, Douglasville, GA, by facsimile and electronic (LOGIC) on November 28, 2007 and by letter on November 29, 2007. Manufacturer: The American National Red Cross – Southern Region, Douglasville, GA. Firm initiated recall is complete. REASON Blood product, collected from a donor for whom donor suitability was not adequately determined, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION CA ___________________________________ PRODUCT Red Blood Cells (Apheresis) Leukocytes Reduced. Recall # B-0945-10 CODE Units: 152026052 (2 units) RECALLING FIRM/MANUFACTURER Recalling Firm: Blood Systems, Inc., Scottsdale, American Samoa, AZ, by facsimile on February 18, 2008. Manufacturer: Blood Systems, Inc - Lubbock Center, Lubbock, TX. Firm initiated recall is complete. REASON Blood products, for which the documentation of the apheresis procedure was incomplete, were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION TX ___________________________________ PRODUCT 1) Red Blood Cells Leukocytes Reduced Irradiated. Recall # B-1077-10; 2) Red Blood Cells Leukocytes Reduced. Recall # B-1078-10 CODE 1) Unit: W230809609236; 2) Units: W230809204317; W230809306667 RECALLING FIRM/MANUFACTURER Coastal Bend Blood Center, Corpus Christi, TX, by fax on August 19, 2009 and January 21, 2010. Firm initiated recall is complete. REASON Blood products, with unacceptably high hematocrits, were distributed. VOLUME OF PRODUCT IN COMMERCE 3 units DISTRIBUTION TX ___________________ April 21 ___________________ PRODUCT Red Blood Cells (Apheresis) Leukocytes Reduced. Recall # B-0934-10 CODE Units: 004FQ10855P1; 004FQ10855P2; 004FQ10856P1; 004FQ10856P2; 004FQ10857P1; 004FQ10858P1; 004FQ10858P2; 004FQ10859P1; 004FQ10859P2; 004FQ10881P1; 004FQ10881P2; 004FQ10884P1; 004FQ10884P2; 004KG39729P1; 004KG39730P1; 004KG39730P2; 004KG39731P1; and 004KG39731P2 RECALLING FIRM/MANUFACTURER Recalling Firm: ARC Blood Services, New England Region, Dedham, MA, by facsimile and telephone on November 03, 2009 and by facsimile on November 13, 2009. Manufacturer: ARC/Manchester, NH, Manchester, NH. Firm initiated recall is complete. REASON Blood products, collected in a manner that may compromise the sterility of the product, were distributed VOLUME OF PRODUCT IN COMMERCE 18 units DISTRIBUTION ME, NY, MA ___________________________________ PRODUCT 1) Red Blood Cells Leukocytes Reduced. Recall # B-1040-10; 2) Fresh Frozen Plasma. Recall # B-1041-10; 3) Recovered Plasma. Recall # B-1042-10 CODE 1) Units: 2874420, 1645967; 2) Unit: 1645967; 3) Unit: 2874420 RECALLING FIRM/MANUFACTURER Hoxworth Blood Center, University of Cincinnati UC Medical Center, Cincinnati, OH, by letter dated September 28, 2007. Firm initiated recall is complete. REASON Blood products, collected from a donor with a history of high risk behavior, were distributed. VOLUME OF PRODUCT IN COMMERCE 4 units DISTRIBUTION OH, CA ___________________________________ PRODUCT Platelets Pheresis Leukocytes Reduced. Recall # B-1087-10 CODE Unit: 54KP35450 RECALLING FIRM/MANUFACTURER American National Red Cross, Rio Piedras, PR, by telephone on October 16, 2009 and follow up letters on October 21, 2009 and November 23, 2009. Firm initiated recall is complete. REASON Blood product, collected from a donor who had taken aspirin, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION PR ___________________________________ 16 PRODUCT 1) Fresh Frozen Plasma. Recall # B-1088-10; 2) Red Blood Cells Leukocytes Reduced. Recall # B-1090-10 CODE 1) Unit: 2595901; 2) Units: 2595901; 9189067 RECALLING FIRM/MANUFACTURER Central Kentucky Blood Center Inc., Lexington, KY, by letter dated October 20, 2009. REASON Blood products, collected from a donor taking the drug Finasteride, were distributed. VOLUME OF PRODUCT IN COMMERCE 3 units DISTRIBUTION KY ___________________________________ PRODUCT Red Blood Cells Leukocytes Reduced. Recall # B-1091-10 CODE Units: 5030666; 5031177; 5032980; 5033699 RECALLING FIRM/MANUFACTURER Blood Bank of Alaska, Inc., Anchorage, AK, by letter dated September 21, 2009. Firm initiated recall is complete REASON Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed. VOLUME OF PRODUCT IN COMMERCE 4 units DISTRIBUTION AK ___________________________________ PRODUCT Red Blood Cells Leukocytes Reduced. Recall # B-1092-10 CODE Units: W036309506746T; W036309535586N RECALLING FIRM/MANUFACTURER BloodCenter of Wisconsin, Inc., Milwaukee, WI, by fax on November 13, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor who reported travel to a malarial endemic area, were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION WI ___________________________________ PRODUCT Recovered Plasma. Recall # B-1096-10 CODE Unit: W070509321267 RECALLING FIRM/MANUFACTURER Stanford Medical School Blood Center, Palo Alto, CA, by electronic delivery note on October 29, 2009. Firm initiated recall is complete. REASON Blood product, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION RI ___________________________________ PRODUCT 1) Red Blood Cells. Recall # B-1097-10; 2) Fresh Frozen Plasma. Recall # B-1098-10 CODE 1) and 2) W010009006247 RECALLING FIRM/MANUFACTURER Department Of The Army, Armed Services Blood Bank Center, Tacoma, WA, by fax on November 6, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION NJ ___________________________________ PRODUCT Source Plasma. Recall # B-1108-10 CODE Unit: 366116208 RECALLING FIRM/MANUFACTURER Talecris Plasma Resources, Inc., Colorado Springs, CO, by Special Investigation Protocol- Final Report, dated August 15, 2008. Firm initiated recall is complete. REASON Blood product, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION NC ___________________________________ PRODUCT 1) Cryoprecipitated AHF. Recall # B-1124-10; 2) Fresh Frozen Plasma. Recall # B-1125-10; 3) Red Blood Cells Leukocytes Reduced. Recall # B-1126-10; 4) Recovered Plasma. Recall # B-1127-10 CODE 1) and 4) Unit: KL19746; 2) Unit: KL21504; 3) Units: KL19746 and KL21504; RECALLING FIRM/MANUFACTURER BloodCenter of Wisconsin, Inc., Milwaukee, WI, by facsimile on April 11, 2007. Firm initiated recall is complete. REASON Blood products, that tested negative for hepatitis, but were collected from an ineligible donor due to a history of jaundice, were distributed. VOLUME OF PRODUCT IN COMMERCE 5 units DISTRIBUTION WI ___________________________________ PRODUCT Source Plasma. Recall # B-1136-10 CODE Unit: 370084735 RECALLING FIRM/MANUFACTURER Talecris Plasma Resources, Inc., Salem, OR, by fax on May 16, 2008. Firm initiated recall is complete. REASON Blood product, collected using an abbreviated screening process, for which the donor was not eligible, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION NC ___________________________________ PRODUCT Source Plasma. Recall # B-1137-10 CODE Unit: 391051788 RECALLING FIRM/MANUFACTURER Talecris Plasma Resources, Inc., N Las Vegas, NV, by fax on March 06, 2008. Firm initiated recall is complete. REASON Blood product, collected using an abbreviated screening process, for which the donor was not eligible, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION NC ___________________________________ PRODUCT Source Plasma. Recall # B-1141-10 CODE Units: 366121102, 366120336, 366120086, 366122436, 366122238, 366121399 RECALLING FIRM/MANUFACTURER Talecris Plasma Resources, Inc., Colorado Springs, CO, by Special Investigation Protocol - Final Report dated August 15, 2008. Firm initiated recall is complete. REASON Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed. VOLUME OF PRODUCT IN COMMERCE 6 units DISTRIBUTION NC ___________________________________ PRODUCT 1) Red Blood Cells (Apheresis) Leukocytes Reduced. Recall # B-0981-10; 2) Red Blood Cells Leukocytes Reduced. Recall # B-0982-10; 3) Red Blood Cells (Apheresis) Leukocytes Reduced Irradiated. Recall # B-0983-10 CODE 1) Unit: 53E29469; 2) Units: 53FX31502, 53FL58865, 53FP65544, 53V54812, 53T21073, 53FQ15579; 3) Unit: 53FC81282 RECALLING FIRM/MANUFACTURER American National Red Cross-Greater Chesapeake & Potomac Region, Baltimore, MD, by telephone on November 3, 2007 and by letter dated November 8, 2007. Firm initiated recall is complete. REASON Blood products, tested for red cell antigens using equipment for which the daily quality control testing was not performed, were distributed. VOLUME OF PRODUCT IN COMMERCE 8 units 17 DISTRIBUTION MD, VA ___________________________________ PRODUCT Red Blood Cells (Apheresis) Leukocytes Reduced. Recall # B-1142-10 CODE Units: 8996458 (part 1 and 2), 5817416 (part 1 and 2), 5802144 (part 1 and 2), 8995282 (part 1 and 2), 5817826 (part 1 and 2), 1941878 (part 1 and 2), 1943429 (part 1 and 2), 1944787 (part 1 and 2), 8314196 (part 1 and 2), 1947317 (part 1 and 2), 1944450 (part 1 and 2), 1941930 (part 1 and 2) RECALLING FIRM/MANUFACTURER Florida Georgia Blood Alliance, Inc., Jacksonville, FL, by letter dated September 06, 2005. Firm initiated recall is complete. REASON Blood products, for which the quality control testing for total component hemoglobin was not performed, were distributed. VOLUME OF PRODUCT IN COMMERCE 24 units DISTRIBUTION FL __________________________________ April 28 __________________________________ No Report __________________________________ May 5 __________________________________ PRODUCT 1) Platelets Pheresis Leukocytes Reduced Irradiated. Recall # B-1036-10 2) Platelets Pheresis Leukocytes Reduced. Recall # B-1037-10 CODE 1) Unit: W038309117129; 2) Unit: W038309084232 (2 units) RECALLING FIRM/MANUFACTURER Mississippi Valley Reg Building Center, Davenport, IA, by telephone and facsimile on November 4, 2009 and by letter dated November 6, 2009. Firm initiated Recall is complete. REASON Blood products, which were labeled as leukoreduced, but were not tested to verify white blood cell count, were distributed. VOLUME OF PRODUCT IN COMMERCE 3 units DISTRIBUTION NC, MO ___________________________________ PRODUCT Red Blood Cells Leukocytes Reduced. Recall # B-1039-10 CODE Unit: 2008353 RECALLING FIRM/MANUFACTURER Upstate New York Transplant Services, Inc., Buffalo, NY, by telephone and facsimile on November 12, 2009. Firm initiated recall is complete. REASON Blood product, collected from a donor with a history of hepatitis B, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION NY ___________________________________ PRODUCT Source plasma. Recall # B-1068-10 CODE Units 0411156741, 0411149824, 0411147516, 0411146603, 0411132985, 0411122483, 0411121510, 0411121015, 0411119855, 0411119141, 0411117883, 0411117172, 0411115511, 0411113286, 0411112530, 0411098824, 0411091243, 0411090486, 0411088698, 0411088255, 0411086884, 0411085937, 0411085285, 0411075986, 0411098014, 0411097229, 0411096314, 0411095439, 0411094704, 0411093698, 0411092841, 0411092039 RECALLING FIRM/MANUFACTURER ZLB Bioplasma, Inc., Oak Park, MI, by facsimile on or about March 18, 2007. Firm initiated recall is complete. REASON Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD) were distributed. VOLUME OF PRODUCT IN COMMERCE 32 units DISTRIBUTION NC, Germany and Switzerland ___________________________________ PRODUCT 1) Fresh Frozen Plasma. Recall # B-1116-10; 2) Red Blood Cells Leukocytes Reduced. Recall # B-1117-10; 3) Platelets Pheresis Leukocytes Reduced. Recall # B-1118-10; 4) Fresh Frozen Plasma Pheresis. Recall # B-1120-10; 5) Platelets Pheresis Leukocytes Reduced Irradiated. Recall # B-1121-10; 6) Red Blood Cells Pheresis Leukocytes Reduced. Recall # B-1122-10; 7) Plasma Frozen Within 24 hours (FP24). Recall # B-1123-10 CODE 1) Units: 158322668, 158326591, 158326705, 158327268; 2) Units: 157031049, 157031052, 157031057, 157031134, 157031135, 157035112, 157035172, 157035178, 157035185, 157035192, 157035194, 157035241, 157035247, 157035318, 157035328, 157035437, 157035438, 157035440, 157035445, 157035446, 157035449, 157035452, 157037094, 157037097, 157037109, 157037115, 157037177, 157037181, 157037183, 157037189, 157037194, 157037275, 157037277, 157037281, 157037540, 157040402, 157040409, 157040412, 157040414, 157040415, 157040681, 157040697, 157040703, 157041436, 157041479, 157041481, 157041525, 157041546, 157041748, 157041752, 157041756, 157043405, 157043409, 157043416, 157043468, 157043470, 157043486, 157043623, 157043631, 157043633, 157043634, 157043849, 157043870, 157045495, 157045543, 157045546, 157046225, 157046230, 157046233, 157046236, 157046240, 157046243, 157047055, 158327342, 158327347, 158327348, 158327350, 158327352, 158327354, 158327356, 157031202, 157031204, 157031213, 157031214, 157031215, 157031216, 157031261, 157031275, 158322668, 158322761, 158322762, 158325111, 158325116, 158325122, 158325124, 158325126, 158325128, 158325367, 158325368, 158325380, 158325382, 158325860, 158325868, 158325878, 158325890, 158326251, 158326264, 158326277, 158326282, 158326451, 158326517, 158326528, 158326531, 158326537, 158326539, 158326544, 158326546, 158326591, 158326705, 158326719, 158326722, 158326758, 158327017, 158327070, 158327077, 158327080, 158327081, 158327220, 158327225, 158327240, 158327241, 158327244, 158327247, 158327249, 158327255, 158327262, 158327265, 158327268, 157035026, 157035137, 157035182, 157040671, 157040684, 157040689, 157045412, 158327079, 158327132; 3) Units: 157031040, 157031082, 157031139 (2 units), 157037262, 157040661 (2 units), 157040695 (2 units), 157041634, 157041649 (3 units), 157041650 (2 units), 157043841 (3 units), 158322607, 158322621 (2 units), 158322736, 158327012, 158327014 (2 units), 158327124 (2 units), 158327131 (2 units), 158327179, 158327180, 157043838, 158322677; 4) Units: 157037254 (2 units), 157031055, 157035031, 157041634, 158327012, 158327179, 158327180; 5) Units: 157035031, 157043838, 158322677; 6) Units: 157035323 (2 units), 157035329 (2 units), 157035433 (2 units), 157035441 (2 units), 157037254, 157037576 (2 units), 157037591 (2 units), 157040404 (2 units), 157041421 (2 units), 157043403 (2 units), 157043625 (2 units), 157043698 (2 units), 158325370 (2 units), 158326252 (2 units), 158326446 (2 units), 158326513 (2 units), 158326714 (2 units), 157035026, 157035137, 157035182, 157040661, 157040671, 157040684, 157040689, 157045412, 158327014, 158327079, 158327124, 158327126, 158327132, 158327179, 158327180; 7) Units: 157035241, 157037094, 157037097, 157037109, 157037115, 157043409, 157043416, 157043633, 157043634 RECALLING FIRM/MANUFACTURER Recalling Firm: Blood Systems, Inc., Scottsdale, AZ, by facsimile on April 18, 2007 and by letter dated May 18, 2007. Manufacturer: United Blood Services - San Angelo, San Angelo, TX. Firm initiated recall is complete. REASON Blood products, collected from donors for whom donor suitability was not adequately determined, were distributed. VOLUME OF PRODUCT IN COMMERCE 252 units DISTRIBUTION NY, NM, TX, MS, AR, England, Switzerland ___________________________________ PRODUCT 1) Red Blood Cells Leukocytes Reduced. Recall # B-1131-10; 2) Fresh Frozen Plasma. Recall # B-1132-10 CODE 1) and 2) Unit: W04190902807D RECALLING FIRM/MANUFACTURER Blood Systems, Inc., Reno, NV, by facsimile on November 2, 2009 and by letter dated December 14, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor with a history of hepatitis A, were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION UK, NV ___________________________________ 18 PRODUCT Source Plasma. Recall # B-1133-10 CODE Unit: 09SWIG2570 RECALLING FIRM/MANUFACTURER BioLife Plasma Services LLC, Sheboygan, WI, by facsimile on November 20, 2009. Firm initiated recall is complete. REASON Blood product, collected from a donor who did not have a physical exam, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION Austria ___________________________________ PRODUCT Source Plasma. Recall # B-1134-10 CODE Unit: 09FNCE8448 RECALLING FIRM/MANUFACTURER BioLife Plasma Services L.P., Fayetteville, NC, by facsimile on October 23, 2009. Firm initiated recall is complete. REASON Blood product, collected from a donor who did not have a physical exam, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION CA ___________________________________ PRODUCT Source Plasma. Recall # B-1135-10 CODE Unit: 09SWIA2419 RECALLING FIRM/MANUFACTURER BioLife Plasma Services LLC, Sheboygan, WI, by facsimile on October 27, 2009. Firm initiated recall is complete. REASON Blood product, collected from a donor who did not have a physical exam, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION Austria ___________________________________ PRODUCT Platelets Pheresis Leukocytes Reduced. Recall # B-1051-10 CODE 53GK51109 (Parts 1, 2, and 3), 53GK51106 (Parts 1, 2, and 3), 53GK51103 (Part 3) RECALLING FIRM/MANUFACTURER America National Red Cross-Greater Chesapeake & Potomac Reg., Baltimore, MD, by telephone on September 4, 2007 and by letter dated November 5, 2007. Firm initiated recall is complete. REASON Blood products, which were not tested for platelet yield, were distributed. VOLUME OF PRODUCT IN COMMERCE 7 units DISTRIBUTION MD ___________________________________ PRODUCT Recovered Plasma. Recall # B-1119-10; CODE Units: 157031134, 157031135, 157031202, 157031204, 157031213, 157031214, 157031215, 157031216, 157035318, 157037275, 157037277, 157037281, 157037540, 157040402, 157040409, 157040412, 157040415, 157040681, 157041479, 157043405, 157043486, 157043870, 158322762, 158325111, 158325116, 158325122, 158325124, 158325126, 158325128, 158325367, 158325368, 158325380, 158325382, 158325860, 158325868, 158325878, 158325890, 158326251, 158326264, 158326277, 158326282, 158326451, 158326517, 158326528, 158326531, 158326537, 158326539, 158326544, 158326546, 158326719, 158326722, 158326758, 158327017, 158327070, 158327077, 158327080, 158327081, 158327220, 158327225, 158327240, 158327241, 158327244, 158327247, 158327249, 158327255, 158327350, 158327352, 158327354, 157031049, 157031052, 157031057, 157035112, 157035172, 157035178, 157035185, 157035192, 157035194, 157035437, 157035438, 157035440, 157035445, 157035446, 157035449, 157035452, 157037177, 157037181, 157037183, 157037189, 157037194, 157041525, 157041748, 157041752, 157041756, 158327342, 158327347, 158327348, 158327356 RECALLING FIRM/MANUFACTURER Recalling Firm: Blood Systems, Inc., Scottsdale, AZ, by facsimile on April 18, 2007 and by letter dated May 18, 2007. Manufacturer: United Blood Services - San Angelo, San Angelo, TX. Firm initiated recall is complete. REASON Blood products, collected from donors for whom donor suitability was not adequately determined, were distributed. VOLUME OF PRODUCT IN COMMERCE 97 units DISTRIBUTION NY, NM, TX, MS, AR, England, Switzerland _______________________ May 12 _______________________ PRODUCT 1) Platelets Pheresis Leukocytes Reduced. Recall # B-1144-10; 2) Red Blood Cells Leukocytes Reduced. Recall # B-1145-10 3) Red Blood Cells (Apheresis) Leukocytes Reduced. Recall # B-1146-10; 4) Red Blood Cells. Recall # B-1147-10 CODE 1) 9882855 (part b and c), 9876902, 9878395, 9878394 (part a and b), 9884646, 9884642, 5237081, 9885208 (part a, b and c), 9885205, 9882765 (part a, b and c), 9885203, 9932172, 9932227; 2)Units: 4990797, 5238698, 4973455, 4973460, 497349, 4987780, 4987781, 4960348, 5233807, 4960359, 4960349, 4960344, 5233827, 4987178, 4987776, 4997524, 4997575, 4997525, 4997578, 4987185, 4997574, 5235495, 4987184, 4994336, 4994314, 4994330, 4993835, 4993831, 4993830, 4994329, 5235498, 5234245, 5234242, 4994328, 4994317, 4981389, 5236688, 4985719, 5238723, 4985859, 4985830, 5237628, 4985858, 5237625, 5237629, 5238731, 5237611, 4982010, 5238711, 4981114, 4982002, 4982001, 5237612, 5237817, 4990801, 5238707, 5238713, 4990798, 7228345, 4994319, 5236297, 5235490, 4994326, 4985835, 5236295, 5236293, 5236296, 5236294, 5232393, 5232402, 5232399, 5232400, 5232395, 5232396, 5232394, 728365, 7228364, 7228393, 7228661; 3) Units: 9884637 (part 1 and 2), 9884038 (part 1 and 2), 9884039 (part 1 and 2); 4) Unit: 9051913 RECALLING FIRM/MANUFACTURER Florida's Blood Centers, Inc., Orlando, FL, by telephone on June 26, 2006. Firm initiated recall is complete. REASON Blood products, not tested for HIV and HCV NAT, were distributed. VOLUME OF PRODUCT IN COMMERCE 105 units DISTRIBUTION FL ___________________________________ PRODUCT Red Blood Cells Apheresis, Leukocytes Reduced, Irradiated. Recall # B-1150-10 CODE Units: 38C14502, 38C21609, 38C28703, 38FK38377, 38FM66963, 38FV36816, 38KT34643, 38KT40423, 38KT40430, 38KT45599, 38KW00793, 38KW04397, 38KW08996, 38KW09458, 38KW16238, 38LC95517 RECALLING FIRM/MANUFACTURER American National Red Cross Indiana-Ohio Region, Fort Wayne, IN, by telephone on January 30, 2007 and by follow-up letter dated January 30, 2007. Firm initiated recall is complete. REASON Red Blood Cells, mislabeled with an extended expiration date, were distributed. VOLUME OF PRODUCT IN COMMERCE 16 units DISTRIBUTION IN ___________________________________ PRODUCT Source Plasma. Recall # B-1151-10 CODE Units: LC0516598, LC0516908, LC0517538, LC0517781, LC0518554, LC0518735, LC0519382, LC0519544, LC0520194, LC0520398, LC0528587, LC0528968, LC0529253, LC0529769 RECALLING FIRM/MANUFACTURER Las Cruces Biologicals LLC, Las Cruces, NM, by letter dated March 15, 2007. Firm initiated recall is complete. REASON Source Plasma, collected from an ineligible donor, was distributed. VOLUME OF PRODUCT IN COMMERCE 8.769 Liters (14 units) DISTRIBUTION NY, CA ___________________________________ PRODUCT Red Blood Cells, Leukocytes Reduced. B-1152-10 CODE Units 38GZ07400 (split unit) RECALLING FIRM/MANUFACTURER American National Red Cross Indiana-Ohio Region, Fort Wayne, IN, by telephone on December 28, 2006. Firm initiated recall is complete. REASON Blood products, collected from an ineligible donor, were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION IN ___________________________________ 19 PRODUCT 1) Red Blood Cells Leukocytes Reduced. Recall # B-1162-10; 2) Recovered Plasma. Recall # B-1163-10; 3) Source Leukocyte. Recall # B-1164-10 CODE 1), 2), 3) Unit: 4916905 RECALLING FIRM/MANUFACTURER Gulf Coast Regional Blood Center, Houston, TX, by facsimile on October 21, 2009 and November 3, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor who was previously deferred for a history of hepatitis, were distributed. VOLUME OF PRODUCT IN COMMERCE 3 units DISTRIBUTION NJ, TX ___________________________________ PRODUCT 1) Red Blood Cells Leukocytes Reduced. Recall # B-1166-10; 2) Fresh Frozen Plasma. Recall # B-1167-10; 3) Platelets Leukocytes Reduced, Recall # B-1168-10 CODE 19GH76830 RECALLING FIRM/MANUFACTURER American Red Cross Blood Services Tennessee Valley Region, Nashville, TN, by facsimile on November 12, 2009 and by letter dated November 12, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor for whom donor suitability was not adequately determined, were distributed. VOLUME OF PRODUCT IN COMMERCE 3 units DISTRIBUTION TN, KY, IN ___________________________________ PRODUCT 1) Fresh Frozen Plasma. Recall # B-1171-10; 2) Red Blood Cells Leukocytes Reduced. Recall # B-1172-10; 3) Recovered Plasma. Recall # B-1173-10 CODE 1) Unit: W045006099990; 2) Units: W045006099990, W045009075246; 3) Units: W045009029873, W045009075246 RECALLING FIRM/MANUFACTURER [ NOT NAMED !! ] by e-mail on October 9, 2009 and by letter dated October 14, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor with a history of exposure to hepatitis B, were distributed. VOLUME OF PRODUCT IN COMMERCE 5 units DISTRIBUTION CA, KS, Austria, MO ___________________________________ PRODUCT Source Plasma. Recall # B-1179-10 CODE Units: 377068395, 377068073, 377067522, 377067221, 377058179, 377057309, 377055953, 377054553, 377053631, 377053200, 377052782 RECALLING FIRM/MANUFACTURER Talecris Plasma Resources, Inc., Anderson, IN, by fax on August 20, 2009. Firm initiated recall is complete. REASON Blood products, collected using an abbreviated screening process, for which the donor was not eligible, were distributed VOLUME OF PRODUCT IN COMMERCE 11 units DISTRIBUTION NC ___________________________________ PRODUCT Source Plasma. Recall # B-1180-10 CODE Units: 3260005168, 3260005420, 3260005774 RECALLING FIRM/MANUFACTURER Talecris Plasma Resources Inc., Lake Charles, LA, by fax on August 20, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor who received a tattoo within 12 months of donating, were distributed. VOLUME OF PRODUCT IN COMMERCE 3 units DISTRIBUTION NC ___________________________________ PRODUCT Red Blood Cells. Recall # B-1161-10 CODE Unit: W072109001956 RECALLING FIRM/MANUFACTURER Southern California Permanente Medical Group, San Diego, CA, by telephone on November 11, 2009 and by letter dated November 11, 2009. Firm initiated recall is complete. REASON Blood product, collected from a donor who was at risk for Leishmaniasis, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION CA ___________________________________ PRODUCT Source Plasma. Recall # B-1177-10 CODE Units: 3250010232, 3250004750 RECALLING FIRM/MANUFACTURER Talecris Plasma Resources, Inc., Sioux Falls, SD, by fax on November 5, 2008. Firm initiated recall is complete. REASON Blood products, collected from a donor whose suitability to donate was not adequately determined, were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION NC ___________________________________ PRODUCT Source Plasma. Recall # B-1181-10 CODE Units: 351040499, 351040877, 351041338, 351041838, 351042035, 351042594, 351042965, 351044082, 351044443, 351045096, 351036858, 351036892 RECALLING FIRM/MANUFACTURER Talecris Plasma Resources Inc., Louisville, KY, by fax on February 29, 2008. Firm initiated recall is complete. REASON Blood products, collected from a donor whose suitability to donate was not adequately determined, were distributed. VOLUME OF PRODUCT IN COMMERCE 12 units DISTRIBUTION NC ___________________________________ PRODUCT Red Blood Cells Leukocytes Reduced Irradiated. Recall # B-1183-10 CODE Units: 72F955707, 72F663145 RECALLING FIRM/MANUFACTURER Lifesouth Community Blood Centers Inc - Birmingham Region, Birmingham, AL, by facsimile on July 16, 2008. Firm initiated recall is complete. REASON [ NOT GIVEN!! ] VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION AL ___________________________________ PRODUCT Source Plasma. Recall # B-1188-10 CODE TQ069887, TQ069583, TQ069070, TQ068689, TQ067849, TQ067563, TQ067136, TQ066875, TQ066289, TQ066013, TQ065366, TQ064958, TQ064363, TQ063712, TQ063435, TQ062870, TQ062590, TQ062039, TQ060954, TQ060578, TQ059936, TQ059630, TQ058843 and TQ058522 RECALLING FIRM/MANUFACTURER IBBI dba Knoxville Plasma Corp., Knoxville, TN, by facsimile on 04/08/2009. Firm initiated recall is complete. REASON Blood products, collected from a donor in which donor suitability was not adequately determined, were distributed. VOLUME OF PRODUCT IN COMMERCE 24 units DISTRIBUTION NC __________________________________ May 19 20 __________________________________ PRODUCT 1) Plasma Frozen within 24 hours (FP24). Recall # B-1155-10; 2) Recovered Plasma. Recall # B-1156-10 CODE 1) Unit: W044609220826; 2) Units: W044608211648, W044608322459, W044609340801 RECALLING FIRM/MANUFACTURER Gulf Coast Regional Blood Center, Houston, TX, by facsimile on August 31, 2009 and September 6, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed. VOLUME OF PRODUCT IN COMMERCE 4 units DISTRIBUTION TX, NJ ___________________________________ PRODUCT Recovered Plasma. Recall # B-1160-10 CODE Unit: 9651196, 9715661, 5812088 RECALLING FIRM/MANUFACTURER Gulf Coast Regional Blood Center, Houston, TX, by facsimile on October 16, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed. VOLUME OF PRODUCT IN COMMERCE 3 units DISTRIBUTION NJ ___________________________________ PRODUCT Plasma Frozen within 24 hours (FP24). Recall # B-1201-10 CODE Unit: 003LM38428 RECALLING FIRM/MANUFACTURER The American National Red Cross - Southern Region, Douglasville, GA, by email, fax and letter on October 20, 2009. Firm initiated recall is complete. REASON Blood product, collected from a donor whose suitability to donate was not adequately determined, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION AL, GA ___________________________________ PRODUCT 1) Red Blood Cells Leukocytes Reduced. Recall # B-1202-10; 2) Liquid Plasma. Recall # B-1203-10; 3) Platelets. Recall # B-1204-10; 4) Source Leukocytes. Recall # B-1205-10 CODE 1) Unit: W046609273704; 2), 3) and 4) Unit: W044609273704 RECALLING FIRM/MANUFACTURER Gulf Coast Regional Blood Center, Houston, TX, by fax on August 18 and 21, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor who was previously deferred, were distributed. VOLUME OF PRODUCT IN COMMERCE 4 units DISTRIBUTION TX, NJ ___________________________________ PRODUCT 1) Red Blood Cells Leukocytes Reduced. Recall # B-1207-10; 2) Fresh Frozen Plasma. Recall # B-1208-10 CODE 1) and 2) Units: R41826, R33828, R32312 RECALLING FIRM/MANUFACTURER Blood Center of Northcentral Wisconsin, Inc., Wausau, WI, by e-mail on December 1, 2009 and by letter dated December 3, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor taking the medication Avodart, were distributed. VOLUME OF PRODUCT IN COMMERCE 6 units DISTRIBUTION WI ___________________________________ PRODUCT Source Plasma. Recall # B-1214-10 CODE Units: SS0016801; SS0017094; SS0017873; SS0018201; SS0018653; SS0018896; SS0021917 RECALLING FIRM/MANUFACTURER DCI Biologicals San Marcos, LLC, San Marcos, TX, by fax on September 15, 2009 and e-mail on January 22, 2010. Firm initiated recall is complete. REASON Blood products, collected from a donor with high risk behavior, were distributed VOLUME OF PRODUCT IN COMMERCE 7 units DISTRIBUTION CA ___________________________________ PRODUCT 1) Red Blood Cells. Recall # B-1220-10; 2) Fresh Frozen Plasma. Recall # B-1221-10 CODE 1) and 2) Unit: W001306014125 RECALLING FIRM/MANUFACTURER Recalling Firm: Department of the Air Force, Lackland AFB, TX, by fax on April 27, 2007. Manufacturer: Department of Air Force - BB/HT, Lackland AFB, TX. Firm initiated recall is complete. REASON Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION TX, NJ ___________________________________ PRODUCT 1) Red Blood Cells. Recall # B-1224-10; 2) Platelets Leukocytes Reduced, Recall # B-1225-10 CODE 1) Units: 16GR41674, 16KS09109; 2) Unit: 16GR41674 RECALLING FIRM/MANUFACTURER Recalling Firm: The American National Red Cross, Central Ohio Region, Columbus, OH, by telephone on June 3, 2008 and by follow-up letter on June 6, 2008. Manufacturer: American Red Cross Blood Services, Central Ohio Region, Columbus, OH. Firm initiated recall is complete. REASON Blood products, collected from a donor who reported travel to a malarial endemic area, were distributed. VOLUME OF PRODUCT IN COMMERCE 3 units DISTRIBUTION OH ___________________________________ PRODUCT Red Blood Cells Leukocytes Reduced. Recall # B-1231-10 CODE Unit: 03LC47771 RECALLING FIRM/MANUFACTURER The American National Red Cross - Southern Region, Douglasville, GA, by facsimile on October 6, 2009 and by letter dated October 6, 2009. Firm initiated recall is complete. REASON Blood product, collected from a donor for whom donor suitability was not adequately determined, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION GA ___________________________________ PRODUCT Red Blood Cells Leukocytes Reduced. Recall # B-1233-10 CODE Unit: 003K45761 RECALLING FIRM/MANUFACTURER The American National Red Cross - Southern Region, Douglasville, GA, by facsimile July 16, 2009 and July 17, 2009 and by letters dated July 16, 2009 and July 17, 2009. Firm initiated recall is complete. REASON Blood product, collected from a donor for whom donor suitability was not adequately determined, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION AL, GA ___________________________________ PRODUCT Red Blood Cells Leukocytes Reduced Irradiated. Recall # B-1234-10 CODE Unit: 004GK99276 RECALLING FIRM/MANUFACTURER ARC Blood Services, New England Region, Dedham, MA, by facsimile on January 3, 2008 and April 2, 2008. Firm initiated recall is complete. REASON 21 Blood product, which tested positive for syphilis on an invalidated test run, was distributed VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION NY ___________________________________ PRODUCT Red Blood Cells Leukocytes Reduced. Recall # B-1236-10 CODE Unit: 17KW89860 RECALLING FIRM/MANUFACTURER Recalling Firm: The American National Red Cross, Saint Paul, MN, by letter dated December 9, 2005 or by electronic notification on December 9, 2005. Manufacturer: The American National Red Cross - North Central Region, Saint Paul, MN. Firm initiated recall is complete. REASON Blood product, collected from a donor who received an accidental needle stick, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION PA, IL ___________________________________ PRODUCT 1) Red Blood Cells. Recall # B-1240-10; 2) Recovered Plasma. Recall # B-1241-10 CODE 1) and 2) Unit: 1186066 RECALLING FIRM/MANUFACTURER South Texas Blood & Tissue Center, San Antonio, TX, by facsimile on August 28, 2008 and September 10, 2008. Firm initiated recall is complete. REASON Blood products, collected from a donor with a history of hepatitis, were distributed VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION FL, TX ___________________________________ PRODUCT Fresh Frozen Plasma. Recall # B-1194-10 CODE Unit: W042209010004F RECALLING FIRM/MANUFACTURER Blood Systems, Inc., Las Vegas, NV, by email on March 05, 2009. Firm initiated recall is complete. REASON Blood component, processed from Whole Blood more than 8 hours after collection, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION NV ___________________________________ PRODUCT Source Plasma. Recall # B-1196-10 CODE Units: 368104648, 368103237, 368102784, 368100746, 368096348 RECALLING FIRM/MANUFACTURER Talecris Plasma Resources Inc dba International BioResources. Glendale, AZ, by fax on April 23, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor who was deferred due to receiving a piercing within 12 months of donating, were distributed. VOLUME OF PRODUCT IN COMMERCE 5 units DISTRIBUTION NC ___________________________________ PRODUCT Source Plasma. Recall # B-1197-10 CODE Units: 3600009626, 3600000488, 3600000057, 3600028843, 3600011893, 3600000370, 3600033900, 3600038873, 3600048974, 3600043274, 3600042938, 3600038356, 3600032026, 3600003587, 3600003128, 3600031025, 3600027214 RECALLING FIRM/MANUFACTURER Talecris Plasma Resources, Canton, OH, by fax on April 16, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor whose suitability to donate was not adequately determined, were distributed. VOLUME OF PRODUCT IN COMMERCE 17 units DISTRIBUTION NC ___________________________________ PRODUCT Source Plasma. Recall # B-1198-10 CODE Units: 3990013152, 3990020951, 3990022567, 3990022929, 3990023228, 3990023965, 3990024345, 3990024809, 3990025212, 3990025668, 3990026864, 3990027216, 3990027527, 3990028198, 3990028545, 3990028726 RECALLING FIRM/MANUFACTURER International BioResources LLC, Columbus, OH, by fax on May 29, 2009 and June 1, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor whose suitability to donate was not adequately determined, were distributed. VOLUME OF PRODUCT IN COMMERCE 16 units DISTRIBUTION NC ___________________________________ PRODUCT Source Plasma. Recall # B-1226-10 CODE Units: ST1011282; ST1011801 RECALLING FIRM/MANUFACTURER Stillwater Plasma Center, LLC, Stillwater, OK, by fax on November 24, 2009 and email on February 4, 2010. Firm initiated recall is complete. REASON Blood products, collected from a donor possibly at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION CA ___________________________________ PRODUCT Source Plasma. Recall # B-1235-10 CODE Units: 3920008149, 3920009137, 3920009990, 3920010735, 3920011176, 3920011523, 3920010140, 3920010705, 3920010220, 3920010899, 3920008314, 3920008587, 3920008978, 3920009154, 3920011115, 3920008818, 3920010372, 3920011170, 3920007632, 3920007925, 3920008127, 3920009107, 3920007203, 3920008363, 3920007721, 3920007853, 3920008318, 3920008996, 3920011129, 3920009101, 3920010150, 3920010673, 3920011570, 3920011110, 3920007923, 3920008224, 3920009556, 3920009796, 3920010802, 3920007292, 3920007178, 3920007655, 3920007929, 3920007584, 3920010078, 3920010422, 3920011531, 3920007208, 3920008178, 3920010176, 3920011284, 3920008670, 3920008815, 3920009146, 3920008004, 3920007518, 3920007125, 3920007586, 3920007750, 3920009979, 3920010328, 3920010960, 3920011496, 3920007955, 3920008444, 3920009149, 3920009953, 3920007625, 3920007902, 3920009447, 3920010712, 3920008182, 3920008159, 3920009170, 3920009425, 3920009640, 3920009151, 3920009481, 3920008295, 3920008769, 3920010332, 3920011577, 3920008999, 3920010189, 3920010927, 3920007106, 3920007278, 3920009891, 3920009233, 3920010107, 3920011185, 3920007022, 3920008312, 3920007607, 3920008247, 3920008758, 3920010415, 3920010720, 3920011149, 3920010191, 3920010473, 3920007663, 3920007086, 3920008827, 3920009800, 3920008568, 3920008949, 3920009812, 3920010129, 3920010378, 3920010901, 3920011155, 3920008442, 3920010425, 3920011272, 3920010097, 3920007855, 3920008523, 3920010267, 3920008345, 3920008536, 3920010747, 3920007273, 3920007770, 3920008503, 3920008851, 3920009029, 3920010426, 3920007163, 3920007524, 3920008814, 3920009726, 3920009856, 3920010933, 3920011485, 3920009191, 3920010418, 3920010764, 3920009999, 3920010201, 3920007716, 3920008231, 3920008386, 3920008805, 3920009835, 3920010364, 3920011169, 3920007542, 3920008269, 3920009519, 3920010036, 3920010261, 3920008782, 3920009580, 3920010446, 3920010968, 3920008398, 3920007778, 3920008725, 3920008834, 3920008963, 3920010375, 3920010895, 3920008430, 3920010386, 3920007952, 3920009034, 3920008802, 3920008158, 3920007089, 3920008678, 3920009074, 3920010387, 3920011270, 3920010293, 3920007680, 3920009291, 3920006972, 3920008797, 3920008984, 3920009500, 3920010026, 3920010402, 3920011112, 3920009526, 3920010346, 3920007836, 3920010224, 3920008505, 3920008730, 3920008982, 3920009166, 3920010352, 3920008453, 3920008844, 3920010132, 3920011188, 3920010965, 3920007120, 3920008772, 3920009562, 3920009799, 3920010797, 3920009616, 3920009929, 3920010055, 3920010995, 3920010102, 3920008125, 3920008392, 3920009104, 3920010684, 3920011240, 3920007098, 3920008500, 3920007912, 3920008123, 3920009505, 3920010067, 3920010384, 3920010748, 3920007032, 3920007303, 3920008238, 3920008989, 3920007059, 3920007943, 3920007961, 3920010853, 3920006939, 3920007522, 3920007775, 3920008010, 3920008753, 3920009095, 3920010196, 3920007673, 3920008190, 3920008639, 3920009142, 3920009439, 3920007920, 3920008625, 3920009122, 3920009944, 3920007000, 3920008355, 3920008602, 3920010158, 3920010946, 3920011494, 3920011163, 3920010270, 3920011131, 3920009512, 3920008565, 3920009065, 3920010350, 3920011187, 3920007063, 3920008494, 3920008986, 3920009941, 3920010766, 3920007555, 3920010399, 3920010778, 3920008510, 3920009207 and 3920010769 RECALLING FIRM/MANUFACTURER Recalling Firm: Talecris Plasma Resources Inc, Research Triangle Park, NC, by facsimile and letter between February 17, 2009 and February 27, 2009. Manufacturer: Talecris Plasma Resources Inc., Rockford, IL. Firm initiated recall is complete. REASON Blood products, collected from a donor in which donor suitability was not adequately determined, were distributed. VOLUME OF PRODUCT IN COMMERCE 270 units DISTRIBUTION NC ___________________________________ PRODUCT Recovered Plasma. Recall # B-1237-10 CODE Unit: 17KW89860 RECALLING FIRM/MANUFACTURER Recalling Firm: The American National Red Cross, Saint Paul, MN, by letter dated December 9, 2005 or by electronic notification on December 9, 2005. Manufacturer: The American National Red Cross - North Central Region, Saint Paul, MN. Firm 22 initiated recall is complete. REASON Blood product, collected from a donor who received an accidental needle stick, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION PA, IL ___________________________________ PRODUCT Source Plasma. Recall # B-1242-10 CODE Units: 355034328, 355038068, 355037506, 355034047, 355035400, 355036992, 355034748, 355037509, 355036344, 355034660, 355034049, 355035378, 355035987, 355036600, 355036869, 355038264, 355033763, 355034152, 355035424, 355034420, 355034011, 355034290, 355035689, 355036221, 355037951, 355034066, 355033877, 355036700, 355034213, 355034078, 355034104, 355034436, 355037817, 355038021, 355035933, 355034056, 355034261, 355036710, 355037648, 355034482, 355038011, 355033838, 355033888, 355034315, 355034429, 355035362, 355036110, 355034931, 355034338, 355035465, 355035786, 355036335, 355037644, 355034597, 355035712, 355034729, 355033863, 355036362, 355036072, 355038632, 355034050, 355033835, 355035945, 355034806, 355038194, 355036840, 355035357, 355036402, 355034440, 355034340, 355034662, 355038186, 355034741, 355035947, 355038074, 355037975, 355036071, 355035562, 355035708, 355036321, 355036487, 355035755, 355034718, 355037996, 355038210, 355036532, 355036557, 355034477, 355035590, 355036049, 355036632, 355037735, 355034027, 355034273, 355036235, 355036834, 355035989, 355035549, 355034025, 355034588, 355036964, 355038160, 355034802, 355035365, 355034836, 355036005, 355036431, 355036931, 355036387, 355037596, 355035484, 355034989, 355035545, 355035859, 355035489, 355035734, 355035917, 355035149, 355038071, 355034180, 355033419, 355035701, 355035888, 355034592, 355035004, 355035564, 355035960, 355034371, 355037656, 355034785, 355035963, 355038183, 355036680, 355036281, 355036922, 355038229, 355034678, 355036928, 355035892, 355037550, 355035577, 355037763, 355034271, 355036694, 355034307, 355037586, 355033800, 355035407, 355033884, 355036461, 355037815, 355035984, 355035823, 355035482, 355036035, 355036613, 355036541, 355037675, 355038052, 355038624, 355037652, 355034022, 355038215, 355035986, 355035569, 355033844, 355029700, 355027624, 355023355, 355023897, 355024461, 355024932, 355025431, 355025642, 355026640, 355027187, 355027308, 355028462, 355027767, 355029605, 355024720, 355025378, 355025077, 355025333, 355029640, 355029616, 355021312, 355021396, 355025415, 355025617, 355025909, 355026906, 355027411, 355028682, 355029001, 355026422, 355028987, 355029224, 355023771, 355025029, 355026720, 355027217, 355028783, 355029595, 355025323, 355027132, 355028444, 355023770, 355025169, 355027851, 355025446, 355026897, 355028670, 355028842, 355029293, 355027947, 355027574, 355026480, 355026985, 355026657, 355023375, 355027888, 355027824, 355026913, 355028219, 355028944, 355029317, 355030033, 355023265, 355023840, 355025350, 355026153, 355026646, 355029250, 355024359, 355026326, 355026509, 355027029, 355023340, 355026678, 355027228, 355028227, 355027599, 355025917, 355027892, 355029735, 355023212, 355023669, 355024412, 355025276, 355027446, 355028661, 355025014, 355028033, 355027536, 355023419, 355023835, 355025000, 355023698, 355025355, 355025659, 355026361, 355026629, 355028812, 355023956, 355024676, 355024986, 355026240, 355028875, 355024236, 355023851, 355024838, 355025334, 355023131, 355023742, 355024700, 355025505, 355028006, 355028291, 355029074, 355029411, 355027815, 355027849, 355027674, 355027453, 355026462, 355028903, 355025318, 355029002, 355021438, 355027956, 355027435, 355028461, 355028821, 355029079, 355027680, 355026632, 355029378, 355027808, 355027826, 355026948, 355027311, 355028549, 355029706, 355023394, 355024767, 355025416, 355025929, 355028018, 355028466, 355029472, 355027843, 355023301, 355028179, 355024453, 355027854, 355023256, 355023426, 355024372, 355024911, 355023600, 355024018, 355024524, 355027317, 355029593, 355027544, 355021462, 355024806, 355025104, 355026506, 355028248, 355027946, 355023094, 355023096, 355023114, 355023342, 355027405, 355023527, 355024296, 355024460, 355024943, 355026344, 355027358, 355027419, 355029478, 355030124, 355023693, 355024382, 355024769, 355021349, 355024325, 355024418, 355029326, 355030065, 355023480, 355024483, 355024647, 355029569, 355026231, 355026731, 355028257, 355027575, 355024238, 355024709, 355024304, 355028020, 355028395, 355025398, 355030099, 355021435, 355025140, 355027006, 355028354, 355025002, 355029708, 355029731, 355024284, 355025087, 355026915, 355028210, 355026269, 355027834, 355026991, 355027461, 355028281, 355028808, 355027972, 355023105, 355023874, 355024935, 355025887, 355030097, 355023740, 355024528, 355026983, 355027270, 355028883, 355023556, 355023690, 355024746, 355025042, 355026260, 355028140, 355026625, 355028131, 355021310, 355021481, 355024518, 355025358, 355025405, 355025908, 355026155, 355026283, 355024021, 355024793, 355025079, 355025465, 355026137, 355029707, 355027847, 355023893, 355025427, 355027363, 355027466, 355028907, 355029613, 355030044, 355021493, 355025968, 355028455, 355027918, 355027352, 355023553, 355025675, 355025993, 355021460, 355027920, 355027991, 355025484, 355026117, 355021282, 355024803, 355023328, 355028379, 355029314, 355029730, 355023550, 355024476, 355026907, 355023088, 355024496, 355024975, 355025943, 355026245, 355028266, 355028489, 355028796, 355029046, 355023345, 355023784, 355024473, 355023320, 355027412, 355029010, 355029008, 355027541, 355025013, 355025338, 355025991, 355026345, 355029499, 355027535, 355027871, 355024744, 355025291, 355023838, 355024799, 355025407, 355027840, 355027464, 355023545, 355023875, 355023818, 355023531, 355021385, 355026616, 355023767, 355023349, 355027115, 355029743, 355030122, 355025947, 355026753, 355026988, 355028497, 355029064, 355029383, 355023990, 355024290, 355024762, 355026740, 355027643, 355027688, 355023318, 355023810, 355023919, 355024433, 355026215, 355027211, 355028234, 355027831, 355027244, 355028008, 355028274, 355029257, 355027576, 355027609, 355026439, 355027168, 355028373, 355021371, 355023772, 355024022, 355024293, 355024779, 355029559, 355030084, 355021498, 355026677, 355027654, 355027709, 355027593, 355027612, 355027154, 355023262, 355024407, 355025332, 355028003, 355028518, 355028825, 355029068, 355027868, 355023800, 355023982, 355028523, 355028814, 355029060, 355029379, 355027229, 355029698, 355027836, 355027258, 355028742, 355028918, 355027027, 355029421, 355027711, 355027484, 355024745, 355025041, 355028236, 355029015, 355030078, 355027965, 355027988, 355028994, 355028970, 355027925, 355024914, 355026729, 355027224, 355026770, 355027994, 355027844, 355028127, 355023107, 355029713, 355025187, 355026308, 355026715, 355028196, 355028377, 355028747, 355029354, 355023115, 355023734, 355024832, 355025679, 355026171, 355028371, 355030029, 355030127, 355029555, 355025182, 355024834, 355026612, 355029298, 355030100, 355023424, 355023476, 355023958, 355024517, 355025513, 355025686, 355023409, 355027855, 355021360, 355029738, 355028334, 355028858, 355025460, 355025976, 355026273, 355027480, 355028214, 355030121, 355024265, 355024442, 355024650, 355029403, 355025940, 355026467, 355023995, 355024851, 355023117, 355023599, 355026213, 355028778, 355024738, 355021362, 355029543, 355029037, 355023980, 355027530, 355025108, 355025290, 355023541, 355026445, 355028343, 355030086, 355023587, 355023884, 355025980, 355026109, 355027232, 355023352, 355029302, 355026778, 355023985, 355028822, 355027648, 355027583, 355025690, 355027204, 355023108, 355023347, 355027265, 355028479, 355029005, 355023686, 355024363, 355026256, 355028160, 355023244, 355027415, 355029056, 355023386, 355026672, 355027297, 355025693, 355029460, 355028719, 355028878, 355029267, 355024853, 355026411, 355026622, 355029364, 355027802, 355024394, 355024498, 355025977, 355026468, 355026947, 355028468, 355028313, 355026290, 355027023, 355028270, 355028847, 355023327, 355023764, 355026233, 355024952, 355024489, 355024640, 355025923, 355027350, 355023815, 355024395, 355025084, 355026275, 355027371, 355028393, 355023216, 355023412, 355024811, 355025115, 355025651, 355026097, 355024500, 355025625, 355026758, 355028284, 355027685, 355026263, 355026767, 355027159, 355027483, 355027454, 355027633, 355024670, 355023338, 355024318, 355024942, 355021466, 355024440, 355024921, 355025129, 355023307, 355022592, 355023890, 355024025, 355024404, 355023312, 355023464, 355023855, 355024365, 355024680, 355025317, 355026685, 355024447, 355026324, 355026696, 355023123, 355023728, 355023865, 355024996, 355025315, 355025489, 355026166, 355026315, 355026680, 355027143, 355028200, 355028715, 355023099, 355025293, 355023360, 355027032, 355027129, 355028517, 355023944, 355023752, 355027476, 355028442, 355028743, 355028993, 355030119, 355029241, 355027772, 355027683, 355027180, 355028387, 355030118, 355029629, 355029601, 355027919, 355029349, 355025184, 355024288, 355021404, 355028431, 355029218, 355030088, 355023474, 355025981, 355028030, 355025075, 355028132, 355028973, 355029365, 355024652, 355024883, 355025145, 355030019, 355027316, 355028158, 355024491, 355026168, 355025311, 355021444, 355027838, 355028978, 355027246, 355027845, 355027996, 355029030, 355030135, 355028687, 355028198, 355026320, 355024980, 355023533, 355023401, 355023087, 355023368, 355023579, 355023802, 355023983, 355024509, 355024843, 355024977, 355025480, 355025983, 355026331, 355027041, 355028526, 355029115, 355030040, 355025353, 355026761, 355023581, 355024397, 355024885, 355025105, 355026182, 355026369, 355027197, 355028416, 355028949, 355021314, 355021350, 355024003, 355025438, 355027376, 355028324, 355026338, 355028829, 355029408, 355027644, 355026252, 355028293, 355029373, 355024299, 355025492, 355026247, 355028561, 355023290, 355023125, 355023814, 355024292, 355029385, 355023364, 355029621, 355029652, 355030104, 355023809, 355025386, 355025875, 355021477, 355021476, 355025424, 355029078, 355029259 RECALLING FIRM/MANUFACTURER Talecris Plasma Resources, Inc., Bloomington, IL, facsimile and letter between February 25, 2008 and March 18, 2008. Firm initiated recall is complete. REASON Blood products collected donors whose suitability determination were inadequately performed, were distributed. VOLUME OF PRODUCT IN COMMERCE 875 units DISTRIBUTION NC __________________________________ May 26 __________________________________ ___________________________________ PRODUCT Source Plasma. Recall # B-0678-10 CODE Units: 0530606664, 0530605663, 0530604648, 0530607381 RECALLING FIRM/MANUFACTURER CSL Plasma, Lexington, KY, by letters dated September 3, 2009. Firm initiated recall is complete. REASON Source Plasma, collected from a donor with an expired physical, was distributed. VOLUME OF PRODUCT IN COMMERCE 4 units DISTRIBUTION Switzerland, IL ___________________________________ PRODUCT Red Blood Cells Leukocytes Reduced. Recall # B-1154-10 CODE Units: 157038222, 157039083, 157046855, 157047230 RECALLING FIRM/MANUFACTURER Recalling Firm: Blood Systems, Inc., Scottsdale, AZ, by telephone on March 23, 2007 or by letter dated July 25, 2007. Manufacturer: Blood Systems, Inc - Lubbock Center, Lubbock, TX. Firm initiated recall is complete. REASON Blood products, collected from donors whose hemoglobin determinations were performed incorrectly, were distributed. VOLUME OF PRODUCT IN COMMERCE 4 units 23 DISTRIBUTION NM, TX ___________________________________ PRODUCT 1) Red Blood Cells Leukocytes Reduced. Recall # B-1245-10; 2) Plasma Frozen. Recall # B-1246-10 CODE 1) and 2) Unit: W053309800279 RECALLING FIRM/MANUFACTURER Community Blood Center, Inc., Appleton, WI, by letter dated December 9, 2009 and by e-mail on December 9, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION Switzerland, WI ___________________________________ PRODUCT 1) Recovered Plasma. Recall # B-1248-10; 2) Red Blood Cells. Recall # B-1249-10; 3) Platelets Pooled Leukocytes Reduced. Recall # 1250-10 CODE 1) and 2) Unit: W120609243337; 3) Unit: W-120609383496 RECALLING FIRM/MANUFACTURER Recalling Firm: Michigan Community Blood Centers, Saginaw, MI, by facsimile on December 23, 2009. Manufacturer: Michigan Community Blood Centers, Midland, MI. Firm initiated recall is complete. REASON Blood products, collected from a donor who resided in an area considered at risk for human immunodeficiency virus (HIV) Group O, were distributed. VOLUME OF PRODUCT IN COMMERCE 3 units DISTRIBUTION Switzerland, MI ___________________________________ PRODUCT Source Plasma. Recall # B-1260-10 CODE Unit: 0360131077 RECALLING FIRM/MANUFACTURER Biomat USA, Inc., South Bend, IN, by letter dated December 7, 2007. Firm initiated recall is complete. REASON Blood product, which was not tested for viral markers, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION Spain ___________________________________ PRODUCT 1) Red Blood Cells (Apheresis) Leukocytes Reduced. Recall # B-1268-10; 2) Red Blood Cells Leukocytes Reduced. Recall # B-1269-10 CODE 1) Units: W091009175131 (2 units), 7879207 (2 units); 2) Unit: 7454100 RECALLING FIRM/MANUFACTURER Oklahoma Blood Institute, Sylvan N Goldman Center, Oklahoma City, OK, by facsimile on January 8, 2010 and January 11, 2010. Firm initiated recall is complete. REASON Blood products, collected from a donor who was previously deferred for testing positive for the human immunodeficiency virus (HIV), were distributed. VOLUME OF PRODUCT IN COMMERCE 5 units DISTRIBUTION IN, OK ___________________________________ PRODUCT 1) Red Blood Cells Leukocytes Reduced. Recall # B-1271-10; 2) Recovered Plasma. Recall # B-1272-10 CODE 1) and 2) Unit: W142808306794 RECALLING FIRM/MANUFACTURER Tri-Counties Blood Bank, San Luis Obispo, CA, by telephone on January 12, 2010 and by letter dated February 8, 2010. Firm initiated recall is complete. REASON Blood products, collected from a donor who previously tested positive for Hepatitis C, were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION Switzerland, CA ___________________________________ PRODUCT 1) Red Blood Cells (Apheresis) Leukocytes Reduced. Recall # B-1279-10; 2) Red Blood Cells Leukocytes Reduced. Recall # B-1280-10; 3) Plasma Frozen. Recall # B-1281-10 CODE 1) Units: 151704474 (part 1); 151704474 (part 2);151704482 (part 1); 151704482 (part 2); 151704483 (part 1); 151704483 (part 2); 151704487 (part 1); and 151704487 (part 2); 2)Units:151704472;151704473;151704481;151704469;151704476;151704478;1517 04479;151704480;151704484;151704485;151704490; 3) Unit: 151704480 RECALLING FIRM/MANUFACTURER Recalling Firm: Blood Systems, Inc., Scottsdale, AZ, by facsimile on October 4, 2007. Manufacturer: Blood Systems, Inc - Lubbock Center, Lubbock, TX. Firm initiated recall is complete. REASON Blood product, lacking assurance of having been maintained at an acceptable temperature during shipping, was distributed. VOLUME OF PRODUCT IN COMMERCE 20 units DISTRIBUTION TX ___________________________________ PRODUCT 1) Red Blood Cells Leukocytes Reduced. Recall # B-1288-10; 2) Recovered Plasma. Recall # B-1289-10; 3) Cryoprecipitated AHF. Recall # B-1290-10 CODE 1), 2), and 3) Unit: W149509908890 RECALLING FIRM/MANUFACTURER Northern California Community Blood Bank, Eureka, CA, by fax and e-mail on October 23, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed. VOLUME OF PRODUCT IN COMMERCE 3 units DISTRIBUTION Austria, CA ___________________________________ PRODUCT Platelets Pheresis Leukocytes Reduced Irradiated. Recall # B-1309-10 CODE Units: W036809306420A; W036809306420C RECALLING FIRM/MANUFACTURER Community Blood Centers/S Florida, Inc., Lauderhill, FL, by telephone on September 4, 2009. Firm initiated recall is complete. REASON Blood products, which did not meet QC specifications for pH, were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION FL ___________________________________ PRODUCT 1) Liquid Plasma. Recall # B-1373-10; 2) Red Blood Cells. Recall # B-1374-10; 3) Fresh Frozen Plasma. Recall # B-1375-10 CODE 1) Units: W001708005659, W001708005630; 2) Units: W001708005630, W001708005631, W001708005632, W001708005636, W001708005639, W001708005640, W001708005641, W001708005642, W001708005643, W001708005644, W001708005645, W001708005649, W001708005650, W001708005652, W001708005653, W001708005654, W001708005655, W001708005656, W001708005658, W001708005660; 3) Units: W001708005631, W001708005632, W001708005633, W001708005639, W001708005640, W001708005641, W001708005642, W001708005644, W001708005646, W001708005648, W001708005652, W001708005653, W001708005654, W001708005655, W001708005660 RECALLING FIRM/MANUFACTURER Department AF 81st Med. Group/SGSC Keesler AFB MC Blood Bank, Keesler AFB, MS, by telephone and facsimile on November 25, 2008 and by letter dated November 25, 2008. Firm initiated recall is complete. REASON Blood products, which were incorrectly tested for viral markers, were distributed. VOLUME OF PRODUCT IN COMMERCE 37 units DISTRIBUTION NJ, LA, FL, D.C. _____________________________________ PRODUCT 1) Red Blood Cells Leukocytes Reduced. Recall # B-1266-10; 2) Platelets Pheresis Leukocytes Reduced. Recall # B-1267-10 CODE 1) Units: W040709178309, W040709334574; 2) Units: W040709681421 (2 units) RECALLING FIRM/MANUFACTURER Indiana Blood Center, Indianapolis, IN, by telephone on November 10, 2009. Firm initiated recall is complete. REASON 24 Blood products, which were incorrectly test for human T-lymphotropic virus types I & II (anti-HTLV-I/II), were distributed. VOLUME OF PRODUCT IN COMMERCE 4 units DISTRIBUTION IN ___________________________________ PRODUCT Recovered Plasma. Recall # B-1270-10 CODE Unit: 7454100 RECALLING FIRM/MANUFACTURER Oklahoma Blood Institute, Sylvan N Goldman Center, Oklahoma City, OK, by facsimile on January 8, 2010 and January 11, 2010. Firm initiated recall is complete. REASON Blood product, collected from a donor who was previously deferred for testing positive for the human immunodeficiency virus (HIV), was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION IN, OK _______________________ June 2 _______________________ PRODUCT Red Blood Cells (Apheresis) Leukocytes Reduced. Recall # B-0349-10 CODE Unit: 024FF07722 (2 units) RECALLING FIRM/MANUFACTURER American Red Cross Blood Services, Saint Louis, MO, by telephone on December 15, 2008 and by letters dated January 15, 2009 and April 20, 2009. Firm initiated recall is complete. REASON Blood products, for which quality control testing was not performed, were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION KY ___________________________________ PRODUCT Source Plasma. Recall # B-0530-10 CODE Units: 6120217900, 6120217310, 6120219544 RECALLING FIRM/MANUFACTURER CSL Plasma, Inc., Columbia, SC, by, letter on March 17, 2009. Firm initiated recall is complete. REASON Blood products, for which physical examination was undocumented, were distributed. VOLUME OF PRODUCT IN COMMERCE 3 units DISTRIBUTION Switzerland; IL ___________________________________ PRODUCT Source Plasma. Recall # B-1324-10 CODE Units: TA2002497; TA2002724; TA2003225; TA2004361; TA2143790; TA2144131; TA2145043; TA2145477; TA2146044; TA2146285; TA2146888; TA2147459; TA2148579 RECALLING FIRM/MANUFACTURER DCI Biologicals Texarkana LLC, Texarkana, AR, by fax, letter and e-mail on July 17, 2008. Firm initiated recall is complete. REASON Blood products, collected from a donor with high risk behavior, were distributed. VOLUME OF PRODUCT IN COMMERCE 13 units DISTRIBUTION NC, England ___________________________________ PRODUCT 1) Red Blood Cells Leukocytes Reduced. Recall # B-1328-10; 2) Plasma Frozen. Recall # B-1329-10 CODE 1) and 2) Unit: W117009320905 RECALLING FIRM/MANUFACTURER Recalling Firm: Blood Centers of the Pacific - Irwin Center, San Francisco, CA, by telephone on January 22, 2010 and by letter dated January 22, 2010. Manufacturer: Blood Centers of The Pacific - North Bay Center, Fairfield, CA. Firm initiated recall is complete. REASON Blood products, collected from a donor with a history of hepatitis A, were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION CA ___________________________________ PRODUCT 1) Red Blood Cells. Recall # B-1335-10; 2) Plasma Frozen within 24 hours (FP24). Recall # B-1336-10 CODE 1) Units: KL26509, W088609300606, W088609303912; 2) Units: KL26509, W088609303912 RECALLING FIRM/MANUFACTURER Providence Health System Southern California, Burbank, CA, by letter dated January 13, 2010. Firm initiated recall is complete. REASON Blood products, collected from a donor who was previously deferred for high risk behavior, were distributed. VOLUME OF PRODUCT IN COMMERCE 5 units DISTRIBUTION CA ___________________________________ PRODUCT Source Plasma. Recall # B-1344-10 CODE Units: 0360038200, 0360034032, 0360032192, 0360031470, 0360030857, 0360030527, 030028617, 0360028249, 0360027393 and 0360027156 RECALLING FIRM/MANUFACTURER Biomat USA, Inc., South Bend, IN, by letter dated July 3, 2007. Firm initiated recall is complete. REASON Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed. VOLUME OF PRODUCT IN COMMERCE 10 units DISTRIBUTION Spain ___________________________________ PRODUCT Source Plasma. Recall # B-1349-10 CODE Unit: 09MMTH7388 RECALLING FIRM/MANUFACTURER BioLife Plasma Services, L.P., Missoula, MT, by facsimile on January 8, 2010. Firm initiated recall is complete. REASON Blood product, collected from a donor who had not had an annual physical performed, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION CA ___________________________________ PRODUCT 1) Red Blood Cells Leukocytes Reduced. Recall # B-1356-10; 2) Recovered Plasma. Recall # B-1357-10 CODE 1) and 2) Unit: 016KG36090 RECALLING FIRM/MANUFACTURER American Red Cross Blood Services, Central Ohio Region, Columbus, OH, by telephone on August 18, 2009 and by electronic notification on August 19, 2009. Firm initiated recall is complete. REASON Blood products, which were not quarantined after receiving post donation information concerning an illness following donation, were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION OH, CA ___________________________________ PRODUCT Red Blood Cells Leukocytes Reduced. Recall # B-1364-10 CODE Unit: W090709018777 RECALLING FIRM/MANUFACTURER Blood Bank Of The Redwoods, Santa Rosa, CA, by facsimile and electronic notification on August 13, 2009. Firm initiated recall is complete. REASON Blood product, collected from a donor who was previously deferred for testing positive for the human immunodeficiency virus (HIV), was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION Switzerland and CA __________________ PRODUCT Red Blood Cells Leukocytes Reduced. Recall # B-1333-10 CODE Unit: W142809405927, W142809405931, W142809405924, W142809405925, W142809405922, W142809405939 RECALLING FIRM/MANUFACTURER Recalling Firm: Tri-Counties Blood Bank dba UBS- Central Coast, Santa Barbara, CA, by telephone on December 1, 2009. Manufacturer: Tri-Counties Blood Bank dba Community Blood Bank, Inc., Rancho Mirage, CA. Firm initiated recall is complete. REASON Blood products, which were incorrectly labeled as being collected from volunteer 25 donors, were distributed. VOLUME OF PRODUCT IN COMMERCE 6 units DISTRIBUTION CA ___________________________________ PRODUCT Recovered Plasma. Recall # Recall # B-1365-10 CODE Unit: W090709018777 RECALLING FIRM/MANUFACTURER Blood Bank Of The Redwoods, Santa Rosa, CA, by facsimile and electronic notification on August 13, 2009. Firm initiated recall is complete. REASON Blood product, collected from a donor who was previously deferred for testing positive for the human immunodeficiency virus (HIV), was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION Switzerland and CA ___________________________________ PRODUCT Recovered Plasma. Recall # B-1367-10 CODE Unit: 6312464 RECALLING FIRM/MANUFACTURER South Texas Blood & Tissue Center, San Antonio, TX, by facsimile on October 1, 2009. Firm initiated recall is complete. REASON Blood product, collected from a donor who was taking the medication finasteride, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION Austria, TX _________________________________________ June 9 ___________________________________ PRODUCT 1) Cryoprecipitated AHF, Pooled. Recall # B-0952-10; 2) Recovered Plasma. Recall # B-0953-10 CODE Unit: W036309244038X RECALLING FIRM/MANUFACTURER Recalling Firm: BloodCenter of Wisconsin, Inc., Milwaukee, WI, by fax on June 28, 2009. Manufacturer: BloodCenter of Wisconsin, Inc., Brown Deer, WI. Firm initiated recall is complete. REASON Blood products, collected from a donor considered to be at increased risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION WI, Switzerland ___________________________________ June 16 ___________________________________ PRODUCT Red Blood Cells Leukocytes Reduced. Recall # B-1393-10 CODE Units: 238852, 2439038, 2455159, 2499047 RECALLING FIRM/MANUFACTURER Central Kentucky Blood Center Inc., Lexington, KY, by letter on February 23, 2010. Firm initiated recall is complete. REASON Blood products, which were collected from a donor who had traveled to a malarial endemic area, were distributed. VOLUME OF PRODUCT IN COMMERCE 4 units DISTRIBUTION KY ___________________________________ PRODUCT 1) Red Blood Cells. Recall # B-1408-10; 2) Fresh Frozen Plasma. Recall # B-1409-10 CODE 1) and 2) Unit: 6136713 RECALLING FIRM/MANUFACTURER Hemacare Corp., Van Nuys, CA, by letter dated January 22, 2010. Firm initiated recall is complete. REASON Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION CA ___________________________________ PRODUCT Source Plasma. Recall # B-1429-10 CODE Units: I56009010, I56008001, I56013568, I56013220, I56013070, I56014727, I56014536, I56012710, I56012406, I56012202, I56011624, I56011538, I56010643, I56010603, I56010081, I56009601, I56009421, I56009163, 392024806, 392024519, 392024360, 392023993, 392023885, 392023528, 392023302, 392023025, 392022863, 392022497, 392022309, 392022055, 392021901, 392021628, 392021438, 392020289, 392020152, 392019787, 392019536, 392019354, 392019045, 392018894, 392018605, 392018502, 392018181, 392017941, 392017713, 392017543, 392017310, 392016846, 392016698, 392016353, 392016190, 392015892, 392015684, 392015443, 392015300, 392014971, 392014887, 392014474, 392014367, 392013471, 392013288, 392012960, 392012794, 392012569, 392012368, 392012034, 392011306, 392010624, 392011896, 392010184, 392010022, 392009293, 392008544, 392008340, 392007488, 392007312, 392007029, 392006423, 392006114, 392002497, 392002254, 392002087, 392001836, 392001729, 392001459, 392001325, 392001123, 392000963, 392000739, 392000576, I56024163, I56024048, I56023511, I56023407, I56023247, I56023130, I56022945, I56022832, I56022613, I56021894, I56021805, I56021598, I56021541, I56021369, I56021266, I56021106, I56020827, I56020729, I56020361, I56020168, I56019995, I56019837, I56019618, I56019423, I56019365, I56019172, I56019129, I56018840, I56018751, I56018595, I56018515, I56018300, I56018049, I56017918, I56017753, I56015596, I56015529 and I56014261 RECALLING FIRM/MANUFACTURER Recalling Firm: Talecris Plasma Resources Inc., Research Triangle Park, NC, by fax on April 24, 2008. Manufacturer: Talecris Plasma Resources Inc., Rockford, IL. Firm initiated recall is complete REASON Blood products, collected from a donor who was previously permanently deferred, were distributed. VOLUME OF PRODUCT IN COMMERCE 128 units DISTRIBUTION NC and Austria __________________________ PRODUCT Source Plasma. Recall # B-1486-10 CODE Units: 4920198227, 4920196062, 4920195831, 4920194386, 4920193638, 4920192943, 4920191433, 4920191141, 4920189989, 4920189137, 4920188652, 4920187523, 4920187285, 4920185930, 4920185134, 4920183956, 4920180532, 4920180153, 4920178805, 4920178007, 4920177050, 4920176808, 4920175479, 4920174944, 4920169659, 4920168711, 4920168121, 4920167283, 4920165983, 4920165243, 4920163932, 4920163439, 4920162391, 4920162154, 4920161170, 4920160166, 4920159830, 4920158652, 4920158163, 4920157419, 4920157098 RECALLING FIRM/MANUFACTURER Recalling Firm: CSL Plasma. Boca Raton, FL, by email on June 25, 2009. Manufacturer: CSL Plasma, Springfield, OH. Firm initiated recall is complete. REASON Blood products, collected using an abbreviated screening process for which the donor was not eligible, were distributed. VOLUME OF PRODUCT IN COMMERCE 41 units DISTRIBUTION IL, Germany, Switzerland ___________________________________ PRODUCT Source Plasma. Recall # B-1496-10 CODE Unit: 4030250588 RECALLING FIRM/MANUFACTURER Recalling Firm: ZLB Bioplasma Inc., Boca Raton, FL, by email on July 11, 2008. Manufacturer: ZLB Bioplasma Inc., Louisville, KY. Firm initiated recall is complete. REASON Blood product, untested for Hepatitis B surface antigen (HBsAg), and the antibodies to the human immunodeficiency virus type 1/2 (anti-HIV-1/2), Hepatitis C virus encoded antigen (anti-HCV), Hepatitis B core antigen (anti-HBc), and Syphilis, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION IL ____________________________ June 23 ___________________________________ PRODUCT Source Plasma. Recall # B-1443-10 CODE Units: 05ANCB2927, 05ANCB2106, 05ANCB1986 RECALLING FIRM/MANUFACTURER Plasma Biological Services, Asheville, NC, by facsimile on December 15, 2009. Firm initiated recall is complete. REASON 26 Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed. VOLUME OF PRODUCT IN COMMERCE 3 units DISTRIBUTION CA ___________________________________ PRODUCT Source Plasma. Recall # B-1444-10 CODE Units: 4020414265, 4020412231, 4020411195, 4020384136, 4020382910 RECALLING FIRM/MANUFACTURER CSL Plasma Inc., Akron, OH, by electronic notification on December 12, 2008 and December 15, 2008. Firm initiated recall is complete. REASON Blood products, collected from a donor who did not receive a complete physical examination, were distributed. VOLUME OF PRODUCT IN COMMERCE 5 units DISTRIBUTION Germany, IL ___________________________________ PRODUCT 1) Red Blood Cells. Recall # B-1451-10; 2) Fresh Frozen Plasma. Recall # B-1452-10 CODE 1) Units: W227709392471, W227709390798, W227708313034; 2) Units: W227709390798, W227708313034 RECALLING FIRM/MANUFACTURER Mid-South Regional Blood Center, Memphis, TN, by facsimile on October 27, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor with a history of high risk behavior, were distributed. VOLUME OF PRODUCT IN COMMERCE 5 units DISTRIBUTION TN ___________________________________ PRODUCT Source Plasma. Recall # B-1453-10 CODE Units: 4590054884, 4590054380, 4590053950, 4590053385, 4590053089, 4590052523, 4590051779, 4590051556, 4590050586, 4590048999 RECALLING FIRM/MANUFACTURER Octapharma Plasma, Inc., Jacksonville, FL, by e-mail on December 23, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor who did not receive a complete physical examination, were distributed. VOLUME OF PRODUCT IN COMMERCE 10 units DISTRIBUTION Austria ___________________________________ PRODUCT Cryoprecipitated AHF, Pooled. Recall # B-1458-10 CODE Units: W037909161775, W037909161947, W037909161959, W037909161958, W037909177533 RECALLING FIRM/MANUFACTURER Blood Center of Iowa, Des Moines, IA, by telephone on February 2, 2010. Firm initiated recall is complete. REASON Blood products, which were labeled with extended expiration dates, were distributed. VOLUME OF PRODUCT IN COMMERCE 5 units DISTRIBUTION WI, IA ___________________________________ PRODUCT Red Blood Cells Leukocytes Reduced. Recall # B-1532-10 CODE Unit: W038109025323 RECALLING FIRM/MANUFACTURER Florida's Blood Centers, Inc., Melbourne, FL, by letter dated February 3, 2010. Firm initiated recall is complete. REASON Blood product, which was not tested for HIV/HCV NAT, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION FL ___________________________________ PRODUCT Source Plasma. Recall # B-1445-10 CODE Units: 3260000142, 3260000173, 3260004707, 3260005722 RECALLING FIRM/MANUFACTURER Talecris Plasma Resources Inc., Lake Charles, LA, by facsimile on January 8, 2009. Firm initiated recall is complete. REASON Blood products, which reached unacceptable temperatures during storage, were distributed. VOLUME OF PRODUCT IN COMMERCE 4 units DISTRIBUTION NC __________________________________ PRODUCT Source Plasma. Recall # B-1490-10 CODE Units: 4010407937, 4010407906, 4010407944, 4010407922 RECALLING FIRM/MANUFACTURER ZLB Plasma, Cleveland, OH, by letter on August 14, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor whose suitability to donate was not adequately determined, were distributed. VOLUME OF PRODUCT IN COMMERCE 4 units DISTRIBUTION IL ____________________________ June 30 ___________________________________ PRODUCT Source Plasma. Recall # B-1518-10 CODE Units: TA0009385, TA0009509, TA0009802, TA0009915, TA0010386, TA0010622, TA0009110 RECALLING FIRM/MANUFACTURER Recalling Firm: DCI Biologicals Texarkana, LLC, Gallup, NM, by letters dated July 24, 2008 and July 28, 2008. Manufacturer: DCI Biologicals Texarkana, LLC, Texarkana, AR. Firm initiated recall is complete. REASON Blood products, collected from a donor who received a tattoo within 12 months of donation, were distributed. VOLUME OF PRODUCT IN COMMERCE 7 units DISTRIBUTION NC, Austria ___________________________________ PRODUCT 1) Red Blood Cells. Recall # B-1519-10; 2) Fresh Frozen Plasma. Recall # B-1520-10 CODE 1) and 2) Unit: 2410916 RECALLING FIRM/MANUFACTURER Community Blood Center, Dayton, OH, by letter dated April 17, 2008. Firm initiated recall is complete. REASON Blood products, collected from a donor taking the medication Avodart, were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION OH ___________________________________ PRODUCT Source Plasma. Recall # B-1551-10 CODE Units: TA2027243; TA2027466; TA2027967; TA2028589; TA2029646; TA2034008; TA2034254 RECALLING FIRM/MANUFACTURER DCI Biologicals Texarkana, LLC, Texarkana, AR, by fax, letter and e-mail on October14, 2008. Firm initiated recall is complete. REASON Blood products, collected from a donor who failed to answer questions regarding risk for vCJD, were distributed. VOLUME OF PRODUCT IN COMMERCE 7 units DISTRIBUTION NC ___________________________________ PRODUCT Source Plasma. Recall # B-1552-10 CODE Units: 392024241, 392024888, 392024736, 392024460, 392023913, 392023630, 392022516, 392022315, 392021477, 392019895, 392019018, 392018776, 392017949, 392017800, 392016873, 392015873, 392015695, 392021266, 392014979, 392014796, 392014513, 392014318, 392014004, 392013315, 392011484, 392011296, 392010995, 392010791, 392011918, 392011746, 392010035, 392009822, 392009567, 392009386, 392009013, 392008696, 392007424, 392007190, 392006837, 392006655, 392003751, 392003669, I56018212, I56018076, I56017991, I56016744, I56016629, I56016549, I56016464, I56016382, I56016060, I56015712, I56015693, I56015156, I56015051, I56014305, 27 I56014146, I56013685, I56013373, I56013201, I56012705, I56012233, I56008497 and I56008467 RECALLING FIRM/MANUFACTURER Recalling Firm: Talecris Plasma Resources Inc., Research Triangle Park, NC, by fax on August 21, 2008. Manufacturer: Talecris Plasma Resources, Inc., Rockford, IL. Firm initiated recall is complete. REASON Blood products, collected from a donor who was previously permanently deferred, were distributed. VOLUME OF PRODUCT IN COMMERCE 64 units DISTRIBUTION NC, Austria ___________________________________ PRODUCT Fresh Frozen Plasma. Recall # B-1576-10 CODE Unit: W010407004016 RECALLING FIRM/MANUFACTURER Department of the Army, Brooke Army Medical Center, Fort Sam, Houston, TX, by fax on October 26, 2007. Firm initiated recall is complete. REASON Blood product, collected from a donor whose risk for variant Creutzfeldt-Jakob Disease (vCJD) was undetermined, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION NJ ___________________________________ PRODUCT 1) Red Blood Cells Leukocytes Reduced. Recall # B-1595-10; 2) Recovered Plasma. Recall # B-1596-10 CODE 1) and 2) Unit: W035209185910Z RECALLING FIRM/MANUFACTURER Carter BloodCare/ WE & Lela I Stewart Blood Center, Inc., Tyler, TX, by letter dated March 2, 2010 and by e-mail on March 2, 2010 and March 10, 2010. Firm initiated recall is complete. REASON Blood products, collected from a donor who received a blood transfusion within a year of donation, were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION TX ___________________________________ PRODUCT 1) Platelets Pooled Leukocytes Reduced Irradiated. Recall # B-1597-10; 2) Fresh Frozen Plasma. Recall # B-1598-10; 3) Red Blood Cells. Recall # B-1599-10 CODE 1) Unit: W120609383914; 2) and 3) Unit: W120609207864 RECALLING FIRM/MANUFACTURER Michigan Blood, Saginaw, MI, by facsimile on February 12, 2010 and February 16, 2010. Firm initiated recall is complete. REASON Blood products, collected from a donor with a history of exposure to and treatment for rabies, were distributed. VOLUME OF PRODUCT IN COMMERCE 3 units DISTRIBUTION MI ___________________________________ PRODUCT 1) Red Blood Cells. Recall # B-1603-10; 2) Fresh Frozen Plasma. Recall # B-1604-10; 3) Recovered Plasma. Recall # B-1605-10 CODE 1) and 2) Unit: W035409010150; 3) Unit: 3167933 RECALLING FIRM/MANUFACTURER Community Blood Center, Dayton, OH, by telephone and facsimile on February l, 2010. Firm initiated recall is complete. REASON Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed. VOLUME OF PRODUCT IN COMMERCE 3 units DISTRIBUTION Austria, OH ___________________________________ PRODUCT Platelets Pheresis Leukocytes Reduced. Recall # B-1606-10 CODE Unit: W117010154265 (2 units) RECALLING FIRM/MANUFACTURER Blood Centers of the Pacific – Irwin Center, San Francisco, CA, by telephone on February 10, 2010 and by letter dated February 12, 2010. Firm initiated recall is complete. REASON Blood products, which were not quarantined after receiving post donation information concerning an illness following donation, were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION CA ___________________________________ PRODUCT Platelet Pheresis Leukocytes Reduced. Recall # B-1610-10 CODE Unit: W035410004669 (7 units) RECALLING FIRM/MANUFACTURER Community Blood Center, Dayton, OH, by telephone on February 18, 2010. Firm initiated recall is complete. REASON Blood products, labeled with an extended expiration date, were distributed. VOLUME OF PRODUCT IN COMMERCE 7 units DISTRIBUTION OH ___________________________________ PRODUCT 1) Red Blood Cells Leukocytes Reduced. Recall # B-1613-10; 2) Cryoprecipitated AHF, Pooled. Recall # B-1614-10 CODE 1) Unit: W038110054274; 2) Unit: W038110982894 RECALLING FIRM/MANUFACTURER Florida’s Blood Centers – Lake Park, Lake Park, FL, by telephone on February 17, 2010 and March 12, 2010 and by letters dated February 24, 2010 and March 15, 2010. Firm initiated recall is complete. REASON Blood products, manufactured from units of Whole Blood that were overweight, were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION FL ___________________________________ PRODUCT Red Blood Cells Leukocytes Reduced. Recall # B-1640-10 CODE Unit: W036209625278 RECALLING FIRM/MANUFACTURER Belle Bonfils Memorial Blood Center, Denver, CO, by telephone on February 17, 2010. Firm initiated recall is complete. REASON Blood product, which was incorrectly labeled as negative for the K red cell antigen, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION CO ___________________________________ PRODUCT Platelets Pheresis Leukocytes Reduced Irradiated. Recall # B-1556-10 CODE Unit: 2880059 RECALLING FIRM/MANUFACTURER Hoxworth Blood Center University of Cincinnati Medical Center, Cincinnati, OH, by letter dated June 11, 2007. Firm initiated recall is complete. REASON Blood product, which did not have a platelet count performed, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION OH _______________________________ July 7 ___________________________________ PRODUCT Red Blood Cells, Recall # B-1521-10 CODE Unit: 3157921 RECALLING FIRM/MANUFACTURER Community Blood Center, Dayton, OH, by letter dated November 4, 2008. Firm initiated recall is complete. REASON Blood product, collected from a donor taking the medication Proscar, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit 28 DISTRIBUTION OH ___________________________________ PRODUCT Red Blood Cells. Recall # B-1661-10 CODE Units: 4818826, 4821498 RECALLING FIRM/MANUFACTURER National Naval Medical Center Bb, Bethesda, MD, by fax on September 3, 2008, January 13, 2009, April 21, 2009 and June 30, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor who traveled to an HIV Group O risk area, were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION Afghanistan, Bahrain ___________________________________ PRODUCT Red Blood Cells Leukocytes Reduced. Recall # B- 1662-10 CODE Unit: W03509005931 RECALLING FIRM/MANUFACTURER Community Blood Center dba Community Tissue Services, Dayton, OH, by telephone on January 18, 2010 and letter dated January 19, 2010. Firm initiated recall is complete. REASON Blood product, collected from a donor who was previously deferred, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION OH ___________________________________ PRODUCT Whole Blood. Recall # B-1623-10 CODE Unit: 0822633; 0822638; 0822670; 0822708 RECALLING FIRM/MANUFACTURER LifeShare Community Blood Services, Elyria, OH, by letter on November 17, 2008. Firm initiated recall is complete. REASON Blood products, collected in 500 mL bags but labeled as 450 mL, were distributed. VOLUME OF PRODUCT IN COMMERCE 4 units DISTRIBUTION OH ___________________________________ PRODUCT 1) Red Blood Cells Leukocytes Reduced. Recall # 1668-10; 2) Recovered Plasma. Recall # 1669-10 CODE 1) and 2) Unit: W221609400615 RECALLING FIRM/MANUFACTURER Central Texas Regional Blood and Tissue Center, Austin, TX, by telephone on December 7, 2009 and e-mail and fax on December 8, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor who received a bone graft within one year of donating, were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION Austria, TX ___________________________________ PRODUCT Red Blood Cells (Apheresis) Leukocytes Reduced. Recall # B-1813-10 CODE Units: 7164980, 7131248, 7131274, 7164847, 7131800, 7131665, 7131673, 7131538, 7131348, 7131712 RECALLING FIRM/MANUFACTURER South Texas Blood & Tissue Center, San Antonio, TX, by fax on October 18, 2007. Firm initiated recall is complete. REASON Blood products, for which Quality Control was not performed, were distributed. VOLUME OF PRODUCT IN COMMERCE 10 units DISTRIBUTION TX ___________________________________ PRODUCT Platelet Pheresis Leukocyte Reduced-7 day. Recall # B-1861-10 CODE Unit: 4761440 RECALLING FIRM/MANUFACTURER Florida Blood Services, Inc., St Petersburg, FL, by telephone on July 18, 2007 and fax on July 19, 2007. Firm initiated recall is complete. REASON Blood product, with positive bacterial detection testing, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION FL __________________________________ July 14 ___________________________________ PRODUCT Source Plasma. Recall # B-0778-10 CODE Units: 4210366176; 4210365011; 4210363098 RECALLING FIRM/MANUFACTURER CSL Plasma Inc., Omaha, NB, via online processing on August 14, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor whose suitability to donate was not adequately determined, were distributed. VOLUME OF PRODUCT IN COMMERCE 3 units DISTRIBUTION Switzerland, IL ___________________________________ PRODUCT 1) Red Blood Cells Leukocytes Reduced. Recall # B-1677-10; 2) Fresh Frozen Plasma. Recall # B-1678-10 CODE 1) Units: 93L30356, 93L32026, 93L35684, 93L38435, 93L21450, 93L22596, 93L23904, 93L25347, 93L27618, 93L30043, 93R01203; 2) Units: 93L38435, 93L22596, 93L30043, 93GC02513 RECALLING FIRM/MANUFACTURER Mercy Hospital, BB, Springfield, MA, by facsimile on December 23, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor with a history of hepatitis A, were distributed. VOLUME OF PRODUCT IN COMMERCE 15 units DISTRIBUTION MA ___________________________________ PRODUCT 1) Platelets Pooled Leukocytes Reduced Irradiated. Recall # B-1679-10; 2) Red Blood Cells. Recall # B-1680-10; 3) Platelets Pooled Leukocytes Reduced. Recall # B-1681-10; 4) Recovered Plasma. Recall # B-1682-10 CODE 1) Unit: W120609383914; 2) Units: W120609207863, W120609206376; 3) Units: W120609384771; 4) Units: W120609206376, W120609207863 RECALLING FIRM/MANUFACTURER Michigan Blood, Saginaw, MI, by facsimile on February 16, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor with a history of exposure to and treatment of rabies, were distributed. VOLUME OF PRODUCT IN COMMERCE 6 units DISTRIBUTION Switzerland, Michigan ___________________________________ PRODUCT 1) Red Blood Cells Leukocytes Reduced. Recall # B-1683-10; 2) Plasma Frozen. Recall # B-1684-10 CODE 1) and 2) Unit: 9352826 RECALLING FIRM/MANUFACTURER Blood Centers of the Pacific – Irwin Center, San Francisco, CA, by telephone on February 22, 2010. Firm initiated recall is complete. REASON Unit: Blood products, collected from a donor who was at risk for variant Creutzfeldt- Jakob Disease (vCJD), were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION CA ___________________________________ PRODUCT Red Blood Cells Leukocytes Reduced. Recall # B-1688-10 CODE Unit: 7144298 RECALLING FIRM/MANUFACTURER Oklahoma Blood Institute –Sylvan N Goldman Center, Oklahoma City, OK, by facsimile on March 2, 2010. Firm initiated recall is complete. REASON Blood product, collected from a donor who was permanently deferred, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit 29 DISTRIBUTION OK ___________________________________ PRODUCT Source Plasma. Recall # B-1705-10 CODE Units: 05ANCB0982, 05ANCB0820, 05ANCB0600, 05ANCA9729, 05ANCA9124, 05ANCA8538, 05ANCA8148, 05ANCA7945, 05ANCA7620, 05ANCA7440 RECALLING FIRM/MANUFACTURER Plasma Biological Services, Asheville, NC, by facsimile on November 10, 2005. Firm initiated recall is complete. REASON Blood products, collected from a donor who had previously tested reactive for Hepatitis C (HCV), were distributed. VOLUME OF PRODUCT IN COMMERCE 10 units DISTRIBUTION CA ___________________________________ PRODUCT 1) Red Blood Cells Leukocytes Reduced. Recall # B-1724-10; 2) Platelets. Recall # B-1725-10 3) Fresh Frozen Plasma. Recall # B-1726-10 CODE 1), 2), and 3) Units: 2373937 RECALLING FIRM/MANUFACTURER Central Kentucky Blood Center, Inc., Lexington, KY, by letter dated October 23, 2007. Firm initiated recall is complete. REASON Blood products, collected from a donor who traveled to an area considered at risk for human immunodeficiency virus (HIV) Group O, were distributed. VOLUME OF PRODUCT IN COMMERCE 3 units DISTRIBUTION KY ___________________________________ PRODUCT Source Plasma. Recall # B-1728-10 CODE Units: 4100366459, 4100365389, 4100362907, 4100362151, 4100360549, 4100359558, 4100356716, 4100355069, 4100353523, 4100352574, 4100350951, 4100350183, 4100346510, 4100345847, 4100341596, 4100335593 RECALLING FIRM/MANUFACTURER ZLB Bioplasma, Inc., Kansas City, MO, by electronic notification on August 31, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor who did not receive a complete physical examination, were distributed. VOLUME OF PRODUCT IN COMMERCE 16 units DISTRIBUTION IL ___________________________________ PRODUCT Red Blood Cells Leukocytes Reduced. Recall # B-1765-10 CODE Unit: 53LL00315 RECALLING FIRM/MANUFACTURER American National Red Cross-Greater Chesapeake & Potomac Region, Baltimore, MD, by facsimile on January 29, 2010. Firm initiated recall is complete. REASON Blood product, incorrectly labeled as negative for the Jk (a) red cell antigen, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION MD ___________________________________ PRODUCT 1) Red Blood Cells Leukocytes Reduced. Recall # B-1781-10; 2) Platelets. Recall # B-1782-10; 3) Fresh Frozen Plasma. Recall # B-1783-10; 4) Source Leukocytes. Recall # B-1784-10 CODE 1), 2), 3), 4) Unit: W044608300770 RECALLING FIRM/MANUFACTURER Gulf Coast Regional Blood Center, Houston, TX, by facsimile on May 2, 2008. Firm initiated recall is complete. REASON Blood products, collected from a donor with a history of hepatitis, were distributed. VOLUME OF PRODUCT IN COMMERCE 4 units DISTRIBUTION TX, NJ ___________________________________ PRODUCT Platelets Pheresis Leukocytes Reduced. Recall # B-1785-10 CODE Unit: 09FC37692 (2 units) RECALLING FIRM/MANUFACTURER American Red Cross Blood Services, Omaha, NB, by telephone on January 28, 2010 and by facsimile on February 3, 2010. Firm initiated recall is complete. REASON Blood products, collected in a manner that may have compromised the sterility of the units, were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION NB ___________________________________ PRODUCT Source Plasma. Recall # B-1786-10 CODE Units: 6130023335, 6130023031, 6130024323 RECALLING FIRM/MANUFACTURER CSL Plasma, Inc, Zlb Plasma, Duluth, MN, by letter dated February 3, 2010. Firm initiated recall is complete. REASON Blood products, collected from donors who were previously deferred for high risk behavior, were distributed. VOLUME OF PRODUCT IN COMMERCE 3 units DISTRIBUTION Germany ___________________________________ PRODUCT 1) Fresh Frozen Plasma. Recall # B-1787-10; 2) Red Blood Cells Leukocytes Reduced. Recall # B-1789-10 CODE 1) Unit: 2426762; 2) Units: 2426762, 2917746 RECALLING FIRM/MANUFACTURER Central California Blood Center, Fresno, CA, by facsimile and e-mail on March 19, 2010. Firm initiated recall is complete. REASON Blood products, collected from a donor who was previously deferred for testing positive for the human immunodeficiency virus (HIV), were distributed. VOLUME OF PRODUCT IN COMMERCE 3 units DISTRIBUTION CA, Austria ___________________________________ PRODUCT Recovered Plasma. Recall # B-0790-10 CODE Unit: 53FM05356 RECALLING FIRM/MANUFACTURER American National Red Cross-Greater Chesapeake and Potomac Region, Baltimore, MD, by telephone on July 24, 2009 and follow up letter dated August 21, 2009. Firm initiated recall is complete. REASON Blood product, collected from a donor whose suitability to donate was not adequately determined, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION CA ___________________________________ PRODUCT Red Blood Cells (Apheresis) Leukocytes Reduced. Recall # B-1649-10 CODE Units: W042408019401M, W042408019407A, W0424080194272, W042408019430C, W0424080194336, W042408019497B, W042408019510C, W0424080194088 RECALLING FIRM/MANUFACTURER Recalling Firm: Blood Systems Inc, Scottsdale, AZ, by telephone on October 17, 2008. Manufacturer: Blood Systems, Inc., Rapid City, SD. Firm initiated recall is complete. REASON Apheresis red cells, manufactured using Lactated Ringers Solution instead of Saline as the volume replacement solution for the donor, were distributed. VOLUME OF PRODUCT IN COMMERCE 16 units (Double Collections) DISTRIBUTION CA, TX, MI, SD, NH ___________________________________ PRODUCT Source Plasma. Recall # B-1685-10 CODE Units: 09OUTD7444; 07OUTE7478 RECALLING FIRM/MANUFACTURER BioLife Plasma Services L.P., Ogden, UT, by facsimile on February 15, 2010. Firm initiated recall is complete. REASON Blood products, collected from a donor in which donor suitability was not adequately determined, were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION CA 30 PRODUCT Source Leukocytes. Recall # B-1687-10 CODE Unit: W044609512182 RECALLING FIRM/MANUFACTURER Gulf Coast Regional Blood Center, Houston, TX, by fax on January 11, 2010, January 12, 2010 and January 13, 2010. Firm initiated recall is complete. REASON Blood product, collected from a donor whose suitability to donate was not adequately determined, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION NJ ___________________________________ PRODUCT Source Plasma. Recall # B-1692-10 CODE Units: AQ030479; AQ030602 RECALLING FIRM/MANUFACTURER Plasma Biological Services, Inc., Ashville, NC, by facsimile on October 2, 2007. Firm initiated recall is complete. REASON Blood products, which were collected from a donor in which donor suitability was not adequately determined, were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION NC ___________________________________ PRODUCT Source Plasma. Recall # B-1693-10 CODE Unit: AQ030651 RECALLING FIRM/MANUFACTURER Recalling Firm: Plasma Biological Services, Inc., Memphis, TN, by facsimile on October 2, 2007. Manufacturer: Plasma Biological Services, Ashville, NC. Firm initiated recall is complete. REASON Blood product, which was collected from a donor in which donor suitability was not adequately determined, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION NC ___________________________________ PRODUCT Source Plasma. Recall # B-1695-10 CODE Unit: AQ030628 RECALLING FIRM/MANUFACTURER Plasma Biological Services, Inc., Ashville, NC, by facsimile on October 2, 2007. Firm initiated recall is complete. REASON Blood product, which was collected from a donor in which donor suitability was not adequately determined, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION NC ___________________________________ PRODUCT Source Plasma. Recall # B-1699-10 CODE Unit: AQ030444 RECALLING FIRM/MANUFACTURER Recalling Firm: Plasma Biological Services, Inc., Memphis, TN, by facsimile on October 16, 2007. Manufacturer: Plasma Biological Services, Ashville, NC. Firm initiated recall is complete. REASON Blood product, which was collected from a donor in which donor suitability was not adequately determined, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION NC PRODUCT 1) Red Blood Cells. Recall # B-1762-10; 2) Fresh Frozen Plasma. Recall # B-1763-10 CODE 1) and 2) Unit: W065608014498 RECALLING FIRM/MANUFACTURER Bergen Community Regional Blood Center, Paramus, NJ, by facsimile on August 7, 2009, by telephone and facsimile on April 20, 2010. Firm initiated recall is complete. REASON Blood products, collected from a donor who received the shingles vaccine, were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION NJ ___________________________________ PRODUCT Recovered Plasma. Recall # B-1788-10 CODE Unit: 2917746 RECALLING FIRM/MANUFACTURER Central California Blood Center, Fresno, CA, by facsimile and e-mail on March 19, 2010. Firm initiated recall is complete. REASON Blood product, collected from a donor who was previously deferred for testing positive for the human immunodeficiency virus (HIV), was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION CA, Austria ___________________________________ PRODUCT Recovered Plasma. Recall # B-1791-10 CODE Units: 004J19803, 004KH29553, 004KK80768, 004KM20958 RECALLING FIRM/MANUFACTURER ARC Blood Services, New England Region, Dedham, MA, by facsimile and e-mail on March 18, 2010. Firm initiated recall is complete. REASON Blood products, collected from donors for whom donor suitability was not adequately determined, were distributed. VOLUME OF PRODUCT IN COMMERCE 4 units DISTRIBUTION CA ___________________________________ PRODUCT Recovered Plasma. Recall # B-1795-10 CODE Unit: 004Y18860 RECALLING FIRM/MANUFACTURER Recalling Firm: ARC Blood Services, New England Region, Dedham, MA, by telephone, facsimile and e-mail on January 21, 2010. Manufacturer: ANRC ARC Blood Services, New England Region, Danvers, MA. Firm initiated recall is complete. REASON Blood product, collected from donors for whom donor suitability was not adequately determined, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION CA _______________________________________ July 21 ___________________________________ PRODUCT Source Plasma, Recall # B-1069-10 CODE Units: 09VMNM6140, 09VMNM4297, 09VMNL8158, 09VMNL6969, 09VMNL0562, 09VMNK8176, 09VMNK5683, 09VMNK4450, 09VMNK0982, 09VMNJ7794 and 09VMNJ4860 RECALLING FIRM/MANUFACTURER BioLife Plasma Services L.P., Mounds View, MN, by facsimile on March 10, 2010. Firm initiated recall is complete. REASON Blood products, collected from a donor who had not had an annual physical performed, were distributed VOLUME OF PRODUCT IN COMMERCE 11 units DISTRIBUTION CA ___________________________________ PRODUCT Source Plasma, Recall # B-1284-10; CODE Units: 4920206775, 4920205016, 4920203888, 4920203241, 4920198342, 4920197920, 4920196898, 4920196384, 4920195250, 4920194746, 4920193637, 4920193115, 4920191644, 4920190213, 4920189291, 4920188842, 4920187437, 4920186141, 4920185273, 4920184886, 4920183704, 4920182733, 4920180857, 4920179969, 4920179518, 4920170811, 4920169878, 4920169439, 4920168495, 4920168123, 4920167239, 4920166812, 4920165914, 4920165466, 4920164582, 4920164150, 4920163324, 4920162938 RECALLING FIRM/MANUFACTURER Recalling Firm: CSL Plasma, Boca Raton, FL, by telephone on July 28, 2007. Manufacturer: CSL Plasma, Springfield, OH. Firm initiated recall is complete. REASON Blood products, collected from a donor, whose suitability to donate was not adequately determined, were distributed. VOLUME OF PRODUCT IN COMMERCE 38 units 31 DISTRIBUTION IL, Germany, Switzerland ___________________________________ PRODUCT Source Plasma, Recall # B-1286-10 CODE Units: 0530622293, 0530620404, 0530618722, 0530617861, 0530617047, 0530616124, 0530615083, 0530614455, 0530613150, 0530612740, 0530611053, 0530610490, 0530609346, 0530608732, 0530607573, 0530606970, 0530605820, 0530605309, 0530604211, 0530603610, 0530602636, 0530602065, 0530600978, 0530599819, 0530599356, 0530598411, 0530597977 RECALLING FIRM/MANUFACTURER Recalling Firm: CSL Plasma, Boca Raton, FL, by letter dated November 4, 2007. Manufacturer: CSL Plasma, Lexington, KY. Firm initiated recall is complete. REASON Blood products, collected from a donor whose physical examination was expired, were distributed. VOLUME OF PRODUCT IN COMMERCE 27 units DISTRIBUTION IL, Germany, Switzerland ___________________________________ PRODUCT 1) Red Blood Cells Leukocytes Reduced. Recall # Recall # B-1645-10; 2) Platelets Pooled Leukocytes Reduced. Recall # B-1646-10 CODE 1) Unit: 42H60009; 2) Units: 42FX67497POOL; 42FX67520POOL; 42H60009POOL; 42H60004POOL; 42H60006POOL; 42H59997POOL; 42H60018POOL RECALLING FIRM/MANUFACTURER American Red Cross Blood Services, Cleveland, OH, by telephone on January 28, 2008 and letter on February 1, 2008. Firm initiated recall is complete. REASON Blood products, possibly contaminated with air, were distributed. VOLUME OF PRODUCT IN COMMERCE 8 units DISTRIBUTION OH ___________________________________ PRODUCT Source Plasma. Recall # B-1718-10 CODE Units: 4240226541, 4240220002, 4240218712, 4240217265, 4240216761, 4240215513, 4240215160, 4240214045, 4240213506, 4240211631, 4240210895, 4240209695, 4240208742, 4240207633, 4240206837, 4240205362, 4240204790 RECALLING FIRM/MANUFACTURER ZLB Bioplasma, Inc., Davenport, IA, by electronic notification on April 27, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor who did not receive a complete physical examination, were distributed. VOLUME OF PRODUCT IN COMMERCE 17 units DISTRIBUTION Switzerland, IL ___________________________________ PRODUCT Source Plasma. Recall # B-1722-10 CODE Units: 4100364838, 4100361389, 4100356793, 4100347367, 4100342910 RECALLING FIRM/MANUFACTURER ZLB Bioplasma, Inc., Kansas City, MO, by letter dated October 23, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor who received a tattoo within 12 months of donation, were distributed. VOLUME OF PRODUCT IN COMMERCE 5 units DISTRIBUTION IL ___________________________________ PRODUCT Red Blood Cells Leukocytes Reduced. Recall # B-1727-10 CODE Unit: 8883824 RECALLING FIRM/MANUFACTURER Florida’s Blood Centers, Inc., Ocala, FL, by letters dated December 16, 2009 and December 21, 2009. Firm initiated recall is complete. REASON Blood product, collected from a donor who was previously deferred for testing repeat reactive for HTLV-I/II, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION FL ___________________________________ PRODUCT Source Plasma. Recall # B-1758-10 CODE Units: 09GUTD6504, 09GUTD8499, 09GUTD5081, 09GUTD4387, 09GUTD2986, 09GUTD2235, 09GUTC6434, 09GUTC5653. 09GUTC4209, 09GUTC3441, 09GUTC0173, 09GUTB9405, 09GUTB8011, 09GUTB7278, 09GUTB5903, 09GUTB5174 and 09GUTB3900 RECALLING FIRM/MANUFACTURER BioLife Plasma Services L.P., Saint George, UT, by facsimile on February 3, 2010. Firm initiated recall is complete. REASON Blood products, collected from a donor who had not had an annual physical performed, were distributed. VOLUME OF PRODUCT IN COMMERCE 17 units DISTRIBUTION CA ___________________________________ PRODUCT 1) Recovered Plasma. Recall # B-1772-10; 2) Red Blood Cells Leukocytes Reduced. Recall # B-1773-10; 3) Fresh Frozen Plasma. Recall # B-1774-10 CODE 1) Unit: 6174086; 2) Units: 6205935, 6174086, 6142542; 3) Units: 6205935, 6142542 RECALLING FIRM/MANUFACTURER South Texas Blood and Tissue Center, San Antonio, TX, by facsimile on September 29, 2009, October 6, 2009, November 3, 2009, and November 4, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob Disease (vCJD), were distributed. VOLUME OF PRODUCT IN COMMERCE 6 units DISTRIBUTION Austria, TX ___________________________________ PRODUCT Red Blood Cells Leukocytes Reduced. Recall # B-1823-10 CODE Unit: 9648372 RECALLING FIRM/MANUFACTURER Gulf Coast Regional Blood Center, Houston, TX, by facsimile on May 1, 2008. Firm initiated recall is complete. REASON Blood product, collected from a donor who was previously deferred for testing positive for the human immunodeficiency virus (HIV), was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION TX, NJ ___________________________________ PRODUCT Recovered Plasma, Recall # B-1468-10 CODE Unit: 19LR15032 RECALLING FIRM/MANUFACTURER American Red Cross Blood Services Tennessee Valley Region, Nashville, TN, by facsimile and letter on December 10, 2009. Firm initiated recall is complete. REASON Blood product, collected from a donor for which donor suitability was not adequately determined, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION CA ___________________________________ PRODUCT Recovered Plasma. Recall # B-1510-10 CODE Unit: 53K56871 RECALLING FIRM/MANUFACTURER American National Red Cross-Greater Chesapeake & Potomac Reg., Baltimore, MD, by facsimile, letter and LOGIC on January 12, 2010. Firm initiated recall is complete. REASON Blood product, collected from a donor for whom donor suitability was not adequately determined, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION MD ___________________________________ PRODUCT 1) Red Blood Cells Leukocytes Reduced. Recall # B-1642-10; 2) Platelets Pooled Leukocytes Reduced. Recall # B-1643-10; 3) Platelets Leukocytes Reduced. Recall # Recall # B-1644-10 CODE 1) Units: 442FG33587; 42FG33588; 42FG33598; 42FG33602; 42FG33603; 32 42FG33604; 42FG33606; 42FG33610; 42FG33611; 42FG33613; 42FG33616; 42FG33617; 42FG33618; 42FG33619 2) Units: 11509; 11510; 11526; 3) Units: 42FG33585; 42FG33615 RECALLING FIRM/MANUFACTURER American Red Cross Blood Services, Cleveland, OH, by telephone on September 26, 2007 and letter on October 3, 2007. Firm initiated recall is complete. REASON Blood products, labeled as volunteer were collected from donors who received monetary payment, were distributed. VOLUME OF PRODUCT IN COMMERCE 19 units DISTRIBUTION OH ___________________________________ PRODUCT Red Blood Cells Leukocytes Reduced. Recall # B-1647-10 CODE Units: 42FR48513; 42J86868; 42J86879; 42J86885 RECALLING FIRM/MANUFACTURER American Red Cross Blood Services, Cleveland, OH, by telephone on May 3, 2008 and by letter on May 9, 2008. Firm initiated recall is complete. REASON Blood products, collected using a scales that had unacceptable quality control results, were distributed. VOLUME OF PRODUCT IN COMMERCE 4 units DISTRIBUTION OH ___________________________________ PRODUCT Red Blood Cells Leukocytes Reduced. Recall # B-1648-10 CODE Units: 20M57203; 20KK55929; 20LS32166 RECALLING FIRM/MANUFACTURER The American National Red Cross, Salt Lake City, UT, by fax on October 25, 2007 and letter on October 26, 2007. Firm initiated recall is complete. REASON Blood products, lacking assurance of having been maintained at an acceptable temperature during shipping, were distributed. VOLUME OF PRODUCT IN COMMERCE 3 units DISTRIBUTION UT ___________________________________ PRODUCT Recovered Plasma. Recall # B-1701-10 CODE Units: 22GZ39134 and 22GM60502 RECALLING FIRM/MANUFACTURER American National Red Cross, Penn Jersey Region, Philadelphia, PA, by facsimile on December 11, 2009. Firm initiated recall is complete. REASON Blood products, collected from a donor for which donor suitability was not adequately determined, were distributed. VOLUME OF PRODUCT IN COMMERCE 2 units DISTRIBUTION CA ___________________________________ PRODUCT Recovered Plasma. Recall # B-1743-10 CODE Unit: 24FW31505 RECALLING FIRM/MANUFACTURER The American Red Cross Blood Services, Louisville, KY, by letter and e-mail on December 10, 2007. Firm initiated recall is complete. REASON Blood product, collected from a donor whose suitability to donate was not adequately determined, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION CA ___________________________________ PRODUCT Recovered Plasma. Recall # B-1748-10 CODE Unit: 24KE69016 RECALLING FIRM/MANUFACTURER Recalling Firm: The American National Red Cross, River Valley Region, Louisville, KY, by letter and email on September 21, 2007, September 26, 2007 and October 29, 2007. Manufacturer: American Red Cross Blood Services, River Valley Region, Louisville, KY. Firm initiated recall is complete. REASON Blood product, collected from a donor whose suitability to donate was not adequately determined, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION CA ___________________________________ PRODUCT Recovered Plasma. Recall # B-1750-10 CODE Unit: 24GY32502 RECALLING FIRM/MANUFACTURER Recalling Firm: The American National Red Cross, River Valley Region, Louisville, KY, by letter and email on August 2, 2007. Manufacturer: American Red Cross Blood Services, River Valley Region, Louisville, KY. Firm initiated recall is complete. REASON Blood product, collected from a donor whose suitability to donate was not adequately determined, was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION CA ___________________________________ PRODUCT Recovered Plasma. Recall # B-1822-10 CODE Unit: 9648372 RECALLING FIRM/MANUFACTURER Gulf Coast Regional Blood Center, Houston, TX, by facsimile on May 1, 2008. Firm initiated recall is complete. REASON Blood product, collected from a donor who was previously deferred for testing positive for the human immunodeficiency virus (HIV), was distributed. VOLUME OF PRODUCT IN COMMERCE 1 unit DISTRIBUTION TX, NJ 33 Attachment 5: COTT Press Statement, Coalition for Worker Safety Press Conference Committee of Ten Thousand A d v o c a t e s f o r P e r s o n s w i t h H C V - H I V / A I D S 236 Massachusetts Ave., NE Suite 609 • Washington, DC 20002 (202) 543-0988 • (202) 543-6720 fax • www.cott1.org • cott-dc@earthlink.net Contacts: Dave Cavenaugh-(202) 841-9805 Corey Dubin-(805) 967-6679 Workers at ARC Facilities Raise Safety Concerns The Committee of Ten Thousand is a grass-roots, peer-led, advocacy and support organization in the hemophilia community. Our core constituency is the HIV/AIDS and hepatitis C infected hemophilia community. Our name was taken in honor of the ten thousand persons with hemophilia infected with HIV/AIDS through tainted blood products in the 1980s.Roughly eight thousand have already died and the survivors are dwindling in numbers rapidly. We must also not forget the roughly 12-15 thousand Americans who also contracted HIV/AIDS through tainted transfusions, and blood components, also during the 1980s. The AIDS/blood epidemic was preventable and represented a failure of the blood community, the manufacturers of blood products, the federal government, and the medical community. It remains the worst medical disaster in US history and we, as a community, are still paying the price of this colossal failure. Many measures have been taken since those times to protect the blood supply from such viruses and other contaminants, including better screening of potential donors at the blood collection site, better means for handling and preserving units collected, and most of all vastly improved abilities to test blood collected. None of these safeguards are perfect, but through rigorous application of what the Food and Drug Administration (FDA) calls “layers of safety,” it is generally agreed that the blood supply is safer than it ever has been. However, troubling issues and concerns remain unanswered and difficult to watch for those of us still living with the last failure on a daily basis. We are here today in support of blood collection center workers and the unions who represent them. Earlier this year AFL-CIO approached COTT seeking to voice workers’ concerns regarding safety. We listened and learned of some of the difficulties workers are facing at some ARC blood collection centers. Workers expressed their individual concerns regarding working conditions and the potential impact on safety of long hours and high turnover rates. After much discussion and debate COTT’s Board of Directors, all veterans of the 1980s, realized the importance of the issues and concerns being raised by the workers and the unions representing them. We are still awaiting the substantive response of the American Red Cross to questions that we believe absolutely merit concern and regulatory action. The American Red Cross has been operating under a Federal District Court Consent Decree since 1993. For nearly seventeen years a very significant percentage, now upwards of 40 percent of all blood collected in the US, is done so under the watchful eye of the Federal District Court in Washington D.C. The list of ongoing violations is voluminous if you consider the 17 year life of the Consent Decree and FDA’s repeated initiatives to gain ARC Compliance. What is most troubling for COTT is the potential for harm if we take just a sampling of violations associated with the FDA’s 30 October 2009 Adverse determination Letter: 34 • Three events involving 27 blood products from donors who either had a previously reported history of testing HIV positive, or blood products that were not properly tested for HIV; • Three events involving 25 blood products from donors who previously had a reported history of hepatitis or whom were considered at a higher risk for hepatitis; • One event involving 394 blood products that were not properly tested and screened for syphilis; • Over 100 blood products from donors who should have been deferred for travel due to malaria risk areas; • Hundreds of blood products that Red Cross determined to be “suspect,” but failed to control the products in a timely manner resulting in distribution; • Hundreds of blood products that Red Cross determined to be “suspect,” but failed to control the products in a timely manner resulting in distribution; • Hundreds of blood products from donors who were not asked proper screening questions due to incorrect gender information in blood donor records; • Over 1,800 blood products that were distributed with unacceptable quality control. The level of ongoing violations at ARC is difficult to comprehend when one considers that this is about one of the most precious resources in our nation; The Blood Supply. For COTT, this remains an unacceptable situation that must be rectified with all deliberate national effort and will. How this has become an acceptable part of our national blood supply landscape is unconscionable to the members of COTT’s Board of Directors, many of them HIV/AIDS survivors, or parents and siblings of causalities of the1980s failure. Our thanks to the workers you are meeting today, for their courage in raising difficult issues and for their caring about those who depend on a safe national blood supply to maintain a modicum of health and wellness. To these workers we thank you and want to help ensure that our nation is listening. We support the AFL-CIO, and the Red Cross workers represented here today, and say to them, Thanks for your efforts to keep the blood that we and many others need, as safe as possible. more...
|
|
| Posted by Dave Cavenaugh 08-13-2010 |
WASHINGTON UPDATE |
 |
|
> ACBSA Meets To Consider MSM Blood Donor Deferral Policy Changes On June 10-11 the Department of Health and Human Services’ Advisory Committee On Blood Safety and Availability (ACBSA) met in Washington DC to consider change in the blood donor deferral policy regarding “men who have had sex with men”, or MSM. Currently, a potential male donor who reports having had sex, even once, with another male at any time since 1977, is permanently deferred from donating blood. In the last Update we reported on the proposal to lift the ban which came from Gay Mens Health Crisis in New York and was supported by twenty-one Senators in a joint letter to FDA Commissioner Margaret Hamburg in March of this year. Change in the deferral policy was also supported by the American Red Cross, the American Association of Blood Banks and Americas Blood Centers. The ACBSA heard from both experts and community-based organizations regarding the proposed change. more...
|
|
| Posted by Dave Cavenaugh 05-03-2010 |
WASHINGTON UPDATE |
 |
|
>> BLOOD Supply: Proposed Changes In Donor Deferral Policies. .In early March seventeen members of the Senate signed on to a letter, authored by Massachusetts Senator John Kerry, to the Commissioner of the Food & Drug Administration, Margaret Hamburg, requesting a review of the blood donor deferral regulation regarding Men Having Sex With Men (MSM). The letter is the result of an initiative for change sponsored by Gay Men’s Health Crisis (GMHC) in New York. GMHC commissioned a report on the deferral policy through a law firm and has used that report as the basis for this initiative to re-assess and hopefully relax the ban on blood donations from men who have had sex with men. The report and GMHC view the deferral policy as discriminatory toward gay men and lacking a strong basis in the latest science and epidemiology. more...
|
|
| Posted by Dave Cavenaugh 12-18-2009 |
WASHINGTON UPDATE |
 |
|
> COTT’S 20TH ANNIVERSARY AND FIRST ANNUAL SURVIVORS GATHERING. In addition to the brief report on the event which we provided in the previous Update, we wanted to include a strong Statement of Support which we received for the event. It was necessary to secure written permission, however, to use it in the Update as well as at the Anniversary. Such permission has now been received, and we are pleased to share with you the following:. Warm greetings to everyone gathered in our nation's capital to celebrate the 20th anniversary of the Committee of Ten Thousand. more...
|
|
| Posted by Dave Cavenaugh 10-06-2009 |
WASHINGTON UPDATE |
 |
|
Vol 11 No 4
The COTT Washington Update is posted on the hemophilia-support listserv and on our website, www.cott1.org. To receive the Update directly, send an e-mail to COTT at cott-dc@earthlink.net. Edward M. Kennedy: A Remembrance The passing of Senator Edward Kennedy of Massachusetts saddened the members of the Committee of Ten Thousand. From our first exploratory trips to Washington D.C., Senator Kennedy was responsive and ready to work with COTT and others to ensure a modicum of justice for the HIV/AIDS infected hemophilia community while quickly grasping the issues regarding the HIV/AIDS contamination of our nation’s blood supply. It was Senator Kennedy who offered a National Academy of Science, Institute of Medicine study on the contamination of the blood supply with HIV/AIDS, which infected ten thousand persons with hemophilia through tainted factor concentrates. The IOM study, HIV and the Blood Supply; An Analysis of Crisis Decision Making became the official basis for the passage of the Ricky Ray Hemophilia Relief Fund Act of 1998. The Senator continued throughout the last 16 years to be a strong advocate for a safe national blood supply. We have a long history with the Senator as in 1979 Alfred Dubin, then Chairman of the Board of the Hemophilia Foundation of Southern California, met with Mr. Kennedy to discuss national health insurance and the needs of the hemophilia community. Fourteen years later Alfred Dubin’s son, COTT President Corey Dubin, renewed the relationship with Senator Kennedy. We will sorely miss the Senator and his tireless advocacy and support of individuals and communities in need. For COTT Senator Kennedy was the consummate example of the COTT ethos: Action=Life. more...
|
|
| Posted by Dave Cavenaugh 06-23-2009 |
WASHINGTON UPDATE |
 |
|
> STATE ISSUES California – California continues to be of great concern for our community given the high cost of hemophilia/bleeding disorders treatment and the monumental deficit the State is currently facing. Even more disconcerting for the HIV/AIDS infected hemophilia community are the proposed cuts in HIV/AIDS funding: both treatment and prevention are slated for serious funding cuts. California’s deficit is the largest of any state in our nation at between $20 and 25 billion dollars depending on numbers used. It is deep enough to mean draconian cuts in the State’s social services programs, especially health care. Access to health care is to be greatly limited, as is State reimbursement for that care. Those most in need in California are precisely to be those most severely impacted by the cuts. .The Hemophilia Council of California, working proactively and consistently with the local organizations and the community’s three national organizations as well, have helped to assure that the Genetically Handicapped Persons Program (GHPP) and Crippled Childrens Services (CCS), the two main California public insurance programs for hemophilia and other bleeding disorders, will survive the current round of draconian cuts. There has been some important give and take between the State and the community this year. Discussions in May concluded with agreement that the proposed GHPP enrollment fee increase was an area where the community could compromise given the dire budget landscape facing California and, in fact, GHPP enrollment fees have not been raised in over ten years. The State in turn agreed to provide premium support for members of our community thereby keeping some individuals under private insurance. While welcome, this will be on a case by case basis which raises some concerns for COTT regarding questions of equity in terms of who ultimately GHPP decides to provide premium support for. more...
|
|
| Posted by Dave Cavenaugh 03-17-2009 |
WASHINGTON UPDATE |
 |
|
> BRITISH FIND VCJD IN OLDER MAN WITH HEMOPHILIA The United Kingdom Health Ministry announced on February 17, 2009 that researchers had discovered evidence of variant Creutzfeldt - Jakob disease (vCJD) during a routine autopsy on an older man with hemophilia who had died of unrelated causes. Evidence of vCJD was found in the spleen. Although he had not shown the symptoms associated with vCJD, the presence of prions, thought to be the causal agent of vCJD, was clear. This is the first known confirmatory evidence of vCJD in a person with hemophilia. While there are other known vectors for contracting the disease, the medical history of the man (use of plasma-derived factor until the late 1990s) and the fact that one of the donors to the plasma pool from which the product he used was made contracted the disease shortly after donating, convinced researchers that this was the route of transmission, rather than the more widely recognized beef consumption route. For the second time in a decade, the entire British hemophilia community has been warned about the potential blood-borne transmission of vCJD through factor concentrates. They are to consider themselves at highest risk, and inform medical providers of this before receiving care. There is no treatment for vCJD itself, however, and it is universally fatal. Blood transmission of CJD and vCJD has been debated and discussed since the early 1990s. That debate became more intense and urgent following the vCJD outbreak in the mid 1990s in Great Britain from contaminated beef, leading to a number of deaths in the UK. Those deaths were clearly associated with the consumption of tainted beef. The UK outbreak raised concerns in the hemophilia community regarding the potential for blood and plasma donors who had been exposed to vCJD from beef to transmit the pathogen through their blood and/or plasma donations. more...
|
|
| Posted by Dave Cavenaugh 02-06-2009 |
WASHINGTON UPDATE |
 |
|
> ADMINISTRATION Consider this the “Transition Issue” of the Update – the election, the Transition and the Inauguration have all happened during the time period it covers. The major changes expected from the new leadership began well before Inauguration, as President Obama actively engaged in negotiations on Capitol Hill. In addition to pressing for full and rapid action, the Administration was and is working to maximize the degree to which the Plan can help launch some of the President’s stated proposals in addition to economic recovery – health reform, energy independence and infrastructure repair. Also during the winter months Transition Task Forces fanned out through all federal agencies, bringing back to planners a sense of what works and what doesn’t to support some rapid restructuring. more...
|
|
| Posted by Dave Cavenaugh 11-12-2008 |
WASHINGTON UPDATE |
 |
|
> CONGRESS & THE PRESIDENCY With the clear victory of Sen. Barack Obama (D-IL) over Sen. John McCain (R-AZ) in the Presidential race, after a campaign that lasted just shy of two whole years, the voters have indicated the need for a revolutionary change in America. Change from a White House philosophy which has a) had us committed abroad in an expensive war seeming without end, b) has more than tripled the National Debt, and c) has provided tax incentives to business that we saw turned into sinfully excessive salaries for executives … and layoffs for the rank and file. . The House Democratic majority is now much more clearly established than in the last two years; the Senate finally has a clear Democratic majority, as opposed to the razor-thin edge it has held recently. Thus hopes are high for increasing funding for many social programs that have been cut or held level for years. To provide these increases will require new revenue, particularly given the expense of the bailout(s). Hopefully a large down payment on this can come from winding down the war in Iraq and letting Bush tax cuts for business expire. more...
|
|
| Posted by Dave Cavenaugh 09-30-2008 |
WASHINGTON UPDATE |
 |
|
. > STATE-LEVEL ISSUES .On September 18th, the California Legislature and Governor came together, more than two months after the state’s fiscal year had begun, and agreed to an amount for the 2008-2009 Fiscal Year Budget that all parties were willing to accept. Since over four and a quarter Billion dollars in state expenditures – for health care, education, food and other programs – was held up over this two month period, causing severe hardships on those most in need across the state, pressure was extreme to resolve the matter so checks could flow. The compromise budget creates no new taxes; it does however borrow funds, mostly from future years, to close the current deficit. Savings found also come through increased penalties for corporations late in filing taxes in excess of $1 Million, and in unspecified line-item vetoes by the Governor in months to come. An estimated $7 Billion additional deficit will be accrued between now and next August 30 when Fiscal Year 2009 ends, so these battles are not over. In terms of specific programs of near-term importance to the hemophilia community, the 10% across-the-board budget cut will be implemented at once in state programs such as the Genetically Handicapped Persons Program (GHPP) which serves many persons with hemophilia. It will not be implemented in Medi-Cal (Medicaid) payments to pharmacies, due to a court injunction. Next March 1, the cuts in state-only programs like GHPP will be reduced from 10% to 1%, and cuts in Medi-Cal payments will begin, but only at a 5% level. more...
|
|
| Posted by Dave Cavenaugh 08-29-2008 |
WASHINGTON UPDATE |
 |
|
> STATE –LEVEL ISSUES As we approach the end of summer and the final election run, the serious economic situation in the country does not appear to have yet hit bottom. As we have reported, according to the Center for Budget & Policy Priorities, 27 states face serious deficits totaling almost $50 billion this year; California’s deficit, the largest, equals roughly one-third of this amount. As the national economy deteriorates, incomes fall and less taxes are paid; state revenues are reduced accordingly. For chronic disease communities such as hemophilia the situation is rapidly going from bad to worse. Expensive chronic diseases are on the radar screen of those states facing serious deficits. Local hemophilia organizations and the three national organizations, COTT, NHF and HFA, are all spending a greater degree of time and resources putting out fires in places like Sacramento, California; Austin, Texas; and Frankfort, Kentucky as well as elsewhere. In all of these capitals the story is similar: a relatively small number of state-assisted chronic disease clients are found to have been spending a comparatively inordinate amount of a given state’s available health care dollars. Therefore states immediately look at hemophilia treatment and care as a line item that certainly must be adjusted downward to save critical dollars. No medical decision-making is involved when this is then done. For chronic disease communities, the impact of these cuts is substantial and for some chronic diseases communities catastrophic. more...
|
|
| Posted by Dave Cavenaugh 07-30-2008 |
WASHINGTON UPDATE |
 |
|
.> STATE-LEVEL ISSUES .The California Legislature continues to grapple with the Governor’s proposed across-the-board cuts for the fiscal year which has just begun (as of July 1). The Legislature acceded to the Governor’s requests in the spirit of looming crisis and enacted these cuts in February, shortly after they were proposed. Much work has ensued between then and this month to modify them substantially. It appears that the will has been expressed, in both chambers and across both parties, to seek a moderation of the cuts, although some debate persists as to the source of the revenues to make up the savings if certain programs are not cut. COTT continues to work closely with the Hemophilia Council of California as matters proceed over the summer. COTT President Corey Dubin has been appointed to the Advocacy Committee of the Southern California Hemophilia Foundation, known as SoCal, earlier this month. This presents broadened opportunities for coordination between COTT and local, grass-roots organizations as the budget crisis unfolds. more...
|
|
| Posted by Dave Cavenaugh 06-27-2008 |
WASHINGTON UPDATE |
 |
|
. > STATE-LEVEL ISSUES. In California, draconian budget cuts resulting from a 2 year 20 billion dollar deficit for fiscal years 2008 and 2009 has resulted in the Governor calling for 10% across the board cut in state program reimbursement for health care services. Starting July 1, these cuts will result in a 10% cut in reimbursement for factor concentrates for those enrolled in state-funded programs. This is likely to create a significant, and in some cases unworkable situation for many of the home care providers and Hemophilia Treatment Centers who deliver factor concentrates and associated services to the hemophilia/bleeding disorders community. For some chronic disease communities, such as pulmonary hypertension, these cuts will result in a serious interruption in access to care. In our community the cuts certainly will impact both access to care and the quality of that care. As we go to press the California Senate Budget Committee will meet to consider the cuts and the Budget Legislation that is the roadmap for the budget. Meanwhile the Assembly continues to oppose the cuts in health care. The entire budget debate in Sacramento is even more convoluted on the revenue side of the equation as State law mandates a two-thirds vote in the Legislature to raise revenues through new taxes. This rule allows the Republican minority to block any revenue-raising proposal, even those emanating from the Republican Governor, leaving only program cuts as a means to reduce the deficit. However, across the board cuts, including health in with all other state functions, clearly is the most damaging plan. more...
|
|
| Posted by Dave Cavenaugh 06-04-2008 |
WASHINGTON UPDATE |
 |
|
> CONGRESS GINA, the Genetic Information Nondiscrimination Act, was signed into law May 21st by the President, ending a harrowing three years of being bounced between the chambers of Congress and then stalled last year and this, only to emerge to the surprise of many and sail through approval. The bill prohibits discrimination through use of genetic testing in health insurance and in employment. more...
|
|
| Posted by Dave Cavenaugh 04-21-2008 |
WASHINGTON UPDATE |
 |
|
> Congress Recoiling from the Proposed Fiscal Year 2009 Budget sent to the Hill by the President in late February, yet burned by the memory from last December of his rigid refusal to sign any funding bill that went over his targets, the two chambers began their annual process to develop their own Budget documents in March, necessary before Appropriations bills can be developed. Ideological lines do not seem to be drawn in the same way as last year, when the two sides of the Hill could not agree on a single Budget (and therefore were less equipped to resist efforts to exceed targets). Instead this year’s Economic Stimulus Package of several hundred billion, the enormity of the expenditures for US actions in Iraq and Afghanistan, and the rising profile of the Presidential election have had their attention. Oh and of course major league baseball drug use. more...
|
|
| Posted by Dave Cavenaugh 04-01-2008 |
WASHINGTON UPDATE |
 |
|
Medicaid (Medi-Cal), Genetics Program, AIDS Care on the block.
Recently enacted cuts in California state health and other programs threaten access to care for those dependent on Medicaid and other state programs. The governor proposed in February an across-the-board 10% cut in all areas of the state budget, effective with the beginning of the new fiscal year July 1. Using the threat of a possible downgrade in the state’s bond ratings from Wall Street, he persuaded the legislature to quickly approve his proposal with few modifications. COTT has been assisting in the substantial efforts now going on in the state to urge Legislators to reconsider these cuts, both in their severity and in their blind application across even programs dealing with life-threatening situations. We have given testimony before the State Legislature's Health Committee in Sacramento, and met with several key Budget Committee offices. More advocacy work will be needed to achieve success at giving the legislators the commitment to undo their rushed consent to the Governor's proposed cuts. Any such cuts must be targeted in a way that exempts services to health communities like ours. Key legislators tell us that for the most part members of both the Governor's party and the Majority party are by now well aware of the dire implications of the cuts, but need to see evidence from their home district constituencies of public outcry against these threatened services reductions before they can take the strong stands needed to undo what has been approved and block further cuts. Californians: Mobilize!! your resources for visible, local statements (op-ed, etc.) and events (rallies or speeches at other events, with media). Contact Legislators using this link to register your concerns and, particularly, convey how these cuts would affect you. COTT is working closely with the Hemophilia Council of California (510-234-8655) on this campaign; contact either organization for more information. COTT is next due to speak to community members on this at the Advocacy Day being held by the Hemophilia Association of SoCal (888-371-4123) later this month in Los Angeles. Special Note for those outside of California: The California Medicaid program (Medi-Cal) serves one-fifth of all Medicaid clients in the country. Other states' Medicaid programs are also in fiscal crisis. If California’s cuts are the deepest, that will quickly become the norm across the land. Contacting Legislators: more...
|
|
| Posted by Dave Cavenaugh 02-26-2008 |
WASHINGTON UPDATE |
 |
|
> CONGRESS Congress spent much of the first month of the Second Session of the 110th Congress (that is, January) in meetings and party-member retreats, as is customary. Back on the Hill, machinery was oiled to prepare to push this year selected major bills from last year that did not pass. But one legislative issue dominated the month: the Economic Stimulus Package, a $146 billion response to the sagging US economy triggered by widespread mortgage foreclosures. Signed into law February 13th after three or more weeks of very public negotiations with the White House, it provides tax rebates of several hundred dollars to all filers; expands the Federal Housing Administration (FHA) loan program through raising the ceiling on the amount that can be financed; and permits accelerated depreciation for business owners. more...
|
|
| Posted by Dave Cavenaugh 01-24-2008 |
WASHINGTON UPDATE |
 |
|
> CONGRESS Aprropriations (funding): Democratic leaders, having a hard time tearing their attention away from the first of the primaries now under way, find themselves both reeling from the ragged, humbling end of the FY08 appropriations struggle last month, and at the same time trying to forge (with little apparent success) a strategy for the same matters this year. The President has gone on record recently saying that this year will be conducted with the same rigidity from his side – vetoing any spending bill in the fall that exceeds the budget he lays down in the spring, to be released February 5. (CQToday of 1/14: “Bush vows to hold the line again on taxes and spending.”) As a result, even though it looks to all like the next President will be a Democrat, with different budget priorities tha we have seen from the White House these last seven years, that begins with inauguration – which is in 2009, not in time to help with this year’s budget fights. more...
|
|
| Posted by Dave Cavenaugh 12-21-2007 |
WASHINGTON UPDATE |
 |
|
The Update adds three new features with this issue, located at the end of the current format. These include: a regular section on COTT Operations; a Blood Safety Summary drawing from the articles; and an Errata listing. . > INTERNATIONAL - JapanThe judge overseeing last spring’s huge settlement between the HCV-infected hemophilia community and fractionators and the government this month recommended the two parties negotiate a settlement. Since all are agreed on the general size range of the settlement, albeit not as great as the initial award would have been, Judge Katsutoshi Yokota suggested that negotiation, overseen by the court, is the best way to resolve remaining differences – which include the scope of the compensation, and that the companies offer formal apology. more...
|
|
| Posted by Dave Cavenaugh 12-18-2007 |
WASHINGTON UPDATE |
 |
|
FDA Recalls Report Follows
November 29, 2007 An Open Letter to the Manufacturers of Clotting Factor Products and the Government Agencies who Regulate Them: Individuals affected by bleeding disorders depend on the availability of safe and efficacious clotting factor concentrates for their very lives. In the 1980s, the community was ravaged by the proliferation of HIV/AIDS and HCV tainted plasma derivatives. Many lessons were learned during that period about the importance of vigilance, and today we are fortunate to have an adequate supply of safe products, both recombinant and plasma-derived. However, recent events have created the perception that vigilance has started to wane. more...
|
|
| Posted by Dave Cavenaugh 12-07-2007 |
WASHINGTON UPDATE |
 |
|
“Si no está rompido, no se lo fijo”
Las miles de personas con la afección coagularse de hemofilia quiénes viven en cinco estados están siendo dicho que ellos ya no puedan comprar su medicina por medio de su farmacia actual – por lo general enviandola a la casa al debido del costo y exigencias de refrigeración – y en cambio dijeron que todos/as deben usar una nueva farmacia, del dueño que se llama “Cruz Azul” o “Blue Cross.” Los estados son Indiana, Kentucky, Missouri, Ohio, y Wisconsin. more...
|
|
| Posted by Dave Cavenaugh 11-16-2007 |
WASHINGTON UPDATE |
 |
|
“If it ain’t broke, don’t fix it” Thousands of people with the clotting disorder hemophilia who live in five states are being told they can no longer purchase their medicine through their current pharmacy – usually having it shipped to the home due to cost and refrigeration requirements – and instead told they must use a new pharmacy, owned by their insurer, Blue Cross. The states are Indiana, Kentucky, Missouri, Ohio, and Wisconsin. more...
|
|
| Posted by Dave Cavenaugh 10-25-2007 |
WASHINGTON UPDATE |
 |
|
> INTERNATIONAL Court Acquits 4 Doctors, Drug Company For Selling Treated But Unsafe Blood In a decision that shocked the Canadian hemophilia community, Ontario provincial Superior Court Justice Mary Lou Benotto concluded that that 3 Canadian doctors, US drug company, Armour Pharmaceutical and one of it’s former vice-presidents, Dr. Michael Rodell, were not guilty of negligence in the HIV infection of over 1000 Canadian persons with hemophilia through tainted blood products. Justice Benotto, announced the verdict to a packed courthouse on September 28th. Members of the Canadian Hemophilia Society present in the courtroom were visibly shaken as the Justice spoke. more...
|
|
| Posted by Dave Cavenaugh 08-17-2007 |
WASHINGTON UPDATE |
 |
|
> CONGRESS Since the last COTT Washington Update, published June 8, Congress has wrestled, with little success, with several large-scope authorization issues, while attempting to work through the annual set of appropriations bills simultaneously. Examples of the former include renewal of the major energy and farm bills, and, more recently, the Genetic Information Nondiscrimination Act (GINA) and the State Childrens’ Health Insurance Program (SCHIP). Neither of the last two, both important to the hemophilia community, succeeded in obtaining passage before Congress adjourned for its month-long Summer Recess last week. more...
|
|
| Posted by Dave Cavenaugh 07-17-2007 |
WASHINGTON UPDATE |
 |
|
COTT Washington Alert! ................................. Call Now! Vote is in next 10 days!!
The House of Representatives on July 11th passed its version of legislation to re-authorize the Prescription Drug User Fee Act (PDUFA), which since 1992 has permitted the drug industry to pay FDA for FDA’s reviews of industry applications for new drug licenses. That’s right, the regulated industry pays the federal regulators for regulating the safety of the drugs the industry then sells us. more...
|
|
| Posted by Dave Cavenaugh 06-08-2007 |
WASHINGTON UPDATE |
 |
|
> CONGRESS Congress occupied itself in the last month with development of a War Supplemental bill to replace the one vetoed by the President; with forging a new immigration House-Senate compromise, although at this writing success is not assured; and with one more attempt to agree on a House-Senate FY2008 Budget Resolution, which succeeded on May 17th. Appropriations hearings are in high gear; first subcommittee bills are expected shortly. more...
|
|
| Posted by Dave Cavenaugh 05-02-2007 |
WASHINGTON UPDATE |
 |
|
May 2, 2007
Ten days ago, COTT had delivered to the offices of the American Thrombosis and Hemostasis Network (ATHN) a Memo posing questions left in our mind after the ATHN presentations we attended in February and March. Ranging from narrow to broad, we believe that many of these questions are the same that most of the hemophilia community is asking. Perhaps key among other things, we’re asking how ATHN and its creators propose to collect data from our health records at our HTCs – and then sell those health records to private corporations for their purposes, and perhaps for further resale. more...
|
|
| Posted by Dave Cavenaugh 04-19-2007 |
WASHINGTON UPDATE |
 |
|
> CONGRESS When this Update began publication in 1998, we were at the height of the efforts to get Ricky Ray passed and then funded. Nearly every issue had specific requests for you to engage in political action. Time has passed since then, but this spring so much is possible and so much is being attempted that we call on the community again to be ready to act. We will provide specifics as needed. There are multiple bills affecting FDA which are likely to pass this year. The two biggest are two of the three FDA bills COTT is concerned with. One of these, labeled FDA Reform, is for changes in FDA’s drug review process, and substantially increased programs for monitoring of post-market problems, findings and of television advertising. The other is the renewal of the Prescription Drug User Fee Act (PDUFA), for the third time allowing industry to pay FDA for review of its candidate drugs. Committee action on PDUFA took place April 18 in the Senate; a date has not been set in the House although a four-hour hearing on PDUFA was held there April 17th. more...
|
|
| Posted by Dave Cavenaugh 03-30-2007 |
WASHINGTON UPDATE |
 |
|
> CONGRESS Congress heads into its first two week recess of the year. Republican entrenchment, triggered by the new Democratic majority’s “100 hours” in the House in January (during which no Republican amendments were heard), grew in February and became a force to be reckoned with in March. Four major money bills demonstrate this. more...
|
|
| Posted by Dave Cavenaugh 01-24-2007 |
WASHINGTON UPDATE |
 |
|
> CONGRESS COTT is pursuing seven legislative agendas this spring, all with implications for agency regulatory policy once enacted. The first three concern FDA: 1) Make consumer participation on all FDA Advisory Committees mandatory. Of 47 committees, many have an industry representative but no consumer representative. 2) Block renewal of the Prescription Drug User Fee Act, which since 1994 has permitted drug companies to pay FDA for reviewing applications from the companies for new products. 3) Restructure FDA New Drug Review and oversight functions, placing the Office of New Drugs where its voice can be heard vs. its present situation within the New Drug office, which repeatedly has ignored its safety findings. Empowering much stronger oversight on drugs once approved, and on advertising. 4) MediGap – enact the language COTT and others have developed to help with the costs of Medicare co-payments of twenty percent – impossible when drugs cost $20,000/month. 5) Mad Cow – work for more realistic USDA sampling of the American herd, not the whitewash to date; press FDA to base its reporting on risk to the blood supply on sound risk estimates. 6) Hepatitis Care – work for the passage of the Hepatitis Epidemic Control Act, introduced in May of 2003 by Senators Kennedy and Hutchison but never considered even for a hearing in four years’ time. (Hepatitis Compensation remains on COTT’s list, awaiting optimum conditions.) 7) HTC Funding – Identify areas in the HTC 340b program in need of rectification to comply with federal law, such as use of profit funds, out-of-area marketing, and offering true choice to consumers. Explore alternative federal support strategies for current 340b HTCs. more...
|
|
| Posted by Dave Cavenaugh 12-21-2006 |
WASHINGTON UPDATE |
 |
|
> CONGRESS Having decided that staying in session another week closer to Christmas would not permit passage of pending appropriations bills nor provide a chance to raise support for any of the many remaining Republican initiatives remaining unfulfilled, Congress has adjourned, terminating the 109th two-year “Congress” (session) in the pre-dawn hours of December 9th. We are pleased to report, in one of the largest cliff-hangers in the health community, that the Ryan White CARE Act, in place since 1990 and overdue for its periodic renewal, was one of the last votes taken as the House closed down. The new law, which must itself be renewed in three years rather than the normal five, makes major changes in the way AIDS programs operate. more...
|
|
| Posted by Dave Cavenaugh 11-22-2006 |
WASHINGTON UPDATE |
 |
|
> CONGRESS Exceeding nervous Democrats’ expectations, the results of the 2006 Mid-Term Congressional elections gave that party control of the House by 34 seats vs. the 29-seat control the Republican party has enjoyed the last two years, a sixty-three-seat change in party. After a several-days cliffhanger over one particular race (VA), Democrats won control of the Senate as well (by one vote only, however). more...
|
|
| Posted by Dave Cavenaugh 10-26-2006 |
WASHINGTON UPDATE |
 |
|
> CONGRESS Since our September-October Washington Update was published October 6, Congress has not been in session (except for the newly reconstituted and refurbished House Ethics Committee, which has already spent days and days hearing testimony from those involved, however peripherally, in the Mark Foley scandal). What HAS been going on during this time is a steady and perhaps accelerating shift in the public’s support of the Administration. Between 10/15 and 10/20, results of three national polls were released, showing almost the same results: NBC reported the following: more...
|
|
| Posted by Dave Cavenaugh 09-01-2006 |
WASHINGTON UPDATE |
 |
|
> CONGRESS During the August recess, a number of Congressional agendas have kept rolling. For example, all expect the Ryan White Care Act re-authorization to be passed and enacted during September, but its substantial changes in funding formulas and non-medical care reductions are still provoking public outcry. Hilary Clinton (D-NY), a member of the Senate Health Committee, has said she will put a hold on the bill to keep it from coming to the Senate floor for a vote, unless formula changes are made that do not penalize areas with a history of AIDS cases and cost burden in redirecting resources to areas much more recently impacted (like the rural South). more...
|
|
| Posted by Dave Cavenaugh 07-27-2006 |
WASHINGTON UPDATE |
 |
|
COTT Washington Update
> CONGRESS The period between the week of Fourth of July Recess and the beginning of the month-long August recess is a frenetic time in Congress. It is last chance to move legislative policy issues (as opposed to purely funding bills) through the process. This election year provides even more interesting theater, as the majority works harder to pass party-backbone bills despite embarrassing failures in that regard before the break. We have seen renewal of the Voting Rights Act, more work to reconcile widely divergent House and Senate immigration reform bills, a Stem Cell Act that triggered the first veto of this administration (which was not overridden), energy, gay marriage and war costs hearings, and lengthy debate on the trial rights of detainees such as at the US base at Guantanamo, Cuba. more...
|
|
| Posted by Dave Cavenaugh 06-30-0006 |
WASHINGTON UPDATE |
 |
|
COTT Washington Update
> CONGRESS Congress finished out its month between Easter recess and Memorial Day with a concerted push in the Senate, resulting in a new and complicated Immigration Bill. Though authors of the comparable bill in the House view the Senate’s bill as weak, the bill is particularly threatening to long-term US-resident non-citizens, of which there are many. more...
|
|
| Posted by Dave Cavenaugh 05-19-0006 |
WASHINGTON UPDATE |
 |
|
COTT Washington Update
> CONGRESS It was an intense few months for COTT and other opponents of S.1955, a small business health insurance plan on steroids: the bill would have permitted pre-emption of all state health insurance protections, impeded oversight of insurers, and made it more difficult to appeal bad claims awards. Working with HFA and NHF, the Alpha-1 Advocacy Alliance and many other health consumer organizations, COTT conducted Hill visits to potential swing-vote Senators’ offices throughout that time, escalating as the May 11 evening crucial vote neared. more...
|
|
| Posted by Greg Ederer 05-12-0006 |
WASHINGTON UPDATE |
 |
|
May 12, 2006 ENZI BILL DEFEATED!! HEALTH COMMUNITY RALLIES! The Enzi Bill, S. 1955, about which the US Senate debated May 9-11, was defeated in a 55-43 vote last evening at 7:00 pm when the sponsor of the bill could not summon sufficient votes to meet the required 60 to shut off debate on the bill. (As a result the bill was withdrawn by leadership rather than permit Democratic amendments and possibly a filibuster.) To win the “closure” vote Sen. Enzi would have needed the assistance of six Democrats, but could not get them. more...
|
|
| Posted by Greg Ederer 05-11-0006 |
WASHINGTON UPDATE |
 |
|
May 11, 2006
ENZI “LOSE YOUR HEALTH INSURANCE” BILL NEAR DEFEAT: FINAL VOTE 4 PM TODAY Senate bill S. 1955, (HIMMA), introduced by Sen. Mike Enzi (R-WY), Chair of the Senate Health Committee, has been the subject of Senate floor debate all this week. During that time, thousands of people from disease communities to national media, unions, health care providers and others have been learning of the bill’s dangers and registering their strong opposition with Senators. more...
|
|
| Posted by Greg Ederer 05-05-0006 |
WASHINGTON UPDATE |
 |
|
May 5, 2006 ENZI “LOSE YOUR HEALTH INSURANCE” BILL COMING TO SENATE FLOOR – ACT NOW TO HELP DEFEAT IT As we’ve discussed in the last two COTT Washington Updates and a March COTT Alert, Senate bill S. 1955, the “Health Insurance Marketplace Modernization and Affordability Act” (HIMMA), introduced in its present form by Sen. Mike Enzi (R-WY), Chair of the Senate Health, Education, Labor and Pensions (HELP) Committee, and approved by that Committee March 14th, has continued its steady progress toward a floor vote. more...
|
|
| Posted by Greg Ederer 04-21-0006 |
WASHINGTON UPDATE |
 |
|
COTT Washington Update
> CONGRESS Eight months after House Majority Leader Tom DeLay had to step down from that post due to legal troubles, he announced his resignation from the US Congress altogether, both because a key staffer in his office had been indicted days earlier and because it became clear that he faced defeat in the polls. more...
|
|
| Posted by Greg Ederer 03-24-0006 |
WASHINGTON UPDATE |
 |
|
COTT Washington Update
> CONGRESS On March 7th, Senate Health, Education, Labor and Pensions (HELP) Committee Chairman Mike Enzi (R-WY) introduced legislation (S. 1955) for a sweeping reform of employer-based health insurance, very likely at the cost of massively reduced access to care for many. The Enzi bill permits formation of plans developed by groups of companies acting together, and grants them exemption from all state-mandated protections for specific population groups, including hemophilia, AIDS, cancer, diabetes, maternity care and neonates, and many many more. more...
|
|
| Posted by Greg Ederer 03-17-0006 |
WASHINGTON UPDATE |
 |
|
On March 7th , Senate Health, Education, Labor and Pensions (HELP) Committee Chairman Mike Enzi (R-WY) introduced legislation for a sweeping reform of employer-based health insurance, granting plans developed by groups of companied acting together exemption from all state-mandated protections for specific population groups, including hemophilia, AIDS, cancer, diabetes, maternity care and neonates, and many many more. In their place, the bill proposes a weak set of rating adjustments to factor in geography, gender, age, race, and health status. more...
|
|
| Posted by Dave Cavenaugh 02-24-0006 |
WASHINGTON UPDATE |
 |
|
COTT Washington Update
> CONGRESSThere were two major pieces of legislation left over from before Christmas as Congress returned from its winter recess, the Reconciliation bill which cuts $40 Billion from Medicare over the next five years, and the Tax Cut Package, which had passed only the House. more...
|
|
| Posted by Greg Ederer 06-25-2005 |
WASHINGTON UPDATE |
 |
|
Warning from the CDC
The Centers for Disease Control announced September 3rd the possible infection of transfusion recipients with West Nile Virus (WNV) through blood, and the certain infection of organ recipients through transplant. COTT was invited onto a conference call with FDA and CDC staff the following day to discuss events and plans forthcoming. more...
|
|
|
Washington Update is a bi-monthly primer on government related issues of importance to COTT's constituency. From health care legislation, to regulatory affairs to Administration policy for chronic diseases. A hands-on journal for grass roots health care advocacy in our Nation's capital.
|
 |
COTT News A range of information, reportage and viewpoints regarding issues and events of importance to grass roots health care advocacy and support. In COTTs vision information is power and part of the empowered community equation. From Washington D.C. to State capitals to the HIH and the FDA, look to COTT for grass roots health care news.
|
 |
COTT Canary tracks safety issues in our Nation's blood supply. It provides regular reporting, information and viewpoints from the grass roots end user communities. It is based on the historical practice of taking Canaries into the coalmines to gauge problems with breathable air. If the Canary passed out then it was time to evacuate the mine. Persons with hemophilia and other bleeding disorders are the canaries in the coalmine, the blood supply. If problems are present they will surface first in the hemophilia community.
|
 |
Treatment Updates: News, information and analysis about living with HIV/AIDS, hepatitis C, and hemophilia and related problems associated with living with multiple life threatening diseases.
|
 |
|